2015 Cancer Drug List PDF

2015 Medicines in Development for Cancer
Bladder Cancer
Product Name Sponsor Indication Development Phase
ABI-009 AADi non-muscle invasive bladder cancer Phase I/II

(nanoparticle albumin-bound Pacific Palisades, CA
mTOR inhibitor)
ACP-196 Acerta Pharma platinum-refractory bladder cancer Phase II

(Btk inhibitor) San Carlos, CA (combination therapy) www.acerta-pharma.com
(see also head/neck, hematological, leukemia,
lung, lymphoma, myeloma, pancreatic)
ALT-801 Altor BioScience advanced bladder cancer, Phase II

(immunotherapy fusion protein) Miramar, FL non-muscle invasive bladder cancer www.altorbioscience.com
ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also hematological, myeloma, skin) www.altorbioscience.com
apatorsen OncoGenex Pharmaceuticals metastatic bladder cancer Phase II

(Hsp27 inhibitor) Bothell, WA (see also lung, pancreatic, prostate) www.oncogenex.com
apaziquone Spectrum Pharmaceuticals non-muscle invasive bladder cancer Phase III

(DNA synthesis inhibitor) Henderson, NV (Fast Track) www.sppirx.com
ASG-15ME Agensys relapsed bladder cancer Phase I

(antibody drug conjugate) Santa Monica, CA www.agensys.com
Seattle Genetics www.seattlegenetics.com
Bothell, WA
B-701 BioClin Therapeutics metastatic bladder cancer (2nd-line) Phase II

(anti-FGFR3 mAb) San Ramon, CA www.bioclintherapeutics.com
BC-819 BioCancell Therapeutics bladder cancer (2nd-line) Phase II

(gene therapy) Jerusalem, Israel (see also pancreatic) www.biocancell.com
Bladder Cancer
CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II/III

(oncolytic virus therapy) Newport Beach, CA www.coldgenesys.com
CV-301 Bavarian Nordic bladder cancer Phase II

(CEA/MUC-1 targeted active Mountain View, CA www.bavarian-nordic.com
immunotherapy)
Cyramza Eli Lilly urothelial cancer Phase III

ramucirumab Indianapolis, IN (see also liver, lung, stomach) www.lilly.com
bladder cancer (2nd-line) Phase II

www.lilly.com
DN24-02 Dendreon HER2-positive urothelial cancer Phase II

(active cellular immunotherapy) Seattle, WA www.dendreon.com
Halaven Eisai bladder cancer Phase I/II

eribulin Woodcliff Lake, NJ (see also lung, sarcoma) www.eisai.com
Orphan Drug
instiladrin FKD Therapies superficial bladder cancer Phase II

(gene therapy) Kuopia, Finland
JNJ-42756493 Janssen Research & Development urothelial cancer Phase II

(FGFR inhibitor) Raritan, NJ (see also lymphoma) www.janssenrnd.com
MCNA Telesta Therapeutics refractory non-muscle invasive application submitted

(mycobacterium phlei cell Point Claire, Canada bladder cancer (Fast Track) www.telestatherapeutics.com
wall-nucleic acid complex)
Keytruda Merck bladder cancer Phase III

pembrolizumab Kenilworth, NJ (see also breast, head/neck, lung, lymphoma, www.merck.com
stomach)
Bladder Cancer
mocetinostat Mirati Therapeutics bladder cancer Phase II

(HDAC inhibitor) San Diego, CA (see also hematological, lymphoma) www.mirati.com
Opdivo Bristol-Myers Squibb bladder cancer (2nd-line) Phase II

nivolumab Princeton, NJ (see also brain, colorectal, head/neck, hematological, www.bms.com
kidney, liver, lung, lymphoma, skin, solid tumors,
stomach, other)
RG7446 Genentech/Roche bladder cancer (2nd-line) (Breakthrough Therapy) Phase III

(anti-PD-L1 mAb) South San Francisco, CA muscle invasive bladder cancer (adjuvant) www.roche.com
(see also breast, kidney, lung, lymphoma, skin)
bladder cancer (1st-line) Phase II

www.roche.com
TMX-101 Telormedix bladder cancer Phase II

(TLR7 agonist) Bioggio, Switzerland www.telormedix.com
Orphan Drug
vesigenurtucel-L Heat Biologics bladder cancer Phase II

(cancer immunotherapy) Durham, NC www.heatbio.com
2B3-101 BBB Therapeutics brain metastases in advanced solid tumors, Phase II

(doxorubicin liposomal) Leiden, Netherlands brain metastases in breast cancer (combination therapy) www.bbbtherapeutics.com
ABT-414 AbbVie glioblastoma Phase I/II

(antibody drug conjugate) North Chicago, IL (see also solid tumors) www.abbvie.com
Orphan Drug
ADU-623 Aduro Biotech glioblastoma Phase I

(therapeutic bivalent vaccine) Berkeley, CA www.adurobiotech.com
Brain Cancer
AG-120 Agios Pharmaceuticals glioma Phase I

(IDH1 inhibitor) Cambridge, MA (see also leukemia, solid tumors) www.agios.com
Celgene www.celgene.com
Summit, NJ
aglatimagene besadenovec Advantagene glioma Phase II

(gene therapy) Auburndale, MA (see also pancreatic, prostate) www.advantagene.com
Orphan Drug
glioma (pediatric) Phase I/II

www.advantagene.com
aldoxorubicin CytRx glioblastoma Phase II

(delivery-enhanced doxorubicin) Los Angeles, CA (see also lung, sarcoma) www.cytrx.com
Orphan Drug
AMG 595 Amgen anaplastic astrocytoma, recurrent glioblastoma Phase I

(anti-EGFRvIII antibody drug Thousand Oaks, CA www.amgen.com
conjugate)
ANG 1005 Angiochem brain metastases from breast cancer and Phase II
(peptide-paclitaxel conjugate) Montreal, Canada NSCLC, recurrent glioblastoma (Fast Track) www.angiochem.com
Orphan Drug
antineoplaston A10/AS2-1 Burzynski Research Institute diffuse intrinsic brainstem glioma Phase II
Orphan Drug Houston, TX www.burzynskiresearch.com
Avastin Genentech/Roche glioblastoma (1st-line) Phase III

bevacizumab South San Francisco, CA (see also breast, lung, ovarian, other) www.roche.com
BGJ398 Novartis Pharmaceuticals recurrent glioblastoma Phase II

(FGF-R kinase inhibitor) East Hanover, NJ (see also solid tumors) www.novartis.com
Brain Cancer
buparlisib (BKM120) Novartis Pharmaceuticals glioblastoma Phase I/II

(PI3K inhibitor) East Hanover, NJ (see also breast, solid tumors) www.novartis.com
CC-122 Celgene glioblastoma Phase I

(pleiotropic pathway modifier) Summit, NJ (see also leukemia, liver, lymphoma) www.celgene.com
Cometriq Exelixis astrocytoma, glioblastoma Phase II completed

cabozantinib South San Francisco, CA (see also kidney, liver) www.exelixis.com
Cotara Peregrine Pharmaceuticals recurrent glioblastoma (Fast Track) Phase II completed

iodine I 131 derlotuximab biotin Tustin, CA www.peregrine.com
Orphan Drug
crenolanib AROG Pharmaceuticals glioma (pediatric) Phase II

(PDGFR inhibitor) Dallas, TX (see also leukemia, lung, stomach) www.arogpharma.com
Orphan Drug
CTO Tactical Therapeutics glioma (combination therapy) Phase I/II

(carboxyamidotriazole orotate) New York, NY (Fast Track) www.tacticaltherapeutics.com
DCVax-L Northwest Biotherapeutics glioblastoma Phase III

dendritic cell-based vaccine Bethesda, MD www.nwbio.com
Orphan Drug
DM-CHOC-PEN Dekk-Tec brain tumors Phase II

(non-neurotoxic derivative of New Orleans, LA www.dekk-tec.com
penclomidine)
DNX-2401 DNAtrix glioblastoma (Fast Track) Phase I

(oncolytic virus) Houston, TX www.dnatrix.com
Orphan Drug
Brain Cancer
ERC1671 Epitopoietic Research grade IV glioblastoma Phase II

(therapeutic vaccine) Pasadena, CA www.ercbelgium.com
University of California
Irvine, CA
ETS2101 e-Therapeutics glioma Phase I

(dexanabinol) Oxfordshire, England www.etherapeutics.co.uk
Moores UCSD Cancer Center
La Jolla, CA
evofosfamide (TH-302) Threshold Pharmaceuticals high grade glioma Phase I/II

(hypoxia-activated prodrug) South San Francisco, CA (see also hematological, lung, pancreatic, sarcoma, www.thresholdpharm.com
University of Texas skin)
San Antonio, TX
galunisertib Eli Lilly glioblastoma Phase II

(TGF-beta 1 kinase inhibitor) Indianapolis, IN (see also liver, pancreatic) www.lilly.com
glioma Phase I/II

www.lilly.com
Gilotrif Boehringer Ingelheim Pharmaceuticals recurrent glioma Phase II

afatinib Ridgefield, CT (see also head/neck, lung) www.boehringer-ingelheim.com
heat shock protein vaccine Agenus recurrent or newly-diagnosed glioblastoma Phase II

(Prophage Series) Lexington, MA (see also skin) www.agenus.com
Orphan Drug
ICT-107 ImmunoCellular Therapeutics newly-diagnosed glioblastoma Phase II

(dendritic cell-based vaccine) Calabasas, CA www.imuc.com
Orphan Drug
Brain Cancer
ICT-121 ImmunoCellular Therapeutics recurrent glioblastoma Phase I

(dendritic cell-based vaccine) Calabasas, CA www.imuc.com
indoximod NewLink Genetics primary malignant brain tumors Phase I/II

(IDO pathway inhibitor) Ames, IA (see also breast, prostate) www.newlinkgenetics.com
INXN-2001 ZIOPHARM Oncology anaplastic oligo astrocytoma, glioblastoma Phase I/II

(Ad-RTS-IL-12 gene therapy) Boston, MA (see also breast, skin) www.ziopharm.com
Jevtana Sanofi US malignant central nervous system tumors Phase I/II

cabazitaxel Bridgewater, NJ (see also prostate) www.sanofi.com
KX02 Kinex Pharmaceuticals glioma Phase I

(Src kinase/pre-tubulin inhibitor) Buffalo, NY www.kinexpharma.com
Orphan Drug
MM-398 Baxalta glioma Phase I

(encapsulated irinotecan Cambridge, MA (see also pancreatic, solid tumors) www.baxalta.com
nanotherapeutic)
macitentan Actelion Pharmaceuticals glioblastoma Phase I

(endothelin A/B receptor antagonist) South San Francisco, CA www.actelion.com
marizomib Triphase Accelerator glioblastoma Phase I

(proteasome inhibitor) San Diego, CA (see also myeloma) www.triphaseco.com
mibefradil Cavion high-grade glioma Phase I

(T-type calcium channel antagonist) Charlottesville, VA www.cavionpharma.com
Orphan Drug
mipsagargin GenSpera glioblastoma Phase II

(thapsigargin analogue) San Antonio, TX (see also liver) www.genspera.com
Brain Cancer
NEO-100 NEONC Technologies recurrent glioblastoma Phase I

(highly purified perillyl alcohol) Tucson, AZ www.neonctech.com
Orphan Drug
NVX-108 NuvOx Pharma glioblastoma Phase I/II

(radiation-sensitizing agent) Tucson, AZ www.nuvoxpharma.com
National Cancer Institute
Bethesda, MD
Odomzo Novartis Pharmaceuticals medulloblastoma Phase II

sonidegib East Hanover, NJ (see also leukemia) www.novartis.com
Opdivo Bristol-Myers Squibb glioblastoma Phase III

nivolumab Princeton, NJ (see also bladder, colorectal, head/neck, hematological, www.bms.com
stomach, other)
PEPIDH1M Annias Immunotherapeutics glioblastoma Phase I/II

(dendritic cell vaccine) Chapel Hill, NC www.anniasimmuno.com
PLX3397 Plexxikon glioblastoma (adjuvant) Phase II

(CSF-1R inhibitor) Berkeley, CA (see also breast, ovarian, skin, other) www.plexxikon.com
Poly-ICLC Oncovir glioblastoma Phase II

Orphan Drug Washington, DC www.oncovir.com
Reolysin Oncolytics Biotech high grade glioma (pediatrics) Phase I

pelareorp Calgary, Canada (see also colorectal, head/neck, lung, www.oncolyticsbiotech.com
Orphan Drug myeloma, ovarian, other, pancreatic)
Brain Cancer
rindopepimut Celldex Therapeutics glioblastoma (1st-line) (Fast Track) Phase III

(EGFR antagonist) Hampton, NJ www.celldex.com
Orphan Drug
recurrent glioblastoma (Fast Track) Phase II

www.celldex.com
selinexor (oral) Karyopharm Therapeutics glioblastoma Phase II

(XPO1 antagonist) Newton, MA (see also head/neck, hematological, leukemia, www.karyopharm.com
lymphoma, myeloma, prostate, sarcoma, other)
Seprehvir Virttu Biologics glioblastoma Phase I

HSV1716 Glasgow, Scotland (see also solid tumors) www.virttu.com
Bethesda, MD
SL-701 Stemline Therapeutics adult glioblastoma (first recurrence) Phase I/II

(immunotherapy) New York, NY www.stemline.com
SurVaxM MimiVax malignant glioma Phase I

BIRC5 protein inhibitor Buffalo, NY www.mimivax.com
Toca 511 + Toca FC Tocagen anaplastic astrocytoma, glioblastoma Phase II/III

(gene therapy) San Diego, CA (Fast Track) www.tocagen.com
TPI 287 Cortice Biosciences recurrent glioblastoma Phase II

(abeotaxane) New York, NY www.corticebio.com
breast cancer brain metastases, Phase I

secondary brain metastases www.corticebio.com
Brain Cancer
TRC105 TRACON Pharmaceuticals glioblastoma Phase II

(END protein inhibitor) San Diego, CA (see also breast, colorectal, kidney, liver, lung, www.traconpharma.com
National Cancer Institute sarcoma, other)
Bethesda, MD
TSC Diffusion Pharmaceuticals glioblastoma Phase I/II

(trans-sodium crocetinate) Charlottesville, VA www.diffusionpharma.com
Orphan Drug
TVI-Brain-1 TVAX Biomedical glioma Phase II

(personalized cancer immunotherapy) Lenexa, KS www.tvaxbiomedical.com
Orphan Drug
VAL-083 DelMar Pharmaceuticals glioblastoma Phase I/II

(N7-alkylating agent) Vancouver, Canada www.delmarpharma.com
Orphan Drug
VB-111 VBL Therapeutics recurrent glioblastoma (Fast Track) Phase II

(targeted anti-angiogenic agent) Tel Aviv, Israel (see also ovarian, other) www.vblrx.com
Orphan Drug
veliparib AbbVie brain metastases Phase II

(PARP inhibitor) North Chicago, IL (see also breast, colorectal, lung, skin) www.abbvie.com
Breast Cancer
abemaciclib Eli Lilly metastatic breast cancer Phase III

(CDK 4/6 inhibitor) Indianapolis, IN (see also lung, lymphoma) www.lilly.com
ABP 980 Allergan breast cancer Phase III

(trastuzumab biosimilar) Parsippany, NJ www.amgen.com
Amgen
Thousand Oaks, CA
Breast Cancer
Abraxane Celgene triple-negative breast cancer (1st-line) Phase III

paclitaxel protein-bound Summit, NJ (see also pancreatic) www.celgene.com
particles for injectable
suspension (albumin-bound)
ADI-PEG 20 Polaris Pharmaceuticals HER2-negative breast cancer Phase I

(PEG arginine deiminase) San Diego, CA (see also liver, lung, ovarian, pancreatic, skin, www.polarispharma.com
stomach)
AE37 Antigen Express breast cancer Phase II

(immunotherapeutics) Worcester, MA (see also prostate) www.antigenexpress.com
anti-HER2 Bristol-Myers Squibb breast cancer Phase I

Princeton, NJ www.bms.com
ARRY-380/ONT-380 Array BioPharma breast cancer Phase I

(HER2 inhibitor) Boulder, CO www.arraybiopharma.com
Oncothyreon www.oncothyreon.com
Seattle, WA
Avastin Genentech/Roche HER2-negative breast cancer (adjuvant), Phase III

bevacizumab South San Francisco, CA HER2-positive breast cancer (adjuvant) www.roche.com
(see also brain, lung, ovarian, other)
AZD5363 AstraZeneca breast cancer Phase II

(Akt kinase inhibitor) Wilmington, DE www.astrazeneca.com
AZD9496 AstraZeneca estrogen receptor (ER)-positive breast cancer Phase I

(selective estrogen receptor Wilmington, DE www.astrazeneca.com
downregulator [SERD])
bavituximab Peregrine Pharmaceuticals HER2-negative breast cancer Phase I completed

Tustin, CA (see also colorectal, lung, skin) www.peregrineinc.com
Breast Cancer
BBI608 Boston Biomedical breast cancer Phase II

(cancer stem cell inhibitor) Cambridge, MA (see also colorectal, hematological, liver, lung, www.bostonbiomedical.com
ovarian, pancreatic, skin, stomach)
BEL-0222 Belrose Pharma triple-negative breast cancer Phase II

(angiogenesis inhibitor) Princeton, NJ (see also other) www.belrosepharma.com
buparlisib (BKM120) Novartis Pharmaceuticals metastatic breast cancer (2nd-line) Phase III
(PI3K inhibitor) East Hanover, NJ (ER-positive aromatase inhibitor (AI)- www.novartis.com
resistant mTOR nave) (combination therapy)
(see also brain, solid tumors)
metastatic breast cancer Phase II

(ER-positive post-AI and mTOR inhibitor) www.novartis.com
CC-486 Celgene metastatic breast cancer Phase II

(DNA methylation inhibitor) Summit, NJ (see also hematological, leukemia, lung, lymphoma, www.celgene.com
other)
cobimetinib Genentech/Roche triple-negative breast cancer (combination therapy) Phase II

(MEK inhibitor) South San Francisco, CA (see also skin) www.roche.com
Cynviloq NantPharma breast cancer in clinical trials

paclitaxel polymeric micelle Lincolnshire, IL www.nantpharma.com
for injection
docetaxel injection concentrate, Teikoku Pharma USA breast cancer application submitted
non-alcohol formula San Jose, CA (see also head/neck, lung, prostate, stomach) www.teikokuusa.com
DPX-0907 Immunovaccine breast cancer Phase I

(T lymphocyte modulator) Halifax, Canada (see also ovarian, prostate) www.imvaccine.com
Breast Cancer
ENMD-2076 CASI Pharmaceuticals triple-negative breast cancer Phase II

(aurora A/angiogenic kinase Rockville, MD (see also ovarian, sarcoma) www.casipharmaceuticals.com
inhibitor)
enobosarm GTx ER-positive and androgen receptor (AR)-positive Phase II

(SARM) Memphis, TN breast cancer, AR-positive triple-negative www.gtxinc.com
breast cancer
entinostat Syndax Pharmaceuticals hormone receptor (HR)-positive metastatic Phase III

(HDAC inhibitor) Waltham, MA breast cancer www.syndax.com
(see also lung, skin)
etirinotecan pegol (NKTR-102) Nektar Therapeutics metastatic breast cancer (Fast Track) Phase III
(PEGylated irinotecan) San Francisco, CA (see also colorectal, ovarian) www.nektar.com
Faslodex AstraZeneca HR-positive advanced breast cancer (1st-line) Phase III

fulvestrant Wilmington, DE www.astrazeneca.com
ganetespib Synta Pharmaceuticals breast cancer Phase II

(Hsp90 inhibitor) Lexington, MA (see also leukemia, lung, ovarian) www.syntapharma.com
GDC-0810 Genentech/Roche ER-positive HER2-negative breast cancer Phase I

(SERD) South San Francisco, CA www.roche.com
glembatumumab vedotin CellDex Therapeutics triple-negative breast cancer (Fast Track) Phase II
(antibody drug conjugate) Hampton, NJ (see also skin) www.celldex.com
HER2 cancer immunotherapy AlphaVax late-stage breast cancer Phase I/II

(AVX901) Research Triangle Park, NC www.alphavax.com
Breast Cancer
Ibrance Pfizer high-risk early breast cancer, Phase III

palbociclib New York, NY recurrent advanced breast cancer www.pfizer.com
(see also hematological)
IMMU-132 Immunomedics relapsed/refractory triple-negative breast cancer Phase II

(sacituzumab govitecan) Morris Plains, NJ (Fast Track) www.immunomedics.com
(see also other)
indoximod NewLink Genetics metastatic HER2-negative breast cancer Phase II

(IDO pathway inhibitor) Ames, IA (see also brain, prostate) www.newlinkgenetics.com
INO-1400 Inovio Pharmaceuticals breast cancer Phase I

(hTERT immunotherapy) Plymouth Meeting, PA (see also lung, pancreatic) www.inovio.com
interleukin-12 gene therapy OncoSec Medical triple-negative breast cancer Phase II

San Diego, CA (see also head/neck, skin) www.oncosec.com
INXN-2001 ZIOPHARM Oncology breast cancer Phase II

(Ad-RTS-IL-12 gene therapy) Boston, MA (see also brain, skin) www.ziopharm.com
ipatasertib Array BioPharma triple-negative breast cancer Phase II

(Akt inhibitor) Boulder, CO (see also prostate, stomach) www.roche.com
Genentech/Roche
South San Francisco, CA
Jakafi Incyte breast cancer Phase II

ruxolitinib Wilmington, DE (see also colorectal, lung, pancreatic) www.incyte.com
Kadcyla Genentech/Roche HER2-positive breast cancer (adjuvant monotherapy), Phase III

ado-trastuzumab emtansine South San Francisco, CA HER2-positive breast cancer (adjuvant combination www.roche.com
therapy), HER2-positive breast cancer
(neoadjuvant combination therapy)
(see also lung, stomach)
Breast Cancer
Keytruda Merck breast cancer Phase II

pembrolizumab Kenilworth, NJ (see also bladder, head/neck, lung, lymphoma, www.merck.com
stomach)
LEE011 Novartis Pharmaceuticals HR-positive HER2-negative postmenopausal Phase III

(CDK4/6 inhibitor) East Hanover, NJ advanced breast cancer (1st-line) www.novartis.com
(combination therapy)
HR-positive HER2-negative premenopausal Phase II

advanced breast cancer (1st-line) www.novartis.com
HR-positive HER2-negative premenopausal Phase I

advanced breast cancer (1st-/2nd-line) www.novartis.com
lucitanib Clovis Oncology metastatic breast cancer Phase II

(FGFR/VEGFR/PDGFR inhibitor) Boulder, CO (see also lung) www.clovisoncology.com
LY2606368 Eli Lilly metastatic breast cancer Phase II

(Chk1 inhibitor) Indianapolis, IN (see also ovarian) www.lilly.com
Lynparza AstraZeneca germline BRCA-mutated triple-negative breast Phase III

olaparib Wilmington, DE cancer (adjuvant), germline BRCA-mutated www.astrazeneca.com
metastatic breast cancer
(see also ovarian, pancreatic, prostate, stomach)
margetuximab MacroGenics metastatic breast cancer Phase II

(anti-HER2 mAb) Rockville, MD www.macrogenics.com
MEDI-573 MedImmune metastatic breast cancer Phase II

(anti-CD19 mAb) Gaithersburg, MD www.medimmune.com
Breast Cancer
mifepristone Corcept Therapeutics triple-negative breast cancer Phase I

Menlo Park, CA www.corcept.com
MM-302 Merrimack Pharmaceuticals advanced HER2-positive breast cancer Phase II

(HER2-targeted nanotheraputic) Cambridge, MA www.merrimackpharma.com
NeuVax Galena Biopharma node-positive breast cancer Phase III

nelipepimut-S Portland, OR (HER2 IHC 1+/2+) www.galenabiopharma.com
(see also stomach)
node-positive and triple-negative Phase II

breast cancer (HER2 IHC 1+/2+) www.galenabiopharma.com
neoadjuvant node-positive and negative Phase II

breast cancer (HER2 IHC 3+) www.galenabiopharma.com
niraparib TESARO BRCA-positive breast cancer Phase III

(PARP inhibitor) Waltham, MA (see also ovarian, sarcoma) www.tesarobio.com
NK012 Nippon Kayaku breast cancer Phase II

(DNA topoisomerase I inhibitor) Tokyo, Japan (see also colorectal, lung) www.nipponkayaku.co.jp
ONT-10 Oncothyreon breast cancer Phase I

(cancer immunotherapy) Seattle, WA (see also ovarian) www.oncothyreon.com
OPT-822/OPT-821 OBI Pharma metastatic breast cancer Phase II/III

(cancer immunotherapy) Taipei, Taiwan www.obipharma.com
patritumab Daiichi Sankyo breast cancer Phase II

(anti-HER3 antibody) Parsippany, NJ (see also lung) www.dsi.com
Breast Cancer
PB272 Puma Biotechnology breast cancer (adjuvant), metastatic Phase III

(neratinib) Los Angeles, CA breast cancer (combination therapy) www.pumabiotechnology.com
(see also lung)
metastatic breast cancer (combination Phase II

therapy), breast cancer with brain www.pumabiotechnology.com
metastases (combination therapy)
(combination therapy), breast cancer
(neoadjuvant)
Perjeta Genentech/Roche early HER2-positive breast cancer, Phase III

pertuzumab South San Francisco, CA HER2-positive metastatic breast cancer www.roche.com
(2nd-line)
(see also stomach)
PF-05280014 Pfizer metastatic breast cancer Phase III

(trastuzumab biosimilar) New York, NY www.pfizer.com
pictilisib Genentech/Roche ER-positive breast cancer, metastatic Phase II

(PI3K inhibitor) South San Francisco, CA HER2-negative/HR-positive breast cancer www.roche.com
(see also lung)
PLX3397 Plexxikon metastatic breast cancer Phase II

(CSF-1R inhibitor) Berkeley, CA (see also brain, ovarian, skin, other) www.plexxikon.com
PM01183 Pharma Mar metastatic breast cancer Phase II

(marine-derived alkylating agent) Madrid, Spain (see also leukemia, ovarian) www.pharmamar.com
POL6326 Polyphor metastatic breast cancer Phase I

(CXCR4 receptor antagonist) Allschwil, Switzerland (see also hematological) www.polyphor.com
pyrotinib Jiangsu Hengrui Medicine HER2-positive breast cancer Phase I

(tyrosine kinase inhibitor) Jiangsu Province, China (see also stomach) www.hrs.com.cn
Breast Cancer
RAD1901 Radius Health metastatic breast cancer Phase I

(SERM modulator) Waltham, MA www.radiuspharm.com
reparixin Dompe early-stage breast cancer Phase II

(IL-8A/B receptor antagonist) Milan, Italy www.dompe.com
metastatic breast cancer Phase I

www.dompe.com
RG6047 Genentech/Roche ER-positive HER2-negative metastatic breast cancer Phase I

(SERD) South San Francisco, CA www.roche.com
RG7116 Genentech/Roche metastatic breast cancer Phase I

(ERBB-3 receptor antagonist) South San Francisco, CA www.roche.com
RG7446 Genentech/Roche triple-negative breast cancer Phase III

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, kidney, lung, lymphoma, skin) www.roche.com
rucaparib Clovis Oncology breast cancer Phase II

(PARP inhibitor) Boulder, CO (see also ovarian, pancreatic, other) www.clovisoncology.com
seribantumab (MM-121) Merrimack Pharmaceuticals breast cancer Phase II

(ErbB-3 receptor antagonist) Cambridge, MA (see also lung, ovarian) www.merrimackpharma.com
SGN-LIV1A Seattle Genetics relapsed breast cancer Phase I

(antibody drug conjugate) Bothell, WA www.seattlegenetics.com
TAK-228 Takeda Oncology breast cancer Phase II

(mTORC1/2 inhibitor) Cambridge, MA (see also kidney, other) www.takedaoncology.com
talazoparib BioMarin Pharmaceutical metastatic breast cancer Phase III

(PARP inhibitor) Novato, CA (genetically defined) www.bmrn.com
Breast Cancer
taselisib Genentech/Roche ER-positive HER2-negative metastatic Phase III

(PI3K inhibitor) South San Francisco, CA breast cancer www.roche.com
ER-positive HER2-negative breast cancer Phase II

www.roche.com
tesevatinib (KD019) Kadmon Pharmaceuticals HER2-positive metastatic breast cancer Phase I/II
(TKI inhibitor) Warrendale, PA (see also lung) www.kadmon.com
ThermoDox Celsion recurrent breast cancer Phase II

doxorubicin liposomal Lawrenceville, NJ (see also liver) www.celsion.com
TPIV100 TapImmune breast cancer Phase I

(cancer immunotherapy) Seattle, WA www.tapimmune.com
TPIV200 TapImmune breast cancer (combination therapy) Phase I

(folate receptor alpha vaccine) Seattle, WA (see also ovarian) www.tapimmune.com
TRC105 TRACON Pharmaceuticals breast cancer Phase I

(END protein inhibitor) San Diego, CA (see also brain, colorectal, kidney, liver, lung, sarcoma, www.traconpharma.com
other)
trebananib Amgen metastatic breast cancer Phase I

(Ang 1 / Ang 2 inhibitor) Thousand Oaks, CA (see also lung, ovarian) www.amgen.com
vantictumab OncoMed Pharmaceuticals HER2-negative breast cancer (combination therapy) Phase I

(anti-Fzd7) Redwood City, CA (see also lung, pancreatic) www.oncomed.com
veliparib AbbVie BRCA-deficient breast cancer, triple-negative Phase III

(PARP inhibitor) North Chicago, IL breast cancer (neoadjuvant therapy) www.abbvie.com
(see also brain, colorectal, lung, skin)
Breast Cancer
Xgeva Amgen delay of prevention of bone metastases in Phase III

denosumab Thousand Oaks, CA breast cancer www.amgen.com
(see also lung, myeloma)
Xtandi Astellas Pharma US breast cancer Phase II

enzalutamide Northbrook, IL (see also liver, prostate) www.astellas.com
Medivation www.medivation.com
San Francisco, CA
Zytiga Janssen Research & Development metastatic ER-positive HER2 negative Phase II
abiraterone acetate Raritan, NJ breast cancer in post-menopausal women www.janssenrnd.com
Colorectal Cancer
ABP 494 Allergan metastatic colorectal cancer Phase III

(bevacizumab biosimilar) Parsippany, NJ www.amgen.com
Amgen
Thousand Oaks, CA
bavituximab Peregrine Pharmaceuticals rectal cancer Phase I

Tustin, CA (see also breast, lung, skin) www.peregrineinc.com
BBI608 Boston Biomedical colorectal cancer Phase III

(cancer stem cell inhibitor) Cambridge, MA (see also breast, hematological, liver, www.bostonbiomedical.com
lung, ovarian, pancreatic, skin, stomach)
colorectal cancer (combination therapy) Phase III

www.bostonbiomedical.com
Colorectal Cancer
CEA cancer immunotherapy AlphaVax late-stage colorectal cancer Phase I/II

(AVX701) Research Triangle Park, NC www.alphavax.com
Duke University
Durham, NC
CPX-1 Celator Pharmaceuticals colorectal cancer Phase II

(irinotecan/floxuridine liposomal) Ewing, NJ www.celatorpharma.com
CRLX101 Cerulean Pharma non-metastatic rectal cancer Phase II

(nanoparticle drug conjugate) Cambridge, MA (see also kidney, ovarian) www.ceruleanrx.com
E7820 Eisai colorectal cancer Phase II

(integrin alpha2 inhibitor) Woodcliff Lake, NJ www.eisai.com
encapsulated cell therapy Rogosin Institute metastatic colorectal cancer Phase II

New York, NY (see also pancreatic, prostate) www.rogosin.org
Metromedia Bio-Science www.metromediabioscience.com
New York, NY
ensituximab Precision Biologics advanced colorectal cancer Phase II

(neoplasm antigen inhibitor) Dallas, TX (see also pancreatic) www.precision-biologics.com
ETBX-011 Etubics colorectal cancer Phase II

(vector cancer vaccine) Seattle, WA www.etubics.com
etirinotecan pegol (NKTR-102) Nektar Therapeutics colorectal cancer (2nd-line) Phase II completed
(PEGylated irinotecan) San Francisco, CA (see also breast, ovarian) www.nektar.com
GEN 1 Celsion colorectal cancer Phase II

(cancer immunotherapy) Lawrenceville, NJ (see also ovarian) www.celsion.com
imalumab (BAX 069) Baxalta metastatic colorectal cancer Phase II

(MIF inhibitor) Cambridge, MA www.baxalta.com
Colorectal Cancer
Imprime PGG Biothera metastatic colorectal cancer (3rd-line) Phase III

intravenous immunostimulant Eagan, MN (see also leukemia, lung, lymphoma, pancreatic) www.biothera.com
Jakafi Incyte colorectal cancer Phase II

ruxolitinib Wilmington, DE (see also breast, lung, pancreatic) www.incyte.com
labetuzumab-SN-38 Immunomedics metastatic colorectal cancer Phase II

(IMMU-130) Morris Plains, NJ www.immunomedics.com
MGD007 MacroGenics late-stage colorectal cancer Phase I

(gpA33/CD3 bispecific antibody) Rockville, MD www.macrogenics.com
MORAb-004 Eisai colorectal cancer Phase II

(CD248 antigen inhibitor) Woodcliff Lake, NJ (see also sarcoma, skin) www.eisai.com
NK012 Nippon Kayaku colorectal cancer Phase II

(DNA topoisomerase I inhibitor) Tokyo, Japan (see also breast, lung) www.nipponkayaku.co.jp
OncoVAX Vaccinogen stage II colon cancer (Fast Track) Phase III

cancer immunotherapy Frederick, MD www.vaccinogeninc.com
Opdivo Bristol-Myers Squibb microsatellite instability (MSI)-positive colon cancer Phase II

nivolumab Princeton, NJ (see also bladder, brain, head/neck, hematological, www.bms.com
stomach, other)
polyclonal antibody stimulator Cancer Advances colorectal cancer Phase II completed

(G17DT) Durham, NC (see also pancreatic, stomach) www.canceradvancesinc.com
Reolysin Oncolytics Biotech metastatic colorectal cancer Phase I

pelareorp Calgary, Canada (see also brain, head/neck, lung, myeloma, ovarian, www.oncolyticsbiotech.com
other, pancreatic)
Colorectal Cancer
RG7221 Genentech/Roche metastatic colorectal cancer Phase II

(Ang2-VEGF mAb) South San Francisco, CA www.roche.com
RRx-001 EpicentRx metastatic colorectal cancer Phase II

(free radical stimulant) Mountain View, CA (see also liver, lung, lymphoma, other) www.radiorx.com
SM04755 Samumed advanced colorectal cancer Phase I

(Wnt inhibitor) San Diego, CA (see also liver, pancreatic, stomach) www.samumed.com
Stivarga Bayer HealthCare Pharmaceuticals colorectal cancer with resected liver metastases Phase III
regorafenib Whippany, NJ (see also kidney, liver) www.healthcare.bayer.com
Tafinlar Novartis Pharmaceuticals BRAF V600-positive colorectal cancer Phase I/II

dabrafenib East Hanover, NJ (see also lung, skin) www.novartis.com
Mekinist
trametinib
combination
TAS-102 Taiho Oncology colorectal cancer (Fast Track) application submitted

(tipiracil/trifluridine) Princeton, NJ (see also stomach) www.taihooncology.com
TRC105 TRACON Pharmaceuticals colorectal cancer Phase I

(END protein inhibitor) San Diego, CA (see also brain, breast, kidney, liver, lung, www.traconpharma.com
sarcoma, other)
Vargatef Boehringer Ingelheim Pharmaceuticals metastatic colorectal cancer Phase III

nintedanib Ridgefield, CT (see also lung, ovarian) www.boeringer-ingelheim.com
Vectibix Amgen chemo refractory wild-type KRAS exon 2 Phase III

panitumumab Thousand Oaks, CA metastatic colorectal cancer www.amgen.com
veliparib AbbVie metastatic colorectal cancer Phase II

(PARP inhibitor) North Chicago, IL (see also brain, breast, lung, skin) www.abbvie.com
Head and Neck Cancer
Xilonix XBiotech metastatic colorectal cancer (Fast Track) Phase III

IgG1k Mab Austin, TX www.xbiotech.com
Zelboraf Genentech/Roche BRAF mutation-positive metastatic Phase III

vemurafenib South San Francisco, CA colorectal cancer (adjuvant) www.roche.com
Daiichi Sankyo (see also skin, other)
Parsippany, NJ
ACP-196 Acerta Pharma advanced head and neck cancer Phase II

(Btk inhibitor) San Carlos, CA (combination therapy) www.acerta-pharma.com
(see also bladder, hematological, leukemia, lung,
lymphoma, myeloma, pancreatic)
Ad-IL-24 MultiVir head and neck cancer Phase II

(interleukin-24 gene therapy) San Diego, CA www.multivir.com
ADXS-HPV Advaxis head and neck cancer (neoadjuvant) Phase II

(immunotherapy vaccine) Princeton, NJ (see also other) www.advaxis.com
Orphan Drug
metastatic head and neck cancer Phase I/II

(combination therapy) www.advaxis.com
docetaxel injection concentrate, Teikoku Pharma USA head and neck cancer application submitted
non-alcohol formula San Jose, CA (see also breast, lung, prostate, stomach) www.teikokuusa.com
GC4419 Galera Therapeutics head and neck cancer (1st-line) Phase I

(superoxide dismutase modulator) Malvern, PA www.galeratx.com
Gilotrif Boehringer Ingelheim Pharmaceuticals squamous cell carcinoma of the head and neck Phase III
afatinib Ridgefield, CT (see also brain, lung) www.boehringer-ingelheim.com
GL-0817 Gliknik squamous cell cancer of the oral cavity Phase II

(cancer immunotherapy) Baltimore, MD www.gliknik.com
Orphan Drug
GL-ONC1 Genelux head and neck cancer Phase I

(oncolytic virus immunomodulator) San Diego, CA (see also lung, other) www.genelux.com
HF10 Takara Bio head and neck cancer Phase I

(oncolytic virus immunomodulator) Shiga, Japan (see also skin) www.takara-bio.com
INO-3112 Inovio Pharmaceuticals head and neck cancer caused by HPV Phase I/II
(cancer immunotherapy) Plymouth Meeting, PA types 16 and 18 www.inovio.com
(see also other)
interleukin-12 gene therapy OncoSec Medical metastatic head and neck cancer Phase II
San Diego, CA (see also breast, skin) www.oncosec.com
IRX-2 IRX Therapeutics head and neck cancer Phase II

(immunostimulant) New York, NY www.irxtherapeutics.com
Keytruda Merck head and neck cancer Phase III

pembrolizumab Kenilworth, NJ (see also bladder, breast, lung, lymphoma, www.merck.com
stomach)
MEDI4736 MedImmune squamous cell head and neck cancer (2nd-line) Phase III
(anti-PD-L1 mAb) Gaithersburg, MD (see also lung, solid tumors) www.medimmune.com
MGA271 Macrogenics squamous cell cancer of the head and neck Phase I
(CD276 protein inhibitor) Rockville, MD (combination therapy) www.macrogenics.com
(see also lung, skin)
Multikine CEL-SCI head and neck cancer (1st-line) Phase III

leukocyte interleukin injection Vienna, VA www.cel-sci.com
motolimod VentiRx Pharmaceuticals head and neck cancer Phase II

(TLR8 agonist immunotherapy) Seattle, WA (see also ovarian) www.ventirx.com
Opdivo Bristol-Myers Squibb head and neck cancer (2nd-line) Phase III
nivolumab Princeton, NJ (see also bladder, brain, colorectal, hematological, www.bms.com
stomach, other)
Reolysin Oncolytics Biotech platinum-refractory head and neck cancer Phase III
pelareorp Calgary, Canada (see also brain, colorectal, lung, myeloma, www.oncolyticsbiotech.com
ovarian, other, pancreatic)
RM-1929 Aspyrian Therapeutics recurrent head and neck cancer Phase I

(EGFR antagonist) San Diego, CA www.aspyriantherapeutics.com
selinexor (oral) Karyopharm Therapeutics head and neck squamous cell carcinoma Phase II
(XPO1 antagonist) Newton, MA (see also brain, hematological, leukemia, lymphoma, www.karyopharm.com
myeloma, prostate, sarcoma, other)
Hematological Malignancies
ACP-196 Acerta Pharma B-cell malignancies (combination therapy) Phase I/II

(Btk inhibitor) San Carlos, CA (see also bladder, head/neck, leukemia, lung, www.acerta-pharma.com
lymphoma, myeloma, pancreatic)
ALT-803 Altor BioScience hematological malignancies Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also bladder, myeloma, skin) www.altorbioscience.com
AMG 319 Amgen hematological malignancies Phase I

(PI3K-delta inhibitor) Thousand Oaks, CA www.amgen.com
AMG 900 Amgen hematological malignancies Phase I

(aurora kinase inhibitor) Thousand Oaks, CA (see also solid tumors) www.amgen.com
anti-LAG3 Bristol-Myers Squibb hematological malignancies Phase I

APTO-253 Aptose Biosciences relapsed/refractory blood cancers Phase I

(MTF-1 inhibitor) San Diego, CA www.aptose.com
AR-42 Arno Therapeutics hematological malignancies Phase I/II

(pan-DAC inhibitor) Flemington, NJ (see also solid tumors) www.arnothera.com
Aranesp Amgen low-risk myelodysplastic syndromes Phase III

darbepoetin alfa Thousand Oaks, CA www.amgen.com
ASB183 Novartis Pharmaceuticals hematological malignancies Phase I

East Hanover, NJ (see also solid tumors) www.novartis.com
ASTX727 Astex Pharmaceuticals myelodysplastic syndromes Phase I

DNA methylation inhibitor/ Pleasanton, CA www.astx.com
nucleoside deaminase inhibitor)
AZD9150 AstraZeneca hematological malignancies Phase I

(STAT3 inhibitor) Wilmington, DE www.astrazeneca.com
Isis Pharmaceuticals www.isispharm.com
Carlsbad, CA
BBI608 Boston Biomedical hematological malignancies Phase I

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, liver, www.bostonbiomedical.com
BB-MPI-03 Benovus Bio myelodysplastic syndromes Phase I

(multi-peptide immunotherapy) Atlanta, GA (see also leukemia, myeloma) www.benovusbio.com
BI 836858 Boehringer Ingelheim Pharmaceuticals myelodysplastic syndromes Phase I/II

Ridgefield, CT (see also leukemia) www.boehringer-ingelheim.com
birinapant TetraLogic Pharmaceuticals myelodysplastic syndromes Phase II

(apoptosis stimulator) Malvern, PA (see also lymphoma, ovarian) www.tetralogicpharma.com
BP-100-1-01 Bio-Path Holdings myelodysplastic syndromes Phase I

(liposomal Grb 2) Houston, TX (see also leukemia) www.biopathholdings.com
BPX-501 Bellicum Pharmaceuticals adjunct T-cell therapy following bone marrow Phase I/II
(T-cell replacement therapy) Houston, TX transplantation in hematological malignancies www.bellicum.com
brontictuzumab OncoMed Pharmaceuticals hematological malignancies Phase I

(NOTCH-1 inhibitor) Redwood City, CA (see also solid tumors) www.oncomed.com
BVD-523 BioMed Valley Discoveries myelodysplastic syndromes Phase I/II

(ERK 1/2 kinase inhibitor) Kansas City, MO (see also leukemia, solid tumors) www.biomed-valley.com
CB-839 Calithera Biosciences hematological malignancies Phase I

(glutaminase inhibitor) South San Francisco, CA (see also solid tumors) www.calithera.com
CC-486 Celgene myelodysplastic syndromes (lower risk) Phase III

(DNA methylation inhibitor) Summit, NJ (see also breast, leukemia, lung, lymphoma, other) www.celgene.com
post hypomethylating agent (HMA) failure in Phase II

myelodysplastic syndromes www.celgene.com
CDX-301 Celldex Therapeutics stem cell transplantation in hematological Phase II

(Fms-like tyrosine kinase 3 ligand) Hampton, NJ malignancies www.celldex.com
(see also lymphoma)
CM-CS1 Celyad hematological malignancies Phase I

(NKG2D CAR T-cell therapy) Rochester, MN www.celyad.com
CPI-0610 Constellation Pharmaceuticals myelodysplastic syndromes, Phase I

(BET inhibitor) Cambridge, MA myeloproliferative disorders www.constellationpharma.com
(see also leukemia, lymphoma, myeloma)
DCR-MYC Dicerna Pharmaceuticals hematological malignancies Phase I

(c-myc inhibitor) Watertown, MA (see also liver) www.dicerna.com
duvelisib AbbVie advanced hematological malignancies Phase I

(PI3K inhibitor) North Chicago, IL (see also leukemia, lymphoma) www.abbvie.com
Infinity Pharmaceuticals www.infi.com
Cambridge, MA
E6201 Strategia Therapeutics hematological malignancies Phase I/II

(MEK-1/Flt3 dual inhibitor) Boston, MA www.strategiarx.com
entospletinib Gilead Sciences hematological malignancies Phase II

(Syk inhibitor) Foster City, CA www.gilead.com
evofosfamide (TH-302) EMD Serono hematological malignancies Phase I

(hypoxia-activated prodrug) Rockland, MA (see also brain, lung, pancreatic, sarcoma, skin) www.emdserono.com
Threshold Pharmaceuticals www.thresholdpharm.com
FF-10501 Strategia Therapeutics hematological malignancies Phase I/II

(cell differentiation stimulant) Boston, MA www.strategiarx.com
FUJIFILM Pharmaceuticals USA
Boston, MA
glasdegib (PF-04449913) Pfizer myelodysplastic syndromes Phase II

(SMO [smoothened] antagonist) New York, NY (see also leukemia) www.pfizer.com
GS-4059 Gilead Sciences B-cell malignancies Phase I

(BTK inhibitor) Foster City, CA www.gilead.com
GS-9901 Gilead Sciences hematological malignancies Phase I

(PI3K delta inhibitor) Foster City, CA www.gilead.com
HDM201 Novartis Pharmaceuticals hematological malignancies Phase I

(tumor suppressor protein East Hanover, NJ (see also sarcoma, solid tumors) www.novartis.com
p53 modulator)
HSC835 Novartis Pharmaceuticals hematological malignancies in single Phase II

(stem cell therapy) East Hanover, NJ umbilical cord blood transplantation www.novartis.com
Ibrance Pfizer hematological malignancies Phase I

palbociclib New York, NY (see also breast) www.pfizer.com
idasanutlin Genentech/Roche hematological malignancies Phase I

(MDM2 antagonist) South San Francisco, CA (see also solid tumors) www.roche.com
imetelstat Janssen Research & Development myelofibrosis Phase II

Raritan, NJ www.janssenrnd.com
INCB40093 Incyte B-cell malignancies Phase I/II

(PI3K-delta inhibitor) Wilmington, DE www.incyte.com
INCB52793 Incyte hematological malignancies Phase I/II

(JAK1 inhibitor) Wilmington, DE www.incyte.com
INCB54329 Incyte hematological malignancies Phase I

(BRD inhibitor) Wilmington, DE www.incyte.com
JNJ-64052781 Janssen Research & Development hematological malignancies Phase I

(CD19 antigen modulator) Raritan, NJ www.janssenrnd.com
JTCR016 Juno Therapeutics myelodysplastic syndromes Phase I/II

(T lymphocyte immunotherapy) Seattle, WA (see also leukemia) www.junotherapeutics.com
KB004 KaloBios Pharmaceuticals EphA3-positive hematological Phase II

(EphA3 kinase inhibitor) South San Francisco, CA malignancies www.kalobios.com
KiroVAX-001 Kiromic hematological malignancies Phase I

(dendritic cell vaccine) Houston, TX www.kiromic.com
luspatercept (ACE-536) Acceleron Pharma myelodysplastic syndromes Phase II

(TGF- protein super family Cambridge, MA www.acceleronpharma.com
inhibitor) Celgene www.celgene.com
Orphan Drug Summit, NJ
MEDI-551 + rituximab MedImmune hematological malignancies Phase I

(anti-CD19 mAb/anti-CD20 mAb) Gaithersburg, MD www.medimmune.com
MK-8628 Merck hematological malignancies Phase II

(BRD-2/3/4 inhibitor) Kenilworth, NJ www.merck.com
mocetinostat Mirati Therapeutics myelodysplastic syndromes Phase II

(HDAC inhibitor) San Diego, CA (see also bladder, lymphoma) www.mirati.com
Orphan Drug
momelotinib Gilead Sciences myelofibrosis Phase III

(JAK inhibitor) Foster City, CA (see also pancreatic) www.gilead.com
Orphan Drug
MRX34 Mirna Therapeutics hematological malignancies Phase I

(liposome-encapsulated Austin, TX (see also liver) www.mirnarx.com
miR-34 mimic)
NiCord Gamida Cell hematological malignancies Phase I/II

cord blood stem cell therapy Jerusalem, Israel www.gamida-cell.com
Orphan Drug
Opdivo Bristol-Myers Squibb hematological malignancies Phase I

nivolumab Princeton, NJ (see also bladder, brain, colorectal, head/neck, kidney, www.bms.com
liver, lung, lymphoma, skin, solid tumors, stomach, other)
oprozomib Onyx Pharmaceuticals Waldenstrom's macroglobulinemia (monotherapy) Phase II

(proteasome inhibitor) South San Francisco, CA (see also myeloma, solid tumors) www.onyx.com
Orphan Drug
hematological malignancies Phase I

(combination therapy) www.onyx.com
OTX015 Merck hematological malignancies Phase I

(BET inhibitor) Kenilworth, NJ (see also solid tumors) ww.merck.com
OXi4503 OxiGENE myelodysplastic syndromes Phase I

(vascular disrupting agent) South San Francisco, CA (see also leukemia) www.oxigene.com
PAC-1 Vanquish Oncology hematological malignancies Phase I

(procaspase activating compound-1) Champaign, IL (see also solid tumors) www.vanquishoncology.com
pacritinib Baxalta myelofibrosis (Fast Track) Phase III

(JAK2/FLT3 dual inhibitor) Cambridge, MA (see also leukemia) www.Baxalta.com
PIM447 Novartis Pharmaceuticals myelodysplastic syndromes Phase I

(proto oncogene protein c East Hanover, NJ (see also leukemia, myeloma) www.novartis.com
pim-1 inhibitor)
POL6326 Polyphor stem cell mobilization in hematological malignancies Phase I

(CXCR4 receptor antagonist) Allschwil, Switzerland (see also breast) www.polyphor.com
pracinostat MEI Pharma myelodysplastic syndromes (1st-line), Phase II

(HDAC inhibitor) San Diego, CA refractory myelodysplastic syndromes www.meipharma.com
(see also leukemia)
PRM-151 Promedior myelofibrosis (Fast Track) Phase II

(rhPTX-1 for injection) Lexington, MA www.promedior.com
Orphan Drug
Promacta Novartis Pharmaceuticals myelodysplastic syndromes Phase II

eltrombopag East Hanover, NJ www.novartis.com
Revlimid Celgene myelodysplastic syndromes (non-deletion 5q) Phase III

lenalidomide Summit, NJ (see also leukemia, lymphoma, myeloma) www.celgene.com
Orphan Drug
rexlemestrocel-L Mesoblast for bone marrow regeneration in patients with Phase III
(allogeneic autologous New York, NY hematological malignancies undergoing bone www.mesoblast.com
mesenchymal precursor cells) marrow transplantation
Orphan Drug
rigosertib Onconova Therapeutics post-HMR high-risk myelodysplastic syndromes Phase III

(PI3K/Plk1 inhibitor) Newtown, PA (see also leukemia) www.onconova.com
Orphan Drug
high-risk myelodysplastic syndromes Phase II

(1st-line) (combination therapy), www.onconova.com
low-risk myelodysplastic syndromes (1st-line)
RP-323 Rich Pharmaceuticals myelodysplastic syndromes Phase II

(tetradecanoylphorbol acetate) Beverly Hills, CA (see also leukemia) www.richpharmaceuticals.com
sapacitabine Cyclacel Pharmaceuticals myelodysplastic syndromes Phase II

(DNA-directed DNA polymerase Berkeley Heights, NJ (see also leukemia, lung) www.cyclacel.com
inhibitor)
Orphan Drug
selinexor (oral) Karyopharm Therapeutics Richter's transformation Phase III

(XPO1 antagonist) Newton, MA (see also brain, head/neck, leukemia, lymphoma, www.karyopharm.com
myeloma, prostate, sarcoma, other)
SGI-110 Astex Pharmaceuticals myelodysplastic syndromes Phase II

(DNMT inhibitor) Pleasanton, CA (see also leukemia, liver, ovarian) www.astx.com
SL-401 Stemline Therapeutics blastic plasmacytoid dendritic cell neoplasm, Phase I/II
(IL-3R inhibitor) New York, NY advanced high risk myeloproliferative neoplasm www.stemline.com
(see also leukemia)
StemEx Gamida Cell-Teva Joint Venture hematological malignancies Phase III

carlecortemcel-L Jerusalem, Israel (Fast Track) www.gamida-cell.com
TAK-659 Takeda Oncology hematological malignancies Phase I

(SYK kinase inhibitor) Cambridge, MA (see also solid tumors) www.takedaoncology.com
TEN-010 Tensha Therapeutics myelodysplastic syndromes Phase I

(BET inhibitor) Cambridge, MA (see also leukemia, solid tumors) www.tenshatherapeutics.com
TGR-1202 TG Therapeutics hematological malignancies Phase I

(PI3K inhibitor) New York, NY www.tgtherapeutics.com
tosedostat CTI BioPharma myelodysplastic syndromes Phase II

(aminopeptidase inhibitor) Seattle, WA (see also leukemia) www.ctibiopharma.com
TZ101 Targazyme cord blood stem cell transplantation Phase I/II

(human recombinant enzyme) San Antonio, TX in hematological malignancies www.targazyme.com
ulocuplumab Bristol-Myers Squibb hematological malignancies Phase I

(anti-CXCR4) Princeton, NJ www.bms.com
urelumab Bristol-Myers Squibb hematological malignancies Phase I

Princeton, NJ (see also solid tumors) www.bms.com
urelumab + Bristol-Myers Squibb hematological malignancies Phase I

Opdivo nivolumab Princeton, NJ (see also solid tumors) www.bms.com
varlilumab Celldex Therapeutics hematological malignancies Phase I

(CD27 antigen inhibitor) Hampton, NJ (see also kidney, skin) www.celldex.com
venetoclax AbbVie hematological malignancies Phase I

(Bcl-2 inhibitor) North Chicago, IL (see also leukemia, lymphoma) www.abbvie.com
Genentech/Roche www.roche.com
WT-1 cancer vaccine SELLAS Life Sciences hematological malignancies Phase II

Zug, Switzerland www.sellaslifesciences.com
WT2725 Sunovion Pharmaceuticals hematological malignancies Phase I

(cancer immunotherapy) Marlborough, MA (see also solid tumors) www.sunovion.com
Kidney Cancer
AGS-003 Argos Therapeutics metastatic renal cell carcinoma Phase III

(personalized dendritic Durham, NC (combination therapy) (Fast Track) www.argostherapeutics.com
cell-based vaccine)
metastatic renal cell carcinoma Phase II

(monotherapy) www.argostherapeutics.com
AGS-16C3F Agensys kidney cancer Phase I

Astellas Pharma www.astellas.com
Tokyo, Japan
AMG 172 Amgen kidney cancer Phase I

(antibody drug conjugate) Thousand Oaks, CA www.amgen.com
Archexin Rexahn Pharmaceuticals metastatic renal cell carcinoma Phase II

Akt1 inhibitor Rockville, MD www.rexahn.com
Orphan Drug
BNC105 Bionomics renal cell carcinoma Phase II

(vascular disrupting agent) Thebarton, Australia (see also ovarian) www.bionomics.com.au
Cometriq Exelixis renal cell carcinoma (Fast Track) Phase III

cabozantinib South San Francisco, CA (see also brain, liver) www.exelixis.com
Kidney Cancer
CRLX101 Cerulean Pharma relapsed renal cell carcinoma Phase II

(nanoparticle drug conjugate) Cambridge, MA (see also colorectal, ovarian) www.ceruleanrx.com
dalantercept Acceleron Pharma renal cell carcinoma Phase II

(ALK1 antagonist) Cambridge, MA (see also liver) www.acceleronpharma.com
HyperAcute Renal NewLink Genetics metastatic renal cancer Phase I

renal cancer immunotherapy vaccine Ames, IA www.newlinkgenetics.com
IMA901 immatics Biotechnologies renal cancer Phase III

(multiple tumor-associated Tuebingen, Germany www.immatics.com
peptides)
Inlyta Pfizer renal cell carcinoma Phase III

axitinib New York, NY (see also solid tumors) www.pfizer.com
Orphan Drug
Lenvima Eisai renal cell carcinoma Phase I/II

lenvatinib Woodcliff Lake, NJ (see also liver, lung, skin, other, solid tumors) www.eisai.com
LY2510924 Eli Lilly clear-cell renal cell carcinoma Phase II

(CXCR4 peptide antagonist) Indianapolis, IN (see also lung) www.lilly.com
Nexavar Bayer HealthCare Pharmaceuticals renal cell carcinoma (adjuvant) Phase III
sorafenib Whippany, NJ (see also other) www.healthcare.bayer.com
OBP-801 Oncolys BioPharma recurrent renal cancer Phase I

(HDAC inhibitor) Tokyo, Japan www.oncolys.com
Opdivo Bristol-Myers Squibb renal cell carcinoma (2nd/3rd-line) Phase III

nivolumab Princeton, NJ (see also bladder, brain, colorectal, head/neck, www.bms.com
hematological, liver, lung, lymphoma, skin,
solid tumors, stomach, other)
Kidney Cancer
Opdivo nivolumab + Bristol-Myers Squibb renal cell carcinoma (1st-line) Phase III
Yervoy ipilimumab Princeton, NJ (see also lung, skin, solid tumors) www.bms.com
pexastimogene devacirepvec SillaJen Biotherapeutics treatment refractory kidney cancer Phase II

(genetically-engineered oncolytic San Francisco, CA (see also liver) www.sillajen.com
vaccinia virus)
PT-2385 Peloton Therapeutics clear cell renal cell carcinoma Phase I

(HIF-2 inhibitor) Dallas, TX www.pelotontherapeutics.com
RG7446 Genentech/Roche renal cell carcinoma Phase III

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, breast, lung, lymphoma, skin) www.roche.com
savolitinib/volitinib AstraZeneca papillary renal cell carcinoma Phase II

(MET tyrosine kinase inhibitor) Wilmington, DE www.astrazeneca.com
SGN-CD70A Seattle Genetics renal cell carcinoma Phase I

(antibody drug conjugate) Bothell, WA (see also lymphoma) www.seattlegenetics.com
sonepcizumab Lpath renal cell carcinoma Phase II

(anti-sphingosine-1-phosphate San Diego, CA www.lpath.com
mAb)
Stivarga Bayer HealthCare Pharmaceuticals renal cell carcinoma Phase II

regorafenib Whippany, NJ (see also colorectal, liver) www.healthcare.bayer.com
Sutent Pfizer renal cell carcinoma (adjuvant) Phase III

sunitinib New York, NY www.pfizer.com
TAK-228 Takeda Oncology renal cancer Phase II

(mTORC1/2 inhibitor) Cambridge, MA (see also breast, other) www.takedaoncology.com
Kidney Cancer
TRC105 TRACON Pharmaceuticals renal cell carcinoma Phase II

(END protein inhibitor) San Diego, CA (see also brain, breast, colorectal, liver, lung, www.traconpharma.com
sarcoma, other)
TVI-Kidney-1 TVAX Biomedical kidney cancer Phase II

(personalized cancer Lenexa, KS (see also brain) www.tvaxbiomedical.com
immunotherapy)
varlilumab Celldex Therapeutics metastatic clear cell renal cell carcinoma Phase I/II
(CD27 antigen inhibitor) Hampton, NJ (combination therapy) www.celldex.com
(see also hematological, skin)
Votrient Novartis Pharmaceuticals renal cell carcinoma (adjuvant) Phase III

pazopanib East Hanover, NJ www.novartis.com
Leukemia
6 peptide Angstrom Pharmaceuticals chronic lymphocytic leukemia (CLL), Phase II

(CD44 antigen stimulant) Solana Beach, CA small lymphocytic leukemia www.angstrominc.com
ABL001 Novartis Pharmaceuticals chromic myeloid leukemia (CML) Phase I

(Bcr-abl tyrosine kinase inhibitor) East Hanover, NJ www.novartis.com
Leukemia
ACP-196 Acerta Pharma CLL Phase III

(Btk inhibitor) San Carlos, CA (see also bladder, head/neck, hematological, www.acerta-pharma.com
lung, lymphoma, myeloma, pancreatic)
relapsed/refractory and treatment nave Phase II

deletion 17p CLL www.acerta-pharma.com
CLL (combination therapy) Phase I

www.acerta-pharma.com
ACP-319 Acerta Pharma CLL (combination therapy) Phase I/II

(Btk inhibitor) San Carlos, CA (see also lymphoma) www.acerta-pharma.com
AG-120 Agios Pharmaceuticals acute myeloid leukemia (AML) Phase I

(IDH1 inhibitor) Cambridge, MA (see also brain, solid tumors) www.agios.com
Summit, NJ
AG-221 Agios Pharmaceuticals AML Phase I

(IDH2 inhibitor) Cambridge, MA (see also solid tumors) www.agios.com
Orphan Drug Celgene www.celgene.com
Summit, NJ
alvocidib Tolero Pharmaceuticals AML (1st-line) Phase III

(angiogenesis inhibitor) Lehi, UT www.toleropharmaceuticals.com
Orphan Drug
relapsed/refractory AML Phase II

www.toleropharmaceuticals.com
AMG 232 Amgen AML Phase I

(MDM2 inhibitor) Thousand Oaks, CA (see also myeloma, skin, solid tumors) www.amgen.com
Leukemia
Arzerra Novartis Pharmaceuticals CLL (maintenance therapy), CLL (relapse) Phase III
ofatumumab East Hanover, NJ (see also lymphoma) www.novartis.com
Orphan Drug
ASP2215 Astellas Pharma US AML Phase III

(FLT3/AXL inhibitor) Northbrook, IL (see also lung) www.astellas.com
AST-VAC1 Asterias Biotherapeutics AML Phase II completed

(telomerase-based cancer vaccine) Menlo Park, CA www.asterias.com
ATTCK20 Unum Therapeutics CLL Phase I

(viral-ACTR+anti-CD20) Cambridge, MA (see also lymphoma) www.unumrx.com
BAY1143572 Bayer HealthCare Pharmaceuticals acute leukemia Phase I

Whippany, NJ (see also other) www.healthcare.bayer.com
BB-MPI-03 Benovus Bio AML Phase I

(multi-peptide immunotherapy) Atlanta, GA (see also hematological, myeloma) www.benovusbio.com
bendamustine ready-to-dilute Eagle Pharmaceuticals CLL application submitted

liquid formulation Woodcliff Lake, NJ (see also lymphoma, solid tumors) www.eagleus.com
Orphan Drug
BI 836826 Boehringer Ingelheim Pharmaceuticals CLL Phase I

Ridgefield, CT www.boehringer-ingelheim.com
BI 836858 Boehringer Ingelheim Pharmaceuticals relapsed/refractory AML Phase I

Ridgefield, CT (see also hematological) www.boehringer-ingelheim.com
BL-8040 BioLineRx AML (combination therapy) Phase II

(CXCR4 receptor antagonist) Jerusalem, Israel www.biolinerx.com
Orphan Drug
Leukemia
Blincyto Amgen relapsed/refractory acute lymphoblastic Phase III

blinatumomab Thousand Oaks, CA leukemia (ALL) in adults www.amgen.com
(see also lymphoma)
relapsed/refractory Philadelphia Phase II

chromosome positive (Ph+) ALL in adults, www.amgen.com
minimal residual ALL in adults
Bosulif Pfizer chronic myeloid leukemia (CML) (1st-line) Phase III

bosutinib New York, NY www.pfizer.com
Orphan Drug
BP-100-1-01 Bio-Path Holdings AML Phase II

(liposomal Grb 2) Houston, TX (see also hematological) www.biopathholdings.com
Orphan Drug
ALL, CML Phase I

www.biopathholdings.com
BVD-523 BioMed Valley Discoveries AML Phase I/II

(ERK 1/2 kinase inhibitor) Kansas City, MO (see also hematological, solid tumors) www.biomed-valley.com
calaspargase pegol Baxalta ALL Phase III

Orphan Drug Cambridge, MA www.baxalta.com
CC-122 Celgene CLL Phase I

(pleiotropic pathway modifier) Summit, NJ (see also brain, liver, lymphoma) www.celgene.com
CC-292 Celgene CLL (combination therapy) Phase I

(Btk inhibitor) Summit, NJ (see also lymphoma) www.celgene.com
CC-486 Celgene post-induction AML maintenance Phase III

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, lung, www.celgene.com
lymphoma, other)
Leukemia
cerdulatinib Portola Pharmaceuticals CLL Phase II

(dual Syk-JAK inhibitor) South San Francisco, CA (see also lymphoma) www.portola.com
CNDO-109 Fortress Biotech AML Phase I/II

(natural killer cell stimulant) New York, NY www.fortressbiotech.com
Orphan Drug
CPI-0610 Constellation Pharmaceuticals leukemia Phase I

(BET inhibitor) Cambridge, MA (see also hematological, lymphoma, myeloma) www.constellationpharma.com
CPX-351 Celator Pharmaceuticals acute AML (Fast Track) Phase II

(cytarabine/daunorubicin) Ewing, NJ www.celatorpharma.com
Orphan Drug
crenolanib AROG Pharmaceuticals relapsed/refractory AML Phase III

(PDGFR inhibitor) Dallas, TX (see also brain, lung, stomach) www.arogpharma.com
newly-diagnosed AML, maintenance therapy Phase II

after bone marrow transplantation in AML www.arogpharma.com
AML (combination therapy) Phase I

www.arogpharma.com
CTL019 Novartis Pharmaceuticals ALL (Breakthrough Therapy) Phase II

(CAR immunotherapy) East Hanover, NJ (see also lymphoma) www.novartis.com
CWP232291 JW Pharmaceutical AML Phase I

(Wnt signaling pathway inhibitor) Seoul, South Korea
CX-01 Cantex Pharmaceuticals AML Phase II

(O-desulfated heparin intravenous) Weston, FL (see also lung, solid tumors) www.cantex.com
Leukemia
DFP-10917 Delta-Fly Pharma ALL, AML Phase I/II

(cell cycle inhibitor) Tokushima, Japan
duvelisib AbbVie relapsed/refractory CLL Phase III

(PI3K inhibitor) North Chicago, IL (see also hematological, lymphoma) www.abbvie.com
Orphan Drug Infinity Pharmaceuticals www.infi.com
Cambridge, MA
relapsed/refractory CLL previously Phase I

treated with a BTK inhibitor therapy www.abbvie.com
www.infi.com
EPZ-5676 Celgene ALL and AML with altered MLL gene Phase I
(DOT1L inhibitor) Summit, NJ www.celgene.com
Orphan Drug Epizyme www.epizyme.com
Cambridge, MA
ERY-ASP ERYTECH Pharma ALL (adults) Phase I/II

(asparaginase pegol) Lyon, France www.erytech.com
Orphan Drug
ganetespib Synta Pharmaceuticals AML Phase II

(Hsp90 inhibitor) Lexington, MA (see also breast, lung, ovarian) www.syntapharma.com
glasdegib (PF-04449913) Pfizer AML Phase II

(SMO [smoothened] antagonist) New York, NY (see also hematological) www.pfizer.com
GMI-1271 GlycoMimetics AML Phase I

(E-selectin antagonist) Gaithersburg, MD www.glycomimetics.com
GO-203-2c Genus Oncology relapsed/refractory AML Phase I/II

(MUC1 inhibitor) Vernon Hills, IL www.genusoncology.com
Leukemia
HSV-Tk MolMed high risk acute leukemia Phase III

(thymidine kinase cell therapy) Milan, Italy www.molmed.com
Orphan Drug
Iclusig ARAID Pharmaceuticals Philadelphia chromosome-positive ALL Phase II

ponatinib Cambridge, MA (Ph+ ALL) www.ariad.com
Orphan Drug (see also stomach)
IGN523 Igenica AML Phase I

(antibody drug conjugate) Burlingame, CA www.igenica.com
Imbruvica Janssen Research & Development relapsed/refractory CLL (combination therapy), Phase III
ibrutinib Raritan, NJ treatment nave CLL, CLL (1st-line) (combination therapy) www.janssenrnd.com
Orphan Drug (see also lymphoma)
IMGN529 ImmunoGen CLL Phase I

(CD37 protein inhibitor) Waltham, MA (see also lymphoma) www.immunogen.com
IMMU-114 Immunomedics CLL Phase I

(humanized anti-HLA-DR) Morris Plains, NJ (see also lymphoma) www.immunomedics.com
Imprime PGG Biothera high-risk CLL (1st-line) Phase II

intravenous immunostimulant Eagan, MN (see also colorectal, lung, lymphoma, pancreatic) www.biothera.com
inotuzumab ozogamicin Pfizer acute lymphoblastic leukemia (ALL) Phase III

(CD22-targeted cytotoxic agent) New York, NY www.pfizer.com
Orphan Drug
Iomab-B Actinium Pharmaceuticals hematopoietic stem cell transplantation in ALL Phase II

BC8-I-131 construct New York, NY www.actiniumpharma.com
JCAR014 Juno Therapeutics acute ALL, refractory CLL Phase I/II

(T lymphocyte immunotherapy) Seattle, WA (see also lymphoma) www.junotherapeutics.com
Leukemia
JCAR015 Juno Therapeutics B-cell ALL Phase I/II

(T lymphocyte immunotherapy) Seattle, WA www.junotherapeutics.com
Orphan Drug
JCAR017 Juno Therapeutics leukemia Phase I/II

JCAR018 Juno Therapeutics ALL Phase I

(T lymphocyte immunotherapy) Seattle, WA (see also lymphoma) www.junotherapeutics.com
JNJ-56022473 CSL AML Phase I

(anti-CD123 mAb) Victoria, Australia www.janssenrnd.com
Janssen Research & Development
Raritan, NJ
JTCR016 Juno Therapeutics ALL, CML Phase I/II

(T lymphocyte immunotherapy) Seattle, WA (see also hematological) www.junotherapeutics.com
KX01 Kinex Pharmaceuticals AML Phase I completed

(non-ATP competitive Sre Buffalo, NY www.kinexpharma.com
kinase inhibitor)
Kyprolis Onyx Pharmaceuticals pediatric ALL (combination therapy) Phase I/II

carfilzomib South San Francisco, CA (see also lung, myeloma) www.onyx.com
lintuzumab Ac-225 Actinium Pharmaceuticals AML (1st-line) Phase I/II

New York, NY www.actiniumpharma.com
Marqibo Spectrum Pharmaceuticals elderly Ph-negative ALL (1st-line) Phase III

vinCRIStine sulfate LIPOSOME Henderson, NV (Fast Track) www.sppirx.com
injection (see also lymphoma)
Orphan Drug
Leukemia
MEDI-551 MedImmune CLL Phase II

(anti-CD19 mAb) Gaithersburg, MD (see also lymphoma) www.medimmune.com
MGD006 MacoGenics AML Phase I

(CD123/CD3 bispecific antibody) Rockville, MD www.macrogenics.com
milatuzumab-doxorubicin conjugate Immunomedics ALL Phase I/II

(antibody drug conjugate) Morris Plains, NJ (see also lymphoma) www.immunomedics.com
mogamulizumab Kyowa Hakko Kirin adult T-cell leukemia-lymphoma Phase II

(anti-CCR4 antibody) Princeton, NJ (see also lymphoma) www.kyowa-kirin.com
Orphan Drug
MOR208 MorphoSys ALL, CLL Phase II

(CD19 antigen inhibitor) Martinsried, Germany (see also lymphoma) www.morphosys.com
Orphan Drug
moxetumomab pasudotox MedImmune hairy cell leukemia Phase III

(anti-CD22 recombinant Gaithersburg, MD www.medimmune.com
immunotoxin)
ALL (pediatric) Phase II

www.medimmune.com
Odomzo Novartis Pharmaceuticals acute leukemia Phase II

sonidegib East Hanover, NJ (see also brain) www.novartis.com
Oncaspar Baxalta lyophilized ALL Phase III

pegaspargase Cambridge, MA www.baxalta.com
Orphan Drug
AML Phase II
www.baxalta.com
Leukemia
Oncoquest-CLL XEME Biopharma CLL (1st-line) Phase I

personalized cancer vaccine Monmouth Junction, NJ www.xemebiopharma.com
Opdivo nivolumab + Bristol-Myers Squibb CML Phase I

Sprycel dasatinib Princeton, NJ www.bms.com
otlertuzumab Emergent BioSolutions CLL Phase II

(CD37 protein inhibitor) Gaithersburg, MD www.emergentbiosolutions.com
OVI-123 (cordycepin) OncoVista Innovative Therapies TdT-positive leukemia Phase I/II

(RNA synthesis inhibitor) San Antonio, TX www.oncovista.com
Orphan Drug
OXi4503 OxiGENE refractory AML Phase I

(vascular disrupting agent) South San Francisco, CA (see also hematological) www.oxigene.com
Orphan Drug
pacritinib Baxalta AML Phase I

(JAK2/FLT3 dual inhibitor) Cambridge, MA (see also hematological) www.baxalta.com
PIM447 Novartis Pharmaceuticals AML Phase I

(proto oncogene protein c East Hanover, NJ (see also hematological, myeloma) www.novartis.com
pim-1 inhibitor)
PKC412 Novartis Pharmaceuticals AML Phase III

(signal transduction inhibitor) East Hanover, NJ www.novartis.com
Orphan Drug
PM01183 Pharma Mar acute leukemia Phase II

(marine-derived alkylating agent) Madrid, Spain (see also breast, ovarian) www.pharmamar.com
Leukemia
pracinostat MEI Pharma AML (1st-line) Phase II

(HDAC inhibitor) San Diego, CA (see also hematological) www.meipharma.com
Orphan Drug
PRI-724 PRISM Pharma AML, CML Phase I/II

(CBP/beta catenin inhibitor) Tokyo, Japan (see also pancreatic) www.prismbiolabs.com
Qinprezzo Sunesis Pharmaceuticals relapsed/refractory AML (Fast Track) Phase III

vosaroxin South San Francisco, CA www.sunesis.com
Orphan Drug
quizartinib Ambit Biosciences relapsed/refractory AML (Fast Track) Phase III

(FLT3 inhibitor) San Diego, CA www.ambitbio.com
Orphan Drug
REGN1979 Regeneron Pharmaceuticals CLL Phase I

(CD20/CD3 antigen inhibitor) Tarrytown, NY (see also lymphoma) www.regeneron.com
Revlimid Celgene CLL maintenance (2nd-line) Phase III

lenalidomide Summit, NJ (see also hematological, lymphoma, myeloma) www.celgene.com
Orphan Drug
RG6016 Genentech/Roche AML Phase I

(LSD1 inhibitor South San Francisco, CA www.roche.com
RG7775 Genentech/Roche AML Phase I

(proto-oncogene protein c South San Francisco, CA www.roche.com
MDM2 inhibitor)
rigosertib Onconova Therapeutics high-risk AML (1st-line) Phase III

(PI3K/Plk1 inhibitor) Newtown, PA (see also hematological) www.onconova.com
Orphan Drug
Leukemia
RP-323 Rich Pharmaceuticals AML Phase II

(tetradecanoylphorbol acetate) Beverly Hills, CA (see also hematological) www.richpharmaceuticals.com
sapacitabine Cyclacel Pharmaceuticals AML Phase III

(DNA-directed DNA polymerase Berkeley Heights, NJ (see also hematological, lung) www.cyclacel.com
inhibitor)
Orphan Drug
selinexor (oral) Karyopharm Therapeutics AML Phase III

(XPO1 antagonist) Newton, MA (see also brain, head/neck, hematological, lymphoma, www.karyopharm.com
Orphan Drug myeloma, prostate, sarcoma, other)
SG2000 Spirogen AML, CLL Phase I/II

(DNA cross linking agent) London, England
SGI-110 Astex Pharmaceuticals AML Phase III

(DNMT inhibitor) Pleasanton, CA (see also hematological, liver, ovarian) www.astx.com
SGN-CD19A Seattle Genetics relapsed ALL Phase I

(antibody drug conjugate) Bothell, WA (see also lymphoma) www.seattlegenetics.com
SGN-CD33A Seattle Genetics AML (1st-line), relapsed AML Phase I

(antibody drug conjugate) Bothell, WA www.seattlegenetics.com
SL-401 Stemline Therapeutics relapsed/refractory AML Phase I/II

(IL-3R inhibitor) New York, NY (see also hematological) www.stemline.com
Sprycel Bristol-Myers Squibb leukemia (pediatric) Phase II

dasatinib Princeton, NJ www.bms.com
TAK-924 Takeda Oncology AML Phase I

(NEDD 8 activating enzyme Cambridge, MA www.takedaoncology.com
inhibitor)
Leukemia
Tasigna Novartis Pharmaceuticals CML treatment free remission Phase III

nilotinib East Hanover, NJ www.novartis.com
Orphan Drug
ALL (pediatric), CML (pediatric) Phase I/II

www.novartis.com
TEN-010 Tensha Therapeutics AML Phase I

(BET inhibitor) Cambridge, MA (see also hematological, solid tumors) www.tenshatherapeutics.com
TG02 Tragara Pharmaceuticals refractory AML, relapsed CLL Phase I

(CDK inhibitor) Carlsbad, CA (see also myeloma) www.tragarapharma.com
TG-1101 TG Therapeutics CLL (combination therapy) Phase III

(anti-CD20 mAb) New York, NY (see also lymphoma) www.tgtherapeutics.com
Orphan Drug
CLL (monotherapy) Phase I/II

www.tgtherapeutics.com
tosedostat CTI BioPharma AML Phase II

(aminopeptidase inhibitor) Seattle, WA (see also hematological) www.ctibiopharma.com
Orphan Drug
venetoclax AbbVie CLL (1st-line), relapsed/refractory CLL Phase III

(Bcl-2 inhibitor) North Chicago, IL (combination therapy) (Breakthrough Therapy) www.abbvie.com
Genentech/Roche (see also hematological, lymphoma) www.roche.com
AML, relapsed/refractory 17p-deletion CLL Phase II

www.abbvie.com
www.roche.com
volasertib Boehringer Ingelheim Pharmaceuticals AML (Breakthrough Therapy) Phase III

(PLK-1 antagonist) Ridgefield, CT www.boehringer-ingelehim.com
Orphan Drug
Leukemia
WT1-CTL Atara Biotherapeutics AML Phase I

(immunostimulant) South San Francisco, CA (see also myeloma) www.atarabio.com
Zydelig Gilead Sciences CLL (1st-line), relapsed/refractory CLL Phase III

idelalisib Foster City, CA (see also lymphoma) www.gilead.com
Liver Cancer
AD-p53 gene therapy MultiVir liver metastases from colorectal cancer Phase I
San Diego, CA www.multivir.com
ADI-PEG 20 Polaris Pharmaceuticals hepatocellular carcinoma Phase III

(PEG arginine deiminase) San Diego, CA (see also breast, lung, ovarian, pancreatic, www.polarispharma.com
Orphan Drug skin, stomach)
BA-003 Onxeo hepatocellular carcinoma (2nd-line) Phase III

(doxorubicin nanoparticles) Paris, France www.onxeo.com
Orphan Drug
BBI503 Boston Biomedical hepatocellular carcinoma Phase I

(cancer stemness kinase inhibitor) Cambridge, MA (see also ovarian) www.bostonbiomedical.com
BBI608 Boston Biomedical hepatocellular carcinoma Phase I

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, hematological, www.bostonbiomedical.com
CC-122 Celgene hepatocellular carcinoma Phase I

(PPM Pleiotropic pathway modifier) Summit, NJ (see also brain, leukemia, lymphoma) www.celgene.com
CF102 Can-Fite BioPharma metastatic hepatocellular carcinoma Phase II

(A3 adenosine receptor agonist) Petach Tikva, Israel www.canfite.com
Liver Cancer
Cometriq Exelixis advanced hepatocellular carcinoma Phase III

cabozantinib South San Francisco, CA (see also brain, kidney) www.exelixis.com
CX-4945 Senhwa Biosciences cholangiocarcinoma (combination therapy) Phase I/II

(CK2 inhibitor) San Diego, CA www.senhwabiosciences.com
Cyramza Eli Lilly hepatocellular carcinoma Phase III

ramucirumab Indianapolis, IN (see also bladder, lung, stomach) www.lilly.com
Orphan Drug
dalantercept Acceleron Pharma hepatocellular carcinoma Phase I/II

(ALK1 antagonist) Cambridge, MA (see also kidney) www.acceleronpharma.com
DCR-MYC Dicerna Pharmaceuticals hepatocellular carcinoma Phase I/II

(c-myc inhibitor) Watertown, MA (see also hematological) www.dicerna.com
galunisertib Eli Lilly metastatic hepatocellular carcinoma Phase II

(TGF-beta 1 kinase inhibitor) Indianapolis, IN (see also brain, pancreatic) www.lilly.com
ipafricept Bayer HealthCare Pharmaceuticals hepatocellular carcinoma Phase I

(Wnt protein inhibitor) Whippany, NJ (combination therapy) www.healthcare.bayer.com
OncoMed Pharmaceuticals (see also ovarian, pancreatic) www.oncomed.com
Redwood City, CA
Lenvima Eisai hepatocellular carcinoma Phase III

lenvatinib Woodcliff Lake, NJ (see also kidney, lung, skin, other, www.eisai.com
Orphan Drug solid tumors)
melphalan drug delivery system Delcath Systems secondary liver cancer arising from application submitted
(drug-device combination) New York, NY metastatic ocular melanoma www.delcath.com
Orphan Drug
hepatocellular carcinoma, Phase II

intrahepatic cholangiocarcinoma www.delcath.com
Liver Cancer
mipsagargin GenSpera hepatocellular carcinoma Phase II

(thapsigargin analogue) San Antonio, TX (see also brain) www.genspera.com
Orphan Drug
MRX34 Mirna Therapeutics unresectable primary liver cancer, Phase I

(liposome-encapsulated Austin, TX liver metastases from other solid tumors www.mirnarx.com
miR-34 mimic) (see also hematological)
oncolytic virus Omnis Pharmaceuticals hepatocellular carcinoma, liver metastases Phase I

(genetically engineered strain Rochester, MN www.omnispharma.com
of vesicular stomatitis virus)
Opdivo Bristol-Myers Squibb hepatocellular carcinoma Phase I

hematological, kidney, lung, lymphoma, skin,
pexastimogene devacirepvec SillaJen Biotherapeutics advanced primary liver cancer Phase II

(genetically-engineered oncolytic San Francisco, CA (see also kidney) www.sillajen.com
vaccinia virus)
Orphan Drug
PDT with Photofrin Concordia Laboratories unresectable advanced perihilar Phase III
porfimer sodium Toronto, Canada cholangiocarcinoma Bismuth type III/IV www.pinnaclebiologics.com
Orphan Drug Pinnacle Biologics
Chicago, IL
PV-10 Provectus Biopharmaceuticals hepatocellular carcinoma, liver metastases Phase I

(rose bengal disodium) Knoxville, TN (see also skin) www.pvct.com
Orphan Drug
RG7686 Genentech/Roche hepatocellular carcinoma Phase II

(glypican-3 mAb) South San Francisco, CA www.roche.com
Liver Cancer
RRx-001 EpicentRx cholangiocarcinoma Phase II

(free radical stimulant) Mountain View, CA (see also colorectal, lung, lymphoma, other) www.radiorx.com
SGI-110 Astex Pharmaceuticals hepatocellular carcinoma Phase II

(DNMT inhibitor) Pleasanton, CA (see also hematological, leukemia, ovarian) www.astx.com
SM04755 Samumed advanced liver cancer Phase I

(Wnt inhibitor) San Diego, CA (see also colorectal, pancreatic, stomach) www.samumed.com
SPI-1620 Spectrum Pharmaceuticals biliary cancer Phase II

(endothelin B receptor agonist) Henderson, NV (see also lung) www.sppirx.com
Stivarga Bayer HealthCare Pharmaceuticals hepatocellular carcinoma (2nd-line) Phase III

regorafenib Whippany, NJ (see also colorectal, kidney) www.healthcare.bayer.com
tepotinib EMD Serono hepatocellular cancer Phase II

(c-Met kinase inhibitor) Rockland, MA (see also lung) www.emdserono.com
ThermoDox Celsion inoperable/unresectable hepatocellular Phase III

doxorubicin liposomal Lawrenceville, NJ carcinoma (1st-line) (Fast Track) www.celsion.com
Orphan Drug (see also breast)
liver metastases Phase II

www.celsion.com
tivantinib ArQule hepatocellular carcinoma Phase III

(c-Met inhibitor) Woburn, MA www.arqule.com
Daiichi Sankyo www.dsi.com
Parsippany, NJ
TRC105 TRACON Pharmaceuticals hepatocellular carcinoma Phase I

(END protein inhibitor) San Diego, CA (see also brain, breast, colorectal, kidney, lung, www.traconpharma.com
sarcoma, other)
Liver Cancer
VT-122 Vicus Therapeutics hepatocellular carcinoma Phase II

(cancer immunotherapy) Morristown, NJ (see also prostate) www.vicustherapeutics.com
Xtandi Astellas Pharma US hepatocellular carcinoma Phase II

enzalutamide Northbrook, IL (see also breast, prostate) www.astellas.com
Medivation www.medivation.com
San Francisco, CA
Lung Cancer
abemaciclib Eli Lilly non-small-cell lung cancer (NSCLC) Phase III

(CDK 4/6 inhibitor) Indianapolis, IN (see also breast, lymphoma) www.lilly.com
ABP 215 Allergan advanced NSCLC Phase III

(bevacizumab biosimilar) Parsippany, NJ www.amgen.com
Amgen
Thousand Oaks, CA
AC0100MA ACEA Biosciences NSCLC Phase I/II

(epidermal growth factor receptor San Diego, CA www.aceabio.com
inhibitor)
ACP-196 Acerta Pharma advanced NSCLC Phase II

leukemia, lymphoma, myeloma, pancreatic)
ADI-PEG 20 Polaris Pharmaceuticals malignant pleural mesothelioma, NSCLC Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, ovarian, pancreatic, www.polarispharma.com
Orphan Drug skin, stomach)
Afinitor Novartis Pharmaceuticals neuroendocrine lung tumors Phase III

everolimus East Hanover, NJ (see also lymphoma, stomach) www.novartis.com
Lung Cancer
aldoxorubicin CytRx small-cell lung cancer (SCLC) Phase II

(delivery-enhanced doxorubicin) Los Angeles, CA (see also brain, sarcoma) www.cytrx.com
Orphan Drug
alectinib Genentech/Roche ALK-positive NSCLC (1st-line) Phase III

(ALK inhibitor) South San Francisco, CA (Breakthrough Therapy) www.roche.com
ALK-positive NSCLC (2nd-line) Phase II

(Breakthrough Therapy) www.roche.com
alisertib Takeda Oncology SCLC Phase II

(aurora A kinase inhibitor) Cambridge, MA www.takedaoncology.com
anti-fucosyl-GM1 Bristol-Myers Squibb lung cancer Phase I

antroquinonol Golden Biotechnology NSCLC Phase II

New Taipei City, Taiwan www.goldenbiotech.com.tw
apatorsen OncoGenex Pharmaceuticals NSCLC Phase II

(Hsp27 inhibitor) Bothell, WA (see also bladder, pancreatic, prostate) www.oncogenex.com
ASP2215 Astellas Pharma US NSCLC Phase I

(FLT3/AXL inhibitor) Northbrook, IL (see also leukemia) www.astellas.com
ASP8273 Astellas Pharma US NSCLC Phase I

(mutant-selective irreversible Northbrook, IL www.astellas.com
EGFR inhibitor)
Lung Cancer
Avastin Genentech/Roche NSCLC (adjuvant) Phase III

bevacizumab South San Francisco, CA (see also brain, breast, ovarian, other) www.roche.com
EGFR-positive NSCLC Phase II

(combination therapy) www.roche.com
avelumab EMD Serono NSCLC (2nd-line) Phase III

(anti-PD-L1 mAb) Rockland, MA (see also skin, solid tumors) www.emdserono.com
Pfizer www.pfizer.com
New York, NY
AZD3759 AstraZeneca advanced EGFR metastatic NSCLC Phase I

(EGFR tyrosine kinase inhibitor) Wilmington, DE www.astrazeneca.com
AZD9291 AstraZeneca advanced EGFR mutation-positive T790M NSCLC Phase II/III

(EGFR tyrosine kinase inhibitor) Wilmington, DE (2nd-line or greater) (Breakthrough Therapy) www.astrazeneca.com
(Fast Track), advanced EGFR mutation-positive NSCLC
(1st-line)
advanced EGFR mutation-positive NSCLC Phase I

(combination therapy) www.astrazeneca.com
bavituximab Peregrine Pharmaceuticals NSCLC (2nd-line) Phase III

Tustin, CA (see also breast, colorectal, skin) www.peregrineinc.com
NSCLC (1st-line) Phase I completed

www.peregrineinc.com
BBI608 Boston Biomedical NSCLC Phase II

liver, ovarian, pancreatic, skin, stomach)
Lung Cancer
Beleodaq Spectrum Pharmaceuticals NSCLC Phase II

belinostat Henderson, NV (see also lymphoma) www.sppirx.com
BGB324 BerGenBio NSCLC Phase I

(RTK inhibitor) Bergen, Norway www.bergenbio.com
BIND-014 BIND Therapeutics KRAS-mutated NSCLC, squamous histology NSCLC Phase II

(PSMA-targeted docetaxel) Cambridge, MA www.bindtherapeutics.com
brigatinib ARIAD Pharmaceuticals ALK-positive NSCLC (Breakthrough Therapy) Phase II

(ALK inhibitor) Cambridge, MA www.ariad.com
CC-486 Celgene advanced NSCLC Phase II

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, leukemia, www.celgene.com
lymphoma, other)
CD40LGVAX Cellular Biomedicine NSCLC Phase II completed

(immunotherapy vaccine) Palo Alto, CA www.cellbiomedgroup.com
crenolanib AROG Pharmaceuticals NSCLC Phase II

(PDGFR inhibitor) Dallas, TX (see also brain, leukemia, stomach) www.arogpharma.com
CRS-207 Aduro BioTech mesothelioma (combination therapy) Phase I

(cancer immunotherapy) Berkeley, CA (see also pancreatic) www.aduro.com
Orphan Drug
custirsen (OGX-111) OncoGenex Pharmaceuticals advanced NSCLC Phase III

(antisense olignucleotide) Bothell, WA (see also prostate) www.oncogenex.com
CX-01 Cantex Pharmaceuticals SCLC Phase II

(O-desulfated heparin intravenous) Weston, FL (see also leukemia, solid tumors) www.cantex.com
Lung Cancer
Cyramza Eli Lilly EGFR-positive NSCLC (1st-line) Phase III

ramucirumab Indianapolis, IN (see also bladder, liver, stomach) www.lilly.com
dacomitinib Pfizer EGFR-mutant NSCLC Phase III

(pan-HER inhibitor) New York, NY www.pfizer.com
Orphan Drug
demcizumab OncoMed Pharmaceuticals non-squamous NSCLC Phase II

(DLL4 inhibitor) Redwood City, CA (see also ovarian, pancreatic) www.oncomed.com
DKN-01 HealthCare Pharmaceuticals NSCLC Phase I

(DKK1 protein inhibitor) Cambridge, MA (see also myeloma, other) www.healthcarepharmaceuticals.com
docetaxel injection concentrate, Teikoku Pharma USA NSCLC application submitted

non-alcohol formula San Jose, CA (see also breast, head/neck, prostate, stomach) www.teikokuusa.com
DPV-001 UbiVac definitely-treated stage IIIA/B NSCLC Phase II

(toll-like receptor agonist) Portland, OR (see also prostate) www.ubivac.com
EGF816 Novartis Pharmaceuticals NSCLC (combination therapy) Phase I/II

(TKI inhibitor) East Hanover, NJ www.novartis.com
emibetuzumab Eli Lilly NSCLC Phase II

(c-Met antibody) Indianapolis, IN (see also other) www.lilly.com
entinostat Syndax Pharmaceuticals NSCLC (combination therapy) Phase I/II

(HDAC inhibitor) Waltham, MA (see also breast, skin) www.syndax.com
epacadostat Incyte NSCLC Phase I/II

(IDO1 inhibitor) Wilmington, DE (see also ovarian, skin, other) www.incyte.com
Lung Cancer
evofosfamide (TH-302) EMD Serono NSCLC Phase II

(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, pancreatic, www.emdserono.com
Threshold Pharmaceuticals sarcoma, skin) www.thresholdpharm.com
ficlatuzumab AVEO Oncology advanced NSCLC Phase II

(HGF/c-Met inhibitor) Cambridge, MA www.aveooncology.com
FP-1039 Five Prime Therapeutics mesothelioma, squamous NSCLC Phase I

(FGF ligand trap) South San Francisco, CA www.fiveprime.com
ganetespib Synta Pharmaceuticals NSCLC (Fast Track) Phase III

(Hsp90 inhibitor) Lexington, MA (see also breast, leukemia, ovarian) www.syntapharma.com
GI-4000 GlobeImmune NSCLC Phase II

(mutated Ras cancer vaccine) Louisville, CO (see also pancreatic) www.globeimmune.com
Gilotrif Boehringer Ingelheim Pharmaceuticals squamous cell carcinoma of the lung Phase III
afatinib Ridgefield, CT (see also brain, head/neck) www.boehringer-ingelheim.com
GL-ONC1 Genelux pleural cavity cancers Phase I

(oncolytic virus immunomodulator) San Diego, CA (see also head/neck, other) www.genelux.com
Halaven Eisai NSCLC Phase III

eribulin Woodcliff Lake, NJ (see also bladder, sarcoma) www.eisai.com
Imprime PGG Biothera metastatic NSCLC (1st-line) Phase II

intravenous immunostimulant Eagan, MN (see also colorectal, leukemia, lymphoma, pancreatic) www.biothera.com
INC280 Novartis Pharmaceuticals NSCLC Phase I/II

(c-Met inhibitor) East Hanover, NJ www.novartis.com
Lung Cancer
INCB39110 Incyte NSCLC Phase II

(JAK1 inhibitor) Wilmington, DE (see also lymphoma, pancreatic) www.incyte.com
INO-1400 Inovio Pharmaceuticals lung cancer Phase I

(hTERT immunotherapy) Plymouth Meeting, PA (see also breast, pancreatic) www.inovio.com
Jakafi Incyte NSCLC Phase II

ruxolitinib Wilmington, DE (see also breast, colorectal, pancreatic) www.incyte.com
Kadcyla Genentech/Roche HER2-positive NSCLC Phase II

ado-trastuzumab emtansine South San Francisco, CA (see also breast, stomach) www.roche.com
Keytruda Merck NSCLC application submitted

pembrolizumab Kenilworth, NJ (see also bladder, breast, head/neck, www.merck.com
lymphoma, stomach)
Kyprolis Onyx Pharmaceuticals SCLC Phase I/II

carfilzomib South San Francisco, CA (see also leukemia, myeloma) www.onyx.com
L-DOS47 Helix BioPharma non-squamous NSCLC Phase I

(urease stimulant) Aurora, Canada www.helixbiopharma.com
Lenvima Eisai NSCLC (3rd-line), NSCLC (RET translocations) Phase II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, skin, solid tumors, other) www.eisai.com
lifastuzumab vedotin Genentech/Roche NSCLC Phase I

(antibody drug conjugate) South San Francisco, CA (see also ovarian) www.roche.com
lucitanib Clovis Oncology squamous NSCLC Phase II

(FGFR/VEGFR/PDGFR inhibitor) Boulder, CO (see also breast) www.clovisoncology.com
Lung Cancer
lung cancer DNA vaccine Immune Cell Therapy NSCLC Phase I

(IC 1001) Chicago, IL www.immcellther.com
LY2510924 Eli Lilly SCLC Phase II

(CXCR4 peptide antagonist) Indianapolis, IN (see also kidney) www.lilly.com
LY3023414 Eli Lilly NSCLC Phase II

(PI3K/mTOR dual inhibitor) Indianapolis, IN (see also prostate) www.lilly.com
ME-344 MEI Pharma SCLC Phase II

(mitochondrial inhibitor) San Diego, CA (see also ovarian) www.meipharma.com
MEDI4736 MedImmune stage III NSCLC, NSCLC (3rd-line) Phase III

(anti-PD-L1 mAb) Gaithersburg, MD (see also head/neck, solid tumors) www.medimmune.com
MEDI4736 + AZD9291 MedImmune advanced EGFR metastatic NSCLC Phase I

(anti-PD-L1 mAb/EGFR tyrosine Gaithersburg, MD www.medimmune.com
kinase inhibitor)
NSCLC Phase I
www.medimmune.com
MEDI4736 + Iressa MedImmune NSCLC Phase I

(anti-PD-L1 mAb/EGFR tyrosinene Gaithersburg, MD www.medimmune.com
kinase inhibitor)
MGA271 Macrogenics metastatic NSCLC (combination therapy) Phase I

(CD276 protein inhibitor) Rockville, MD (see also head/neck, skin) www.macrogenics.com
MGCD265 Mirati Therapeutics late-stage NSCLC Phase I/II

(c-Met/Axl kinase inhibitor) San Diego, CA www.mirati.com
MORAb-003 Eisai NSCLC Phase II

(IgG1 mAb) Woodcliff Lake, NJ (see also ovarian) www.eisai.com
Lung Cancer
MORAb-009 Eisai mesothelioma Phase II

(amatuximab) Woodcliff Lake, NJ www.eisai.com
NC-6004 NanoCarrier NSCLC Phase I/II

(nanoparticle cisplatin) Tokyo, Japan www.nanocarrier.co.jp
necitumumab Eli Lilly squamous NSCLC application submitted

(EGFR inhibitor) Indianapolis, IN www.lilly.com
NGR-TNF MolMed late-stage mesothelioma Phase III

(recombinant fusion protein) Milan, Italy www.molmed.com
NK012 Nippon Kayaku SCLC Phase II

(DNA topoisomerase I inhibitor) Tokyo, Japan (see also breast, colorectal) www.nipponkayaku.co.jp
onalespib (AT13387) Astex Pharmaceuticals NSCLC Phase II

(Hsp90 inhibitor) Pleasanton, CA (see also skin) www.astx.com
Opdivo Bristol-Myers Squibb NSCLC (1st-line), Phase III

nivolumab Princeton, NJ non-squamous NSCLC (2nd-line) www.bms.com
(see also bladder, brain, colorectal, head/neck,
hematological, kidney, liver, lymphoma, skin,
Opdivo nivolumab + Bristol-Myers Squibb NSCLC Phase I

Yervoy ipilimumab Princeton, NJ (see also kidney, skin, solid tumors) www.bms.com
patritumab Daiichi Sankyo NSCLC Phase II

(anti-HER3 antibody) Parsippany, NJ (see also breast) www.dsi.com
PB272 Puma Biotechnology HER2-mutated NSCLC Phase II

(neratinib) Los Angeles, CA (see also breast) www.pumabiotechnology.com
Lung Cancer
PEGPH20 Halozyme Therapeutics NSCLC Phase I/II

(pegylated recombinant San Diego, CA (see also pancreatic) www.halozyme.com
human hyaluronidase)
PF-06439535 Pfizer NSCLC Phase III

(bevacizumab biosimilar) New York, NY www.pfizer.com
PF-06463922 Pfizer ALK-mutant NSCLC Phase I

(ALK/ROS1 inhibitor) New York, NY www.pfizer.com
Orphan Drug
PF-06664178 Pfizer lung cancer Phase I

New York, NY www.pfizer.com
PF-06747775 Pfizer NSCLC Phase I

(EGFR antagonist) New York, NY www.pfizer.com
pictilisib Genentech/Roche metastatic NSCLC Phase II

(PI3K inhibitor) South San Francisco, CA (see also breast) www.roche.com
plinabulin BeyondSpring Pharmaceuticals NSCLC (2nd-line) Phase II

(tumor vascular disrupting agent) New York, NY www.beyondspringpharma.com
PT-107 Pique Therapeutics NSCLC Phase II

(allogeneic B7.1/HLA-A1 Durham, NC www.piquetherapeutics.com
transfected tumor cell vaccine)
Reolysin Oncolytics Biotech NSCLC, squamous cell carcinoma of the lung Phase II
pelareorp Calgary, Canada (see also brain, colorectal, head/neck, www.oncolyticsbiotech.com
myeloma, ovarian, other, pancreatic)
Lung Cancer
RG7446 Genentech/Roche NSCLC (1st-line combination therapy), Phase III

(anti-PD-L1 mAb) South San Francisco, CA NSCLC (2nd-line) www.roche.com
(see also bladder, breast, kidney, lymphoma,
skin)
NSCLC (3rd-line) Phase II

www.roche.com
NSCLC (combination therapy) Phase I

www.roche.com
rociletinib Clovis Oncology EGFR-mutated NSCLC application submitted

(EGFR inhibitor) Boulder, CO (Breakthrough Therapy) www.clovisoncology.com
roniciclib Bayer HealthCare Pharmaceuticals SCLC Phase II

(CDK inhibitor) Whippany, NJ www.healthcare.bayer.com
RRx-001 EpicentRx NSCLC, SCLC Phase II

(free radical stimulant) Mountain View, CA (see also colorectal, liver, lymphoma, other) www.radiorx.com
sapacitabine Cyclacel Pharmaceuticals NSCLC Phase II

(DNA-directed DNA polymerase Berkeley Heights, NJ (see also hematological, leukemia) www.cyclacel.com
inhibitor)
SAR125844 Sanofi US NSCLC Phase II

(c-Met kinase inhibitor) Bridgewater, NJ www.sanofi.com
SC-002 Stemcentrx SCLC Phase I

(immunoconjugate) South San Francisco, CA (see also other) www.stemcentrx.com
SC16LD6.5 Stemcentrx recurrent SCLC Phase I/II

(antibody drug conjugate) South San Francisco, CA www.stemcentrx.com
Lung Cancer
selumetinib AstraZeneca KRAS-positive NSCLC Phase III

(MEK inhibitor) Wilmington, DE (see also other) www.astrazeneca.com
KRAS-negative NSCLC Phase II

www.astrazeneca.com
seribantumab (MM-121) Merrimack Pharmaceuticals NSCLC Phase II

(ErbB-3 receptor antagonist) Cambridge, MA (see also breast, ovarian) www.merrimackpharma.com
SPI-1620 Spectrum Pharmaceuticals NSCLC Phase II

(endothelin B receptor agonist) Henderson, NV (see also liver) www.sppirx.com
Tafinlar Novartis Pharmaceuticals BRAF V600-positive NSCLC Phase II

dabrafenib East Hanover, NJ (see also colorectal, skin) www.novartis.com
Mekinist
trametinib
combination
tarextumab OncoMed Pharmaceuticals extensive-stage SCLC (1st-line) Phase II

(anti-NOTCH 2/3 mAb) Redwood City, CA (see also pancreatic) www.oncomed.com
Orphan Drug
Tavocept BioNumerik pharmaceuticals lung cancer Phase III completed

San Antonio, TX www.bionumerik.com
tepotinib EMD Serono NSCLC Phase II

(c-Met kinase inhibitor) Rockland, MA (see also liver) www.emdserono.com
tergenpumatucel-L NewLink Genetics advanced or metastatic NSCLC Phase II/III

Ames, IA www.newlinkgenetics.com
tesevatinib (KD019) Kadmon Pharmaceuticals NSCLC Phase II

(TKI inhibitor) Warrendale, PA (see also breast) www.kadmon.com
Lung Cancer
TG4010 Transgene advanced NSCLC Phase II/III

(MVA-MUC1-IL2 vaccine) Cambridge, MA www.transgene.fr
TH-4000 Threshold Pharmaceuticals T790M-negative NSCLC Phase II

(EGFR antagonist) South San Francisco, CA www.thresholdpharm.com
TRC105 TRACON Pharmaceuticals lung cancer Phase I

(END protein inhibitor) San Diego, CA (see also brain, breast, colorectal, kidney, liver, www.traconpharma.com
sarcoma, other)
trebananib Amgen NSCLC Phase II

(Ang 1 / Ang 2 inhibitor) Thousand Oaks, CA (see also breast, ovarian) www.amgen.com
tremelimumab MedImmune mesothelioma Phase III

(anti-CTLA-4 mAb) Gaithersburg, MD www.medimmune.com
Orphan Drug
TSR-011 TESARO NSCLC Phase I/II

(ALK/TRK inhibitor) Waltham, MA (see also lymphoma) www.tesarobio.com
TUSC2 Genprex NSCLC Phase I/II

(gene therapy) Austin, TX www.genprex.com
vantictumab OncoMed Pharmaceuticals advanced NSCLC (combination therapy) Phase I

(anti-Fzd7) Redwood City, CA (see also breast, pancreatic) www.oncomed.com
Vargatef Boehringer Ingelheim Pharmaceuticals NSCLC (combination therapy) Phase III

nintedanib Ridgefield, CT (see also colorectal, ovarian) www.boeringer-ingelheim.com
mesothelioma Phase II
www.boehringer-ingelheim.com
veliparib AbbVie NSCLC Phase III

(PARP inhibitor) North Chicago, IL (see also brain, breast, colorectal, skin) www.abbvie.com
Lung Cancer
viagenpumatucel-L Heat Biologics NSCLC Phase II

(cancer immunotherapy) Durham, NC www.heatbio.com
vintafolide Endocyte NSCLC Phase II

(folate-DAVLBH) West Lafayette, IN www.endocyte.com
VS-6063 Verastem KRAS-mutant NSCLC, mesothelioma Phase II

(FAK inhibitor) Cambridge, MA (see also ovarian) www.verastem.com
Orphan Drug
X396 Xcovery ALK-positive NSCLC Phase I/II

(ALK inhibitor) Palm Beach Gardens, FL (see also solid tumors) www.xcovery.com
Xgeva Amgen metastatic NSCLC (1st-line) Phase II

denosumab Thousand Oaks, CA (see also breast, myeloma) www.amgen.com
Yervoy Bristol-Myers Squibb squamous NSCLC (1st-line) Phase III

ipilimumab Princeton, NJ (see also skin) www.bms.com
Zykadia Novartis Pharmaceuticals treatment nave ALK-positive NSCLC (1st-line) Phase II

ceritinib East Hanover, NJ www.novartis.com
Lymphoma
ABC294640 RedHill Biopharma diffuse large B-cell lymphoma (DLBCL) Phase I/II
(sphingosine kinase inhibitor) Tel Aviv, Israel www.redhillbio.com
abemaciclib Eli Lilly mantle cell lymphoma Phase II

(CDK 4/6 inhibitor) Indianapolis, IN (see also breast, lung) www.lilly.com
Lymphoma
abexinostat Pharmacyclics follicular lymphoma, Phase II

(HDAC inhibitor) Sunnyvale, CA mantle cell lymphoma www.pharmacyclics.com
ABP 798 Allergan non-Hodgkin lymphoma (NHL) Phase III

(rituximab biosimilar) Parsippany, NJ www.amgen.com
Amgen
Thousand Oaks, CA
ACP-196 Acerta Pharma mantle cell lymphoma Phase II

leukemia, lung, myeloma, pancreatic)
activated B-cell (ABC) DLBCL, Phase I

follicular lymphoma, Waldenstrom's www.acerta-pharma.com
macroglobulinemia
ACP-319 Acerta Pharma B-cell lymphoma (combination therapy) Phase I/II

(Btk inhibitor) San Carlos, CA (see also leukemia) www.acerta-pharma.com
Adcetris Seattle Genetics post-transplant Hodgkin lymphoma Phase III

brentuximab vedotin Bothell, WA relapse prevention, relapsed CD30-positive www.seattlegenetics.com
Orphan Drug cutaneous T-cell lymphoma, Hodgkin
lymphoma (1st-line), CD30-positive mature
T-cell lymphoma (1st-line)
Hodgkin lymphoma in elderly (1st-line), Phase II

CD30-positive DLBCL www.seattlegenetics.com
AEB071 Novartis Pharmaceuticals CD79-mutant or ABC-subtype DLBCL Phase I/II

(PKC inhibitor) East Hanover, NJ (combination therapy) www.novartis.com
(see also other)
Afinitor Novartis Pharmaceuticals DLBCL Phase III

everolimus East Hanover, NJ (see also lung, stomach) www.novartis.com
Lymphoma
AFM 13 Affimed Therapeutics Hodgkin lymphoma Phase II

(CD30 antigen modulator) Heidelberg, Germany www.affimed.com
Orphan Drug
AR-12 Arno Therapeutics lymphoma Phase I

(PI3K/Akt inhibitor) Flemington, NJ (see also solid tumors) www.arnothera.com
Arzerra Novartis Pharmaceuticals refractory NHL, relapsed NHL Phase III

ofatumumab East Hanover, NJ (see also leukemia) www.novartis.com
ASP4132 Astellas Pharma US advanced lymphoma Phase I

Northbrook, IL (see also solid tumors) www.astellas.com
ATTCK20 Unum Therapeutics NHL Phase I

(viral-ACTR+anti-CD20) Cambridge, MA (see also leukemia) www.unumrx.com
Beleodaq Spectrum Pharmaceuticals peripheral T-cell lymphoma (PTCL) (1st-line) Phase I

belinostat Henderson, NV (see also lung) www.sppirx.com
Orphan Drug
bendamustine ready-to-dilute Eagle Pharmaceuticals NHL application submitted

liquid formulation Woodcliff Lake, NJ (see also leukemia, solid tumors) www.eagleus.com
Orphan Drug
BI 695500 Boehringer Ingelheim Pharmaceuticals follicular lymphoma (1st-line) Phase III

(rituximab biosimilar) Ridgefield, CT www.boehringer-ingelheim.com
birinapant TetraLogic Pharmaceuticals cutaneous T-cell lymphoma (CTCL) Phase II

(apoptosis stimulator) Malvern, PA (see also hematological, ovarian) www.tetralogicpharma.com
Blincyto Amgen DLBCL Phase II

blinatumomab Thousand Oaks, CA (see also leukemia) www.amgen.com
Lymphoma
CC-122 Celgene DLBCL, relapsed/refractory indolent lymphoma Phase I

(pleiotropic pathway modifier) Summit, NJ (see also brain, leukemia, liver) www.celgene.com
CC-292 Celgene relapsed/refractory B-cell lymphoma Phase I

(Btk inhibitor) Summit, NJ (see also leukemia) www.celgene.com
CC-486 Celgene lymphoma Phase I

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, leukemia, lung, other) www.celgene.com
CDX-301 Celldex Therapeutics B-cell lymphoma Phase I/II

(Fms-like tyrosine kinase 3 ligand) Hampton, NJ (see also hematological) www.celldex.com
cerdulatinib Portola Pharmaceuticals NHL Phase II

(dual Syk-JAK inhibitor) South San Francisco, CA (see also leukemia) www.portola.com
CMD-003 Cell Medica EBV-positive, extranodal natural killer/T-cell lymphoma Phase II

(cell therapy) London, England www.cellmedica.co.uk
coltuximab ravtansine ImmunoGen DLBCL Phase II

(antibody drug conjugate) Waltham, MA www.immunogen.com
copanlisib Bayer HealthCare Pharmaceuticals NHL Phase III

(PI3K inhibitor) Whippany, NJ www.healthcare.bayer.com
Orphan Drug
DLBCL Phase II
www.healthcare.bayer.com
CPI-0610 Constellation Pharmaceuticals lymphoma Phase I

(BET inhibitor) Cambridge, MA (see also hematological, leukemia, myeloma) www.constellationpharma.com
CPI-1205 Constellation Pharmaceuticals B-cell lymphoma Phase I

(EZH2 enzyme inhibitor) Cambridge, MA www.constellationpharma.com
Lymphoma
CTL019 Novartis Pharmaceuticals DLBCL Phase I

(CAR immunotherapy) East Hanover, NJ (see also leukemia) www.novartis.com
CUDC-427 Curis late-stage lymphoma Phase I

(IAP inhibitor) Lexington, MA (see also solid tumors) www.curis.com
CUDC-907 Curis late-stage lymphoma Phase I

(HDAC/PI3K inhibitor) Lexington, MA (see also myeloma, solid tumors) www.curis.com
DI-Leu16-IL2 ALOPEXX Oncology NHL Phase I/II

(CD20 antigen inhibitor) Concord, MA www.alopexx.com
DS-3032 Daiichi Sankyo late-stage lymphoma Phase I

(MDM2 inhibitor) Parsippany, NJ (see also solid tumors) www.dsi.com
DS-3078 Daiichi Sankyo lymphoma Phase I

(mTOR inhibitor) Parsippany, NJ (see also solid tumors) www.dsi.com
DS-8273 Daiichi Sankyo late-stage lymphoma Phase I

(anti-DR5 antibody) Parsippany, NJ (see also solid tumors) www.dsi.com
duvelisib AbbVie previously-treated follicular lymphoma Phase III

(PI3K inhibitor) North Chicago, IL (see also hematological, leukemia) www.abbvie.com
Orphan Drug Infinity Pharmaceuticals www.infi.com
Cambridge, MA
refractory indolent NHL Phase II

www.abbvie.com
www.infi.com
treatment nave follicular lymphoma Phase I

www.abbvie.com
www.infi.com
Lymphoma
EPZ-6438 Epizyme NHL Phase I/II

(EZH2 inhibitor) Cambridge, MA (see also solid tumors) www.epizyme.com
Folotyn Spectrum Pharmaceuticals PTCL Phase I

pralatrexate injection Henderson, NV www.sppirx.com
Orphan Drug
Gazyva Genentech/Roche DLBCL, indolent NHL (1st-line), Phase III

obinutuzumab South San Francisco, CA refractory indolent NHL www.roche.com
GDC-0575 (RG7741) Genentech/Roche lymphoma Phase I

(ChK1 inhibitor) South San Francisco, CA (see also solid tumors) www.roche.com
GS-5829 Gilead Sciences DLBCL Phase I

(BET inhibitor) Foster City, CA (see also solid tumors) www.gilead.com
Imbruvica Janssen Research & Development relapsed/refractory mantle cell lymphoma, Phase III
ibrutinib Raritan, NJ treatment nave mantle cell lymphoma www.janssenrnd.com
(combination therapy), relapsed/refractory
indolent NHL (combination therapy),
newly-diagnosed non-germinal center
B-cell subtype of DLBCL, previously treated
Waldenstrom's macroglobulinemia
(see also leukemia)
IMGN529 ImmunoGen NHL Phase I

(CD37 protein inhibitor) Waltham, MA (see also leukemia) www.immunogen.com
IMMU-114 Immunomedics NHL Phase I

(humanized anti-HLA-DR) Morris Plains, NJ (see also leukemia) www.immunomedics.com
Lymphoma
IMO-8400 Idera Pharmaceuticals DLBCL, Waldenstrom's macroglobulinemia Phase I/II

(TLR antagonist) Cambridge, MA www.iderapharma.com
Orphan Drug
Imprime PGG Biothera advanced indolent NHL Phase II

intravenous immunostimulant Eagan, MN (see also colorectal, leukemia, lung, pancreatic) www.biothera.com
INCB39110+INCB40093 Incyte B-lymphoid malignancies Phase I/II

(JAK1 inhibitor) Wilmington, DE (see also lung, pancreatic) www.incyte.com
INCB50465 Incyte B-lymphoid malignancies Phase I

(PI3K-delta inhibitor) Wilmington, DE www.incyte.com
Istodax Celgene PTCL (1st-line) Phase III

romidepsin Summit, NJ www.celgene.com
JCAR014 Juno Therapeutics NHL Phase I/II

JCAR018 Juno Therapeutics NHL Phase I

JNJ-42756493 Janssen Research & Development late-stage lymphoma Phase I

(FGFR inhibitor) Raritan, NJ (see also bladder) www.janssenrnd.com
Keytruda Merck Hodgkin lymphoma Phase II

pembrolizumab Kenilworth, NJ (see also bladder, breast, head/neck, lung, stomach) www.merck.com
Lymphoma
KTE-C19 CAR Kite Pharma B-cell lymphoma Phase II/III

(chimeric antigen receptor) Santa Monica, CA www.kitepharma.com
Orphan Drug
DLBCL Phase I/II

www.kitepharma.com
Marqibo Spectrum Pharmaceuticals aggressive NHL (1st-line) Phase III

vinCRIStine sulfate LIPOSOME Henderson, NV (see also leukemia) www.sppirx.com
injection
MEDI-551 MedImmune DLBCL Phase II

(anti-CD19 mAb) Gaithersburg, MD (see also leukemia) www.medimmune.com
MEDI-551 + MEDI0680 MedImmune DLBCL Phase I

(anti-CD19 mAb/anti-PD-1 mAb) Gaithersburg, MD www.medimmune.com
milatuzumab-doxorubicin conjugate Immunomedics NHL Phase I/II

(antibody drug conjugate) Morris Plains, NJ (see also leukemia) www.immunomedics.com
mocetinostat Mirati Therapeutics DLBCL Phase II

(HDAC inhibitor) San Diego, CA (see also bladder, hematological) www.mirati.com
Orphan Drug
mogamulizumab Kyowa Hakko Kirin CTCL Phase III

(anti-CCR4 antibody) Princeton, NJ (see also leukemia) www.kyowa-kirin.com
Orphan Drug
adult T-cell leukemia-lymphoma Phase II

www.kyowa-kirin.com
MOR208 MorphoSys NHL Phase II

(CD19 antigen inhibitor) Martinsried, Germany (see also leukemia) www.morphosys.com
Lymphoma
MT-3724 Molecular Templates NHL Phase I

(CD20 antigen inhibitor) Georgetown, TX www.moleculartemplates.com
Oncoquest-L XEME Biopharma follicular lymphoma Phase II

personalized cancer vaccine Monmouth Junction, NJ www.xemebiopharma.com
Opdivo Bristol-Myers Squibb Hodgkin lymphoma (Breakthrough Phase II

nivolumab Princeton, NJ Therapy), DLBCL, follicular lymphoma www.bms.com
(see also bladder, brain, colorectal,
head/neck, hematological, kidney, liver,
lung, skin, solid tumors, stomach, other)
PF-05280586 Pfizer follicular lymphoma (1st-line therapy) Phase III

(rituximab biosimilar) New York, NY www.pfizer.com
pidilizumab Medivation DLBCL Phase II completed

San Francisco, CA www.medivation.com
Pixuvri CTI BioPharma DLBCL, follicular grade 3 lymphoma Phase III

pixantrone Seattle, WA www.ctibiopharma.com
PNT2258 ProNAi Therapeutics relapsed/refractory DLBCL, Phase II

(Bcl-2 oncogene inhibitor) Plymouth, MI relapsed/refractory NHL www.pronai.com
polatuzumab vedotin Genentech/Roche DLBCL, NHL Phase II

(antibody drug conjugate) South San Francisco, CA www.roche.com
REGN1979 Regeneron Pharmaceuticals NHL Phase I

(CD20/CD3 antigen inhibitor) Tarrytown, NY (see also leukemia) www.regeneron.com
Resimmune Angimmune CTCL Phase I/II

A-dmDT390-bisFv immunotoxin Rockville, MD (see also skin) www.angimmune.com
Lymphoma
Revlimid Celgene DLBCL (maintenance therapy), Phase III

lenalidomide Summit, NJ DLBCL-ABC subtype (1st-line), www.celgene.com
follicular lymphoma (1st-line),
relapsed/refractory indolent lymphoma
(see also hematological, leukemia, myeloma)
RG7446 Genentech/Roche lymphoma Phase I

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, breast, kidney, lung, www.roche.com
skin)
ricolinostat Acetylon Pharmaceuticals lymphoma Phase I/II

(HDAC inhibitor) Boston, MA (see also myeloma) www.acetylon.com
RRx-001 EpicentRx lymphoma Phase I

(free radical stimulant) Mountain View, CA (see also colorectal, liver, lung, other) www.radiorx.com
SD101 Dynavax Technologies B-cell lymphoma Phase I/II

(TLR9 agonist) Berkeley, CA (combination therapy) www.dynavax.com
selinexor (oral) Karyopharm Therapeutics DLBCL Phase III

(XPO1 antagonist) Newton, MA (see also brain, head/neck, hematological, www.karyopharm.com
Orphan Drug leukemia, myeloma, prostate, sarcoma, other)
SGN-CD19A Seattle Genetics NHL Phase I

(antibody drug conjugate) Bothell, WA (see also leukemia) www.seattlegenetics.com
SGN-CD70A Seattle Genetics relapsed NHL Phase I

(antibody drug conjugate) Bothell, WA (see also kidney) www.seattlegenetics.com
SGX301 Soligenix cutaneous T-cell lymphoma (Fast Track) Phase II

(hypericin) Princeton, NJ www.soligenix.com
Lymphoma
SHAPE TetraLogic Pharmaceuticals CTCL Phase II

(HDAC inhibitor) Malvern, PA www.tetralogicpharma.com
Orphan Drug
SP-02 (darinaparsin) Solasia Pharma PTCL Phase II

(apoptosis stimulant) Tokyo, Japan www.solasia.co.jp
Orphan Drug
TG-1101 TG Therapeutics mantle cell lymphoma Phase III

(anti-CD20 mAb) New York, NY (combination therapy) www.tgtherapeutics.com
Orphan Drug (see also leukemia)
NHL (monotherapy) Phase I/II

www.tgtherapeutics.com
Treanda Teva Oncology indolent B-cell NHL (1st-line) application submitted

bendamustine Frazer, PA www.tevapharm.com
Orphan Drug
mantle cell lymphoma Phase II

www.tevapharm.com
TSR-011 TESARO lymphoma Phase I/II

(ALK/TRK inhibitor) Waltham, MA (see also lung) www.tesarobio.com
veltuzumab Immunomedics NHL Phase II

(humanized anti-CD20 mAb) Morris Plains, NJ www.immunomedics.com
veltuzumab Immunomedics aggressive NHL Phase II

(humanized anti-CD20 mAb)/ Morris Plains, NJ www.immunomedics.com
Y-90 epratuzumab tetraxetan
Lymphoma
venetoclax AbbVie DLBCL, NHL Phase II

(Bcl-2 inhibitor) North Chicago, IL (see also hematological, leukemia) www.abbvie.com
Genentech/Roche www.roche.com
VS-5584 Verastem lymphoma Phase I

(PI3K/mTOR inhibitor) Cambridge, MA (see also solid tumors) www.verastem.com
VX-803 Vertex Pharmaceuticals lymphoma Phase I

Boston, MA (see also solid tumors) www.vrtx.com
Zydelig Gilead Sciences relapsed/refractory indolent NHL Phase III

idelalisib Foster City, CA (see also leukemia) www.gilead.com
indolent NHL (1st-line) Phase II

www.gilead.com
Multiple Myeloma
ABBV-838 AbbVie multiple myeloma Phase I

(antibody drug conjugate) North Chicago, IL www.abbvie.com
ACP-196 Acerta Pharma multiple myeloma Phase I

leukemia, lung, lymphoma, pancreatic)
ACY-241 Acetylon Pharmaceuticals multiple myeloma Phase I

(HDAC6 protein inhibitor) Boston, MA www.acetylon.com
ALT-803 Altor BioScience multiple myeloma Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also bladder, hematological, skin) www.altorbioscience.com
Multiple Myeloma
AMG 232 Amgen multiple myeloma Phase I

(MDM2 inhibitor) Thousand Oaks, CA (see also leukemia, skin, solid tumors) www.amgen.com
AT7519 Astex Pharmaceuticals multiple myeloma Phase II

(CDK inhibitor) Pleasanton, CA www.astx.com
BB-MPI-03 Benovus Bio multiple myeloma Phase I

(multi-peptide immunotherapy) Atlanta, GA (see also hematological, leukemia) www.benovusbio.com
CB-5083 Cleave Biosciences multiple myeloma Phase I

(P97 ATPase inhibitor) Burlingame, CA www.cleavebio.com
CPI-0610 Constellation Pharmaceuticals multiple myeloma Phase I

(BET inhibitor) Cambridge, MA (see also hematological, leukemia, lymphoma) www.constellationpharma.com
CUDC-907 Curis multiple myeloma Phase I

(HDAC/PI3K inhibitor) Lexington, MA (see also lymphoma, solid tumors) www.curis.com
daratumumab Janssen Research & Development double refractory multiple myeloma application submitted
(IgG1k mAb) Raritan, NJ (Breakthrough Therapy) (Fast Track) www.janssenrnd.com
multiple myeloma (1st-line), Phase III

multiple myeloma (1st-line, combination www.janssenrnd.com
therapy), recurrent/relapsed multiple
myeloma (combination therapy)
DKN-01 HealthCare Pharmaceuticals multiple myeloma Phase I/II

(DKK1 protein inhibitor) Cambridge, MA (see also lung, other) www.healthcarepharmaceuticals.com
Multiple Myeloma
elotuzumab AbbVie multiple myeloma (1st-line) Phase III

(CD319 antigen modulator) North Chicago, IL (combination therapy), www.abbvie.com
Bristol-Myers Squibb relapsed/refractory multiple myeloma www.bms.com
Princeton, NJ (combination therapy) (Breakthrough Therapy)
multiple myeloma (2nd-line) Phase II

(combination therapy) www.abbvie.com
www.bms.com
filanesib Array BioPharma multiple myeloma Phase II

(KSP inhibitor) Boulder, CO www.arraybiopharma.com
I-131-CLR1404 Cellector Biosciences relapsed/refractory multiple myeloma Phase I

(molecular radiotherapeutic) Madison, WI www.cellector.com
indatuximab ravtansine (BT062) Biotest Pharmaceuticals multiple myeloma Phase I/II

(tubulin polymerisation inhibitor) Dreiech, Germany www.biotest.de
Orphan Drug
isatuximab Sanofi US multiple myeloma Phase II

(anti-CD38 naked mAb) Bridgewater, NJ www.sanofi.com
ixazomib Takeda Oncology relapsed/refractory multiple myeloma application submitted

(proteasome inhibitor) Cambridge, MA (see also solid tumors) www.takedaoncology.com
Orphan Drug
previously untreated multiple myeloma, Phase III

maintenance therapy in newly-diagnosed www.takedaoncology.com
multiple myeloma following stem cell
transplantation, maintenance therapy in
newly-diagnosed multiple myeloma not
treated with stem cell transplantation
Multiple Myeloma
Kyprolis Onyx Pharmaceuticals relapsed multiple myeloma (combination therapy) application submitted
carfilzomib South San Francisco, CA (see also leukemia, myeloma) www.onyx.com
Orphan Drug
relapsed multiple myeloma, Phase III

multiple myeloma (1st-line) www.onyx.com
lirilumab + elotuzumab Bristol-Myers Squibb multiple myeloma Phase I

marizomib Triphase Accelerator relapsed/refractory multiple myeloma Phase II

(proteasome inhibitor) San Diego, CA (see also brain) www.triphaseco.com
melphalan intravenous Spectrum Pharmaceuticals multiple myeloma autologous stem cell application submitted
(Captisol-enabled melphalan) Henderson, NV transplantation www.sppirx.com
Orphan Drug
NY-ESO-1/LAGE-1-specific T-cells Adaptimmune advanced multiple myeloma Phase I/II

Oxon, England (see also ovarian, sarcoma, skin) www.adaptimmune.com
oprozomib Onyx Pharmaceuticals multiple myeloma (monotherapy) Phase II

(proteasome inhibitor) South San Francisco, CA (see also hematological, solid tumors) www.onyx.com
Orphan Drug
multiple myeloma (combination therapy) Phase I

www.onyx.com
PIM447 Novartis Pharmaceuticals multiple myeloma Phase I/II

(proto oncogene protein c East Hanover, NJ (see also hematological, leukemia) www.novartis.com
pim-1 inhibitor)
plitidepsin PharmaMar relapsed/refractory multiple myeloma Phase III

(marine-derived medicine) Madrid, Spain www.pharmamar.com
Orphan Drug
Multiple Myeloma
PVX-410 OncoPep smoldering multiple myeloma Phase I/II

(therapeutic cancer vaccine) North Andover, MA www.oncopep.com
Orphan Drug
Reolysin Oncolytics Biotech relapsed/refractory multiple myeloma Phase I

pelareorp Calgary, Canada (see also brain, colorectal, head/neck, lung, www.oncolyticsbiotech.com
ovarian, other, pancreatic)
Revlimid Celgene multiple myeloma (maintenance therapy) Phase III

lenalidomide Summit, NJ (see also hematological, leukemia, lymphoma) www.celgene.com
Orphan Drug
ricolinostat Acetylon Pharmaceuticals relapsed/refractory multiple myeloma Phase II

(HDAC inhibitor) Boston, MA (see also lymphoma) www.acetylon.com
selinexor (oral) Karyopharm Therapeutics multiple myeloma Phase III

Orphan Drug leukemia, lymphoma, prostate, sarcoma,
other)
multiple myeloma (combination therapy) Phase II

www.karyopharm.com
Sylvant Janssen Research & Development smoldering multiple myeloma Phase II

siltuximab Raritan, NJ www.janssenrnd.com
TAS-120 Taiho Oncology advanced multiple myeloma Phase I/II

(FGF/FGFR inhibitor) Princeton, NJ (see also solid tumors) www.taihooncology.com
TG02 Tragara Pharmaceuticals multiple myeloma Phase I

(CDK inhibitor) Carlsbad, CA (see also leukemia) www.tragarapharma.com
Multiple Myeloma
urelumab + elotuzumab Bristol-Myers Squibb multiple myeloma Phase I

VLX1570 Vivolux multiple myeloma Phase I/II

(proteasome inhibitor) Ashburn, VA www.vivolux.com
WT1-CTL Atara Biotherapeutics multiple myeloma Phase I

(immunostimulant) South San Francisco, CA (see also leukemia) www.atarabio.com
Xgeva Amgen prevention of skeletal-related events in Phase III

denosumab Thousand Oaks, CA multiple myeloma www.amgen.com
(see also breast, lung)
Ovarian Cancer
ADI-PEG 20 Polaris Pharmaceuticals ovarian cancer Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, pancreatic, skin, stomach) www.polarispharma.com
Avastin Genentech/Roche metastatic ovarian cancer (1st-line) Phase III

bevacizumab South San Francisco, CA (see also brain, breast, lung, other) www.roche.com
Orphan Drug
AZD1775 AstraZeneca ovarian cancer Phase II

(WEE-1 inhibitor) Wilmington, DE www.astrazeneca.com
BBI503 Boston Biomedical ovarian cancer Phase II

(cancer stemness kinase inhibitor) Cambridge, MA (see also liver) www.bostonbiomedical.com
BBI608 Boston Biomedical ovarian cancer Phase II

liver, lung, pancreatic, skin, stomach)
Ovarian Cancer
binimetinib Array BioPharma low-grade serous ovarian cancer Phase III

(MEK inhibitor) Boulder, CO (see also skin) www.arraybiopharma.com
birinapant TetraLogic Pharmaceuticals ovarian cancer Phase II

(apoptosis stimulator) Malvern, PA (see also hematological, lymphoma) www.tetralogicpharma.com
BNC105 Bionomics ovarian cancer Phase I/II

(vascular disrupting agent) Thebarton, Australia (see also kidney) www.bionomics.com.au
CRLX101 Cerulean Pharma relapsed platinum-resistant ovarian cancer Phase I

(nanoparticle drug conjugate) Cambridge, MA (see also colorectal, kidney) www.ceruleanrx.com
Orphan Drug
demcizumab OncoMed Pharmaceuticals platinum-resistant ovarian cancer Phase I/II

(DLL4 inhibitor) Redwood City, CA (see also lung, pancreatic) www.oncomed.com
DPX-0907 Immunovaccine ovarian cancer Phase I

(T lymphocyte modulator) Halifax, Canada (see also breast, prostate) www.imvaccine.com
DPX-Survivac Immunovaccine ovarian cancer Phase I/II

(peptide cancer vaccine) Halifax, Canada www.imvaccine.com
ENMD-2076 CASI Pharmaceuticals ovarian clear cell carcinoma Phase II

(aurora A/angiogenic kinase Rockville, MD (see also breast, sarcoma) www.casipharmaceuticals.com
inhibitor)
Orphan Drug
EP-100 Esperance Pharmaceuticals ovarian cancer Phase II completed

(membrane disrupting peptide) San Francisco, CA www.esperancepharma.com
epacadostat Incyte ovarian cancer Phase II

(IDO1 inhibitor) Wilmington, DE (see also lung, skin, other) www.incyte.com
Ovarian Cancer
etirinotecan pegol (NKTR-102) Nektar Therapeutics platinum-resistant ovarian cancer Phase II completed
(PEGylated irinotecan) San Francisco, CA (see also breast, colorectal) www.nektar.com
Orphan Drug
fosbretabulin OXiGENE ovarian cancer (combination therapy) (Fast Track) Phase II

(vascular targeting agent) South San Francisco, CA (see also stomach) www.oxigene.com
Orphan Drug
GALE-301 Galena Biopharma ovarian cancer Phase II

(folate binding protein Portland, OR (see also other) www.galenabiopharma.com
immunotherapy)
ganetespib Synta Pharmaceuticals ovarian cancer Phase II

(Hsp90 inhibitor) Lexington, MA (see also breast, leukemia, lung) www.syntapharma.com
GEN 1 Celsion ovarian cancer Phase II

(cancer immunotherapy) Lawrenceville, NJ (see also colorectal) www.celsion.com
ipafricept Bayer HealthCare Pharmaceuticals ovarian cancer (combination therapy) Phase I

(Wnt protein inhibitor) Whippany, NJ (see also liver, pancreatic) www.healthcare.bayer.com
OncoMed Pharmaceuticals www.oncomed.com
Redwood City, CA
Karentitecin BioNumerik Pharmaceuticals advanced ovarian cancer Phase III

cositecan San Antonio, TX www.bionumerik.com
lifastuzumab vedotin Genentech/Roche platinum-resistant ovarian cancer Phase II

(antibody drug conjugate) South San Francisco, CA (see also lung) www.roche.com
ovarian cancer Phase I

www.roche.com
Ovarian Cancer
LY2606368 Eli Lilly metastatic ovarian cancer Phase II

(Chk1 inhibitor) Indianapolis, IN (see also breast) www.lilly.com
Lynparza AstraZeneca BRCA-mutated ovarian cancer (1st-line), Phase III

olaparib Wilmington, DE germline BRCA-mutated, platinum-sensitive www.astrazeneca.com
Orphan Drug recurrent ovarian cancer
(see also breast, pancreatic, prostate, stomach)
ME-344 MEI Pharma ovarian cancer Phase II

(mitochondrial inhibitor) San Diego, CA (see also lung) www.meipharma.com
mirvetuximab soravtansine ImmunoGen platinum-resistant ovarian cancer Phase I

(folate receptor 1 inhibitor) Waltham, MA (see also other) www.immunogen.com
Orphan Drug
MORAb-003 Eisai platinum-sensitive ovarian cancer Phase II

(IgG1 mAb) Woodcliff Lake, NJ (see also lung) www.eisai.com
Orphan Drug
motolimod VentiRx Pharmaceuticals ovarian cancer (Fast Track) Phase II

(TLR8 agonist immunotherapy) Seattle, WA (see also head/neck) www.ventirx.com
Orphan Drug
niraparib TESARO ovarian cancer maintenance Phase III

(PARP inhibitor) Waltham, MA (see also breast, sarcoma) www.tesarobio.com
ovarian cancer treatment Phase III

www.tesarobio.com
ovarian cancer (combination therapy) Phase I

www.tesarobio.com
Ovarian Cancer
NY-ESO-1/LAGE-1-specific T-cells Adaptimmune ovarian cancer Phase I/II

Oxon, England (see also myeloma, sarcoma, skin) www.adaptimmune.com
ONT-10 Oncothyreon ovarian cancer Phase I

(cancer immunotherapy) Seattle, WA (see also breast) www.oncothyreon.com
oregovomab Quest PharmaTech ovarian cancer Phase II

Orphan Drug Edmonton, Canada (see also pancreatic) www.questpharmatech.com
ovarian cancer vaccine MabVax Therapeutics ovarian cancer Phase II

(pentavalent) San Diego, CA www.mabvax.com
paclitaxel poliglumex CTI BioPharma ovarian cancer (1st-line) Phase III

Seattle, WA www.ctibiopharma.com
PLX3397 Plexxikon advanced ovarian cancer Phase I

(CSF-1R inhibitor) Berkeley, CA (see also brain, breast, skin, other) www.plexxikon.com
PM01183 Pharma Mar ovarian cancer Phase III

(marine-derived alkylating agent) Madrid, Spain (see also breast, lung) www.pharmamar.com
Orphan Drug
ralimetinib Eli Lilly ovarian cancer Phase II

(p38 MAP kinase inhibitor) Indianapolis, IN www.lilly.com
Reolysin Oncolytics Biotech ovarian cancer Phase II

Orphan Drug myeloma, other, pancreatic)
RG7882 Genentech/Roche ovarian cancer Phase I

(antibody drug conjugate) South San Francisco, CA (see also pancreatic) www.roche.com
Ovarian Cancer
rucaparib Clovis Oncology ovarian cancer (maintenance) Phase III

(PARP inhibitor) Boulder, CO (see also breast, pancreatic, other) www.clovisoncology.com
Orphan Drug
gBRCA-mutation ovarian cancer Phase II

(Breakthrough Therapy) www.clovisoncology.com
seribantumab (MM-121) Merrimack Pharmaceuticals ovarian cancer Phase II

(ErbB-3 receptor antagonist) Cambridge, MA (see also breast, lung) www.merrimackpharma.com
SGI-110 Astex Pharmaceuticals ovarian cancer Phase II

(DNMT inhibitor) Pleasanton, CA (see also hematological, leukemia, liver) www.astx.com
STM 434 Atara Biotherapeutics ovarian cancer Phase I

(activin inhibitor) South San Francisco, CA www.atarabio.com
TPIV200 TapImmune ovarian cancer (combination therapy) Phase I

(folate receptor alpha vaccine) Seattle, WA (see also breast) www.tapimmune.com
trebananib Amgen ovarian cancer Phase III

(Ang 1 / Ang 2 inhibitor) Thousand Oaks, CA (see also breast, lung) www.amgen.com
Vargatef Boehringer Ingelheim Pharmaceuticals ovarian cancer (1st-line) Phase III

nintedanib Ridgefield, CT (see also colorectal, lung) www.boeringer-ingelheim.com
VB-111 VBL Therapeutics ovarian cancer Phase II

(targeted anti-angiogenic agent) Tel Aviv, Israel (see also brain, other) www.vblrx.com
Vigil Gradalis stage III/IV ovarian cancer Phase III

autologous immunotherapy Dallas, TX (see also sarcoma) www.gradalisinc.com
Ovarian Cancer
VS-6063 Verastem late-stage ovarian cancer Phase II

(FAK inhibitor) Cambridge, MA (see also lung) www.verastem.com
Orphan Drug
Yondelis Janssen Research & Development relapsed ovarian cancer Phase III
trabectedin Raritan, NJ (see also sarcoma) www.janssenrnd.com
Orphan Drug
Pancreatic Cancer
Abraxane Celgene pancreatic cancer (adjuvant) Phase III

paclitaxel protein-bound Summit, NJ (see also breast) www.celgene.com
particles for injectable
suspension (albumin-bound)
Orphan Drug
ACP-196 Acerta Pharma advanced pancreatic cancer (combination therapy) Phase II

leukemia, lung, lymphoma, myeloma)
ADI-PEG 20 Polaris Pharmaceuticals pancreatic cancer Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, ovarian, skin, stomach) www.polarispharma.com
aglatimagene besadenovec Advantagene pancreatic cancer Phase I/II

(gene therapy) Auburndale, MA (see also brain, prostate) www.advantagene.com
algenpantucel-L NewLink Genetics pancreatic cancer (resected) (Fast Track), Phase III
(immunotherapy vaccine) Ames, IA pancreatic cancer (borderline resectable of www.newlinkgenetics.com
Orphan Drug locally advanced unresectable)
anti-MUC1 AR20.5 mAb Quest PharmaTech pancreatic cancer Phase I/II

(chemotherapy-enhanced Edmonton, Canada www.questpharmatech.com
immunotherapy)
Pancreatic Cancer
apatorsen OncoGenex Pharmaceuticals metastatic pancreatic cancer Phase II

(Hsp27 inhibitor) Bothell, WA (see also bladder, lung, prostate) www.oncogenex.com
BBI608 Boston Biomedical pancreatic cancer Phase I

liver, lung, ovarian, skin, stomach)
BC-819 BioCancell Therapeutics pancreatic cancer (1st-line) (Fast Track) Phase II

(gene therapy) Jerusalem, Israel (see also bladder) www.biocancell.com
Orphan Drug
CPI-613 Cornerstone Pharmaceuticals pancreatic cancer Phase II

(KGDH/PHD complex inhibitor) Cranbury, NJ (see also other) www.cornerstonepharma.com
Orphan Drug
CRS-207 Aduro BioTech pancreatic cancer (combination therapy) Phase II

(cancer immunotherapy) Berkeley, CA (see also lung) www.aduro.com
Orphan Drug
demcizumab OncoMed Pharmaceuticals metastatic pancreatic ductal cancer Phase II

(DLL4 inhibitor) Redwood City, CA (see also lung, ovarian) www.oncomed.com
Orphan Drug
encapsulated cell therapy Rogosin Institute metastatic pancreatic cancer Phase II

New York, NY (see also colorectal, prostate) www.rogosin.org
New York, NY
ensituximab Precision Biologics advanced pancreatic cancer Phase II

(neoplasm antigen inhibitor) Dallas, TX (see also colorectal) www.precision-biologics.com
Orphan Drug
Pancreatic Cancer
evofosfamide (TH-302) EMD Serono pancreatic cancer (Fast Track) Phase III
(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, lung, sarcoma, skin) www.emdserono.com
Orphan Drug Threshold Pharmaceuticals www.thresholdpharm.com
FG-3019 Fibrogen advanced pancreatic cancer Phase II

(connective tissue growth San Francisco, CA www.fibrogen.com
factor inhibitor)
galunisertib Eli Lilly pancreatic cancer Phase I/II

(TGF-beta 1 kinase inhibitor) Indianapolis, IN (see also brain, liver) www.lilly.com
GI-4000 GlobeImmune pancreatic cancer Phase II

(mutated Ras cancer vaccine) Louisville, CO (see also lung) www.globeimmune.com
glufosfamide Eleison Pharmaceuticals metastatic pancreatic cancer (Fast Track) Phase III
Orphan Drug St. Petersburg, FL www.eleison-pharma.com
Imprime PGG Biothera advanced pancreatic ductal cancer Phase I

intravenous immunostimulant Eagan, MN (see also colorectal, leukemia, lung, lymphoma) www.biothera.com
INCB39110 Incyte pancreatic cancer Phase I

(JAK1 inhibitor) Wilmington, DE (see also lung, lymphoma) www.incyte.com
INO-1400 Inovio Pharmaceuticals pancreatic cancer Phase I

(hTERT immunotherapy) Plymouth Meeting, PA (see also breast, lung) www.inovio.com
ipafricept Bayer HealthCare Pharmaceuticals pancreatic cancer (combination therapy) Phase I

(Wnt protein inhibitor) Whippany, NJ (see also liver, ovarian) www.healthcare.bayer.com
OncoMed Pharmaceuticals www.oncomed.com
Redwood City, CA
Pancreatic Cancer
Jakafi Incyte pancreatic cancer (Fast Track) Phase III

ruxolitinib Wilmington, DE (see also breast, colorectal, lung) www.incyte.com
KLT injection KangLaiTe USA advanced pancreatic cancer Phase II

(kanglaite) Redwood City, CA www.kanglaite-usa.com
LipoPlatin In Ovations Holdings pancreatic cancer Phase III

cisplatin liposomal Doral, FL www.regulon.org
Regulon
Alimos, Greece
Lynparza AstraZeneca pancreatic cancer Phase III

olaparib Wilmington, DE (see also breast, ovarian, prostate, stomach) www.astrazeneca.com
masitinib AB Science USA metastatic pancreatic cancer Phase III

Short Hills, NJ (see also stomach) www.ab-science.com
MM-141 Merrimack Pharmaceuticals metastatic pancreatic cancer (1st-line) Phase II

(IGF-1R/ErbB3 bispecific Cambridge, MA www.merrimackpharma.com
tetravalent antibody)
Orphan Drug
MM-398 Baxalta metastatic pancreatic cancer (1st-line) (Fast Track) application submitted
(encapsulated irinotecan Cambridge, MA (see also brain, solid tumors) www.baxalta.com
nanotherapeutic)
Orphan Drug
momelotinib Gilead Sciences pancreatic cancer Phase III

(JAK inhibitor) Foster City, CA (see also hematological) www.gilead.com
necuparanib Momenta Pharmaceuticals pancreatic cancer (1st-line) Phase II

(angiogenesis inhibitor) Cambridge, MA (Fast Track) www.momentapharma.com
Orphan Drug
Pancreatic Cancer
OGF/MENK Immune Therapeutics pancreatic cancer Phase II

(methionine enkephalin) Orlando, FL www.immunetherapeutics.com
oregovomab Quest PharmaTech pancreatic cancer Phase II

Orphan Drug Edmonton, Canada (see also ovarian) www.questpharmatech.com
PBI-05204 Phoenix Biotechnology pancreatic cancer Phase II

(triple kinase inhibitor) San Antonio, TX www.phoenixbiotechnology.com
PEGPH20 Halozyme Therapeutics metastatic pancreatic cancer Phase II

(pegylated recombinant San Diego, CA (see also lung) www.halozyme.com
human hyaluronidase)
Orphan Drug
PLX7486 Plexxikon pancreatic cancer Phase I

(TRK inhibitor) Berkeley, CA www.plexxikon.com
polyclonal antibody stimulator Cancer Advances pancreatic cancer Phase III completed
(G17DT) Durham, NC (see also colorectal, stomach) www.canceradvancesinc.com
Orphan Drug
PRI-724 PRISM Pharma metastatic pancreatic adenocarcinoma Phase I/II

(CBP/beta catenin inhibitor) Tokyo, Japan (see also leukemia) www.prismbiolabs.com
Reolysin Oncolytics Biotech metastatic pancreatic cancer Phase II

Orphan Drug myeloma, ovarian, other)
RG7882 Genentech/Roche pancreatic cancer Phase I

(antibody drug conjugate) South San Francisco, CA (see also ovarian) www.roche.com
Pancreatic Cancer
rucaparib Clovis Oncology pancreatic cancer Phase II

(PARP inhibitor) Boulder, CO (see also breast, ovarian, other) www.clovisoncology.com
SM04755 Samumed advanced pancreatic cancer Phase I

(Wnt inhibitor) San Diego, CA (see also colorectal, liver, stomach) www.samumed.com
TAK-264 Takeda Oncology pancreatic cancer Phase II

(antibody drug conjugate Cambridge, MA (see also stomach) www.takedaoncology.com
targeting GCC)
tarextumab OncoMed Pharmaceuticals advanced pancreatic cancer Phase II

(anti-NOTCH 2/3 mAb) Redwood City, CA (see also lung) www.oncomed.com
Orphan Drug
TL-118 Tiltan Pharma pancreatic cancer (1st-line) Phase II

(angiogenesis inhibitor) Jerusalem, Israel www.tiltanpharma.com
vantictumab OncoMed Pharmaceuticals advanced pancreatic cancer Phase I

(anti-Fzd7) Redwood City, CA (combination therapy) www.oncomed.com
(see also breast, lung)
X-82 Tyrogenex pancreatic neuroendocrine tumors Phase I/II

(VEGFR/PDGFR antagonist) Palm Beach Gardens, FL www.tyrogenex.com
Y-90 clivatuzumab tetraxetan Immunomedics relapsed pancreatic cancer Phase III

Orphan Drug Morris Plains, NJ (Fast Track) www.immunomedics.com
pancreatic cancer (1st-line) Phase I/II

(Fast Track) www.immomedics.com
Prostate Cancer
177Lu-J591 BZL Biologics metastatic prostate cancer Phase II

(PSMA mAb) New York, NY
Cornell University
Ithaca, NY
ADXS-PSA Advaxis hormone refractory prostate cancer Phase I/II

(immunotherapy vaccine) Princeton, NJ www.advaxis.com
AE37 Antigen Express prostate cancer Phase II

(immunotherapeutics) Worcester, MA (see also breast) www.antigenexpress.com
aglatimagene besadenovec Advantagene newly-diagnosed prostate cancer Phase III

(gene therapy) Auburndale, MA (see also brain, prostate) www.advantagene.com
apatorsen OncoGenex Pharmaceuticals prostate cancer Phase II

(Hsp27 inhibitor) Bothell, WA (see also bladder, lung, pancreatic) www.oncogenex.com
APC100 Adamis Pharmaceuticals prostate cancer Phase I/II

(androgen antagonist) San Diego, CA www.adamispharmaceuticals.com
ASN001 Asana BioSciences prostate cancer Phase I/II

(CYP17 lyase inhibitor) Bridgewater, NJ www.asanabiosciences.com
BPX-201 Bellicum Pharmaceuticals metastatic castration-resistant prostate cancer Phase I

(dendritic cell vaccine) Houston, TX www.bellicum.com
CFG920 Novartis Pharmaceuticals metastatic castration-resistant prostate cancer Phase I/II

(CYP17 inhibitor) East Hanover, NJ www.novartis.com
custirsen (OGX-111) OncoGenex Pharmaceuticals metastatic castration-resistant prostate cancer Phase III
(antisense olignucleotide) Bothell, WA (2nd-line) www.oncogenex.com
Prostate Cancer
docetaxel injection concentrate, Teikoku Pharma USA prostate cancer application submitted
non-alcohol formula San Jose, CA (see also breast, head/neck, lung, stomach) www.teikokuusa.com
DPV-001 UbiVac advanced prostate cancer Phase I

(toll-like receptor agonist) Portland, OR (see also lung) www.ubivac.com
DPX-0907 Immunovaccine prostate cancer Phase I

(T lymphocyte modulator) Halifax, Canada (see also breast, ovarian) www.imvaccine.com
EC1169 Endocyte prostate cancer Phase I

(PSMA tubulysin) West Lafayette, IN www.endocyte.com
encapsulated cell therapy Rogosin Institute metastatic prostate cancer Phase II

New York, NY (see also colorectal, pancreatic) www.rogosin.org
New York, NY
FP-001 Foresee Pharmaceuticals late-stage prostate cancer Phase III

(leuprolide mesylate) Newark, DE www.foreseepharma.com
galeterone Tokai Pharmaceuticals metastatic prostate cancer (1st-line) Phase III

(androgen receptor antagonist) Cambridge, MA (Fast Track www.tokaipharma.com
treatment-resistant prostate cancer Phase I

(Fast Track) www.tokaipharma.com
GTx-758 GTx secondary hormone therapy for Phase II

(ER alpha agonist) Memphis, TN castration-resistant prostate cancer www.gtxinc.com
indoximod NewLink Genetics metastatic castration-resistant Phase II

(IDO pathway inhibitor) Ames, IA prostate cancer www.newlinkgenetics.com
(see also brain, breast)
Prostate Cancer
ipatasertib Array BioPharma prostate cancer Phase II

(Akt inhibitor) Boulder, CO (see also breast, stomach) www.roche.com
Genentech/Roche
IRX4204 Io Therapeutics prostate cancer Phase II

(retinoid X receptor factor) Santa Ana, CA www.io-therapeutics.com
Jevtana Sanofi US metastatic prostate cancer (1st-line) Phase III

cabazitaxel Bridgewater, NJ (see also brain) www.sanofi.com
JNJ927/ARN-509 Janssen Research & Development castration-resistant prostate cancer, Phase III
(androgen receptor antagonist) Raritan, NJ treatment nave metastatic www.janssenrnd.com
castration-resistant prostate cancer
KLT gel cap KangLaiTe USA prostate cancer Phase II

(kanglaite) Redwood City, CA www.kanglaite-usa.com
LY3023414 Eli Lilly prostate cancer Phase II

(PI3K/mTOR dual inhibitor) Indianapolis, IN (see also lung) www.lilly.com
Lynparza AstraZeneca prostate cancer Phase III

olaparib Wilmington, DE (see also breast, ovarian, pancreatic, stomach) www.astrazeneca.com
MER-104 Merrion Pharmaceuticals prostate cancer Phase I

(oral acyline) Dublin, Ireland www.merrionpharma.com
MOR209/ES414 Emergent BioSolutions metastatic castration-resistant prostate cancer Phase I

(bispecific immunotherapeutic) Gaithersburg, MD www.emergentbiosolutions.com
MorphoSys www.morphosys.com
Martinsried, Germany
Prostate Cancer
MVI-816 Madison Vaccines prostate cancer (1st-line) Phase II

(PAP plasmid DNA vaccine) Madison, WI www.madisonvaccinesinc.com
NX-1207 Nymox Pharmaceutical prostate cancer Phase III

(apoptosis stimulant) Hasbrouck Heights, NJ www.nymox.com
ODM-201 Bayer HealthCare Pharmaceuticals prostate cancer Phase III

(androgen receptor antagonist) Whippany, NJ www.healthcare.bayer.com
ONC1-13B AllaChem metastatic prostate cancer Phase I/II

(androgen receptor antagonist) Hallandale Beach, FL www.allachem.com
ozarelix Spectrum Pharmaceuticals hormone dependent prostate cancer Phase II

(GnRH inhibitor) Henderson, NV www.sppirx.com
pasireotide long acting release Novartis Pharmaceuticals castration-resistant prostate cancer Phase I/II
(SOM230) East Hanover, NJ (see also other, skin) www.novartis.com
prostate cancer vaccine OncBioMune prostate cancer Phase I

(PSA/IL-2/GM-CSF vaccine) Baton Rouge, LA www.oncbiomune.com
Prostvac Bavarian Nordic metastatic castration-resistant Phase III

rilimogene galvacirepvec- Mountain View, VA prostate cancer (Fast Track) www.bavarian-nordic.com
rilimogene glafolivec Bristol-Myers Squibb www.bms.com
Princeton, NJ
Provenge Dendreon recurrent early-stage prostate cancer Phase III

sipuleucel-T Seattle, WA www.dendreon.com
recurrent hormone refractory Phase II

metastatic prostate cancer www.dendreon.com
Prostate Cancer
PRX302 Sophiris Bio localized low to intermediate risk Phase II

(recombinant protein) La Jolla, CA prostate cancer www.sophirisbio.com
PSMA ADC therapeutic Progenics Pharmaceuticals prostate cancer Phase II

(antibody drug conjugate) Tarrytown, NY www.progenics.com
REIC gene therapy Momotaro-Gene prostate cancer Phase I/II

Okayama, Japan www.mt-gene.com
relugolix (TAK-385) Takeda Oncology prostate cancer Phase II

(LH-RH antagonist) Cambridge, MA www.takedaoncology.com
RG7450 Genentech/Roche prostate cancer Phase I

(anti-STEAP1 antibody drug South San Francisco, CA www.roche.com
conjugate)
selinexor (oral) Karyopharm Therapeutics prostate cancer Phase II

leukemia, lymphoma, myeloma, sarcoma, other)
stapuldencel-T Sotio metastatic castration-resistant prostate cancer Phase III

(active cellular immunotherapy) Prague, Czech Republic www.sotio.com
TT-100 TriAct Therapeutics prostate cancer Phase II completed

(IGF-1/EGF dual inhibitor) San Francisco, CA
VT-122 Vicus Therapeutics prostate cancer Phase II

(cancer immunotherapy) Morristown, NJ (see also liver) www.vicustherapeutics.com
VT-464 Innocrin Pharmaceuticals castration-resistant prostate cancer Phase II

(CYP17 lyase inhibitor) Durham, NC www.innocrinpharma.com
Prostate Cancer
Xofigo Bayer HealthCare Pharmaceuticals bone metastases in castration-resistant Phase III

radium-223 dichloride Whippany, NJ prostate cancer (1st-line) (combination therapy) www.healthcare.bayer.com
bone metastases in castration-resistant Phase II

prostate cancer (combination therapy) www.healthcare.bayer.com
Xtandi Astellas Pharma US non-metastatic castration-resistant prostate Phase III

enzalutamide Northbrook, IL cancer, prostate cancer in patients with www.astellas.com
Medivation non-metastatic biochemical recurrence www.medivation.com
San Francisco, CA (see also breast, liver)
zoptarelin doxorubicin Aeterna Zentaris castration-/taxane-resistant prostate cancer Phase II

(type II DNA topoisomerase Quebec, Canada (see also other) www.aezsinc.com
inhibitor)
Sarcoma
aldoxorubicin CytRx soft tissue sarcoma (2nd-line) Phase III

(delivery-enhanced doxorubicin) Los Angeles, CA (see also brain, lung) www.cytrx.com
Orphan Drug
Kaposi's sarcoma, Phase II

soft tissue sarcoma (1st-line) www.cytrx.com
ENMD-2076 CASI Pharmaceuticals soft tissue sarcoma Phase II

(aurora A/angiogenic kinase Rockville, MD (see also breast, ovarian) www.casipharmaceuticals.com
inhibitor)
Sarcoma
evofosfamide (TH-302) EMD Serono soft tissue sarcoma (Fast Track) Phase III
(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, lung, pancreatic, skin) www.emdserono.com
Orphan Drug Threshold Pharmaceuticals www.thresholdpharm.com
G100 Immune Design metastatic soft tissue sarcoma Phase I

(TLR4 agonist) Seattle, WA (see also skin) www.immunedesign.com
GPX-150 Gem Pharmaceuticals soft tissue sarcoma Phase II

(type II DNA topoisomerase Birmingham, AL www.gempharmaceuticals.com
inhibitor)
Halaven Eisai soft tissue sarcoma application submitted

eribulin Woodcliff Lake, NJ (see also bladder, lung) www.eisai.com
Orphan Drug
HDM201 Novartis Pharmaceuticals liposarcoma Phase I/II

(tumor suppressor protein East Hanover, NJ (see also hematological, solid tumors) www.novartis.com
p53 modulator)
inhaled lipid-complexed cisplatin Eleison Pharmaceuticals prevention of pulmonary metastases Phase II

St. Petersburg, MD from osteosarcoma (pediatric) www.eleison-pharma.com
MORAb-004 Eisai soft tissue sarcoma Phase II

(CD248 antigen inhibitor) Woodcliff Lake, NJ (see also colorectal, skin) www.eisai.com
Orphan Drug
niraparib TESARO Ewing's sarcoma Phase I

(PARP inhibitor) Waltham, MA (see also breast, ovarian) www.tesarobio.com
NY-ESO-1/LAGE-1-specific T-cells Adaptimmune synovial sarcoma Phase I

Oxon, England (see also myeloma, ovarian, skin) www.adaptimmune.com
Sarcoma
olaratumab Eli Lilly soft tissue sarcoma Phase II

(PDGF-alpha receptor antagonist) Indianapolis, IN www.lilly.com
sarcoma vaccine MabVax Therapeutics metastatic sarcoma Phase II

San Diego, CA www.mabvax.com
selinexor (oral) Karyopharm Therapeutics liposarcoma Phase II

(XPO1 antagonist) Newton, MA (see also brain, head/neck, hematological, leukemia, www.karyopharm.com
lymphoma, myeloma, prostate, other)
TRC105 TRACON Pharmaceuticals soft tissue sarcoma Phase II

lung, other)
Vigil Gradalis Ewing's sarcoma Phase II

autologous immunotherapy Dallas, TX (see also ovarian) www.gradalisinc.com
Yondelis Janssen Research & Development soft tissue sarcoma application submitted
trabectedin Raritan, NJ (see also ovarian) www.janssenrnd.com
Orphan Drug
Skin Cancer
ADI-PEG 20 Polaris Pharmaceuticals melanoma Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, ovarian, pancreatic, www.polarispharma.com
Orphan Drug stomach)
AE-M Antigen Express melanoma Phase I

(immunotherapeutic) Worcester, MA www.antigenexpress.com
Skin Cancer
alpha-gal glycosphingolipid Agalimmune melanoma Phase I

(immunotherapy) Irvine, CA www.agalimmune.com
ALT-803 Altor BioScience metastatic melanoma Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also bladder, hematological, myeloma) www.altorbioscience.com
AMG 232 Amgen metastatic melanoma Phase I/II

(MDM2 inhibitor) Thousand Oaks, CA (see also leukemia, myeloma, solid tumors) www.amgen.com
avelumab EMD Serono metastatic Merkel cell carcinoma Phase II

(anti-PD-L1 mAb) Rockland, MA (see also lung, solid tumors) www.emdserono.com
New York, NY
bavituximab Peregrine Pharmaceuticals advanced melanoma Phase I

Tustin, CA (see also breast, colorectal, lung) www.peregrineinc.com
BBI608 Boston Biomedical melanoma Phase I

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, hematological, liver, www.bostonbiomedical.com
lung, ovarian, pancreatic, stomach)
binimetinib Array BioPharma BRAF-mutant melanoma, NRAS-mutant melanoma Phase III

(MEK inhibitor) Boulder, CO (see also ovarian) www.arraybiopharma.com
Cavatak Vitalytics metastatic melanoma Phase II

coxsackievirus A21 Sydney, Australia www.viralytics.com
Orphan Drug
CDX-1401 Celldex Therapeutics metastatic melanoma Phase II

(NY-ESO-1 cancer vaccine) Hampton, NJ www.celldex.com
Skin Cancer
cobimetinib Genentech/Roche metastatic melanoma application submitted

(MEK inhibitor) South San Francisco, CA (combination therapy) www.roche.com
diphencyprone Rxi Pharmaceuticals cutaneous cancer metastases Phase II

(immunomodulator) Marlborough, MA www.rxipharma.com
dorgenmeltucel-L NewLink Genetics metastatic melanoma Phase II

(cancer immunotherapy) Ames, IA www.newlinkgenetics.com
eltrapuldencel-T (CLBS20) Caladrius Biosciences metastatic melanoma (Fast Track) Phase III
(dendritic cell immunotherapy) New York, NY www.caladrius.com
Orphan Drug
encorafenib (LGX818) Array BioPharma BRAF mutant melanoma Phase III

(BRAF inhibitor) Boulder, CO www.arraybiopharma.com
entinostat Syndax Pharmaceuticals melanoma (combination therapy) Phase I/II

(HDAC inhibitor) Waltham, MA (see also breast, lung) www.syndax.com
epacadostat Incyte metastatic melanoma Phase II

(IDO1 inhibitor) Wilmington, DE (see also lung, ovarian, other) www.incyte.com
Erivedge Genentech/Roche operable basal cell carcinoma Phase II

vismodegib South San Francisco, CA www.roche.com
evofosfamide (TH-302) EMD Serono melanoma Phase II

(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, lung, www.emdserono.com
Threshold Pharmaceuticals pancreatic, sarcoma) www.thresholdpharm.com
G100 Immune Design Merkel cell carcinoma Phase I

(TLR4 agonist) Seattle, WA (see also sarcoma) www.immunedesign.com
Skin Cancer
glembatumumab vedotin CellDex Therapeutics stage III or IV metastatic melanoma Phase II

(antibody drug conjugate) Hampton, NJ (see also breast) www.celldex.com
GR-MD-02 Galectin Therapeutics melanoma Phase II

(galectin-3 inhibitor) Norcross, GA www.galectintherapeutics.com
heat shock protein vaccine Agenus metastatic melanoma Phase II

(Prophage Series) Lexington, MA (see also brain) www.agenus.com
Orphan Drug
HF10 Takara Bio metastatic melanoma Phase II

(oncolytic virus immunomodulator) Shiga, Japan (see also head/neck) www.tkara-bio.com
IMCgp100 Immunocore metastatic melanoma Phase II

(CD3 antigen inhibitor) Oxon, England www.immunocore.com
interleukin-12 gene therapy OncoSec Medical metastatic melanoma Phase II

San Diego, CA (see also breast, head/neck) www.oncosec.com
INXN-2001 ZIOPHARM Oncology metastatic melanoma Phase II

(Ad-RTS-IL-12 gene therapy) Boston, MA (see also brain, breast) www.ziopharm.com
Lenvima Eisai melanoma Phase II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, lung, other, solid tumors) www.eisai.com
Orphan Drug
LN-144 Lion Biotechnologies metastatic melanoma (2nd-line) Phase II completed

(autologous cell therapy) Woodland Hills, CA www.lbio.com
Orphan Drug National Cancer Institute
Bethesda, MD
metastatic melanoma (1st-line) Phase I
(combination therapy) www.lbio.com
Skin Cancer
MEDI4736 + dabrafenib + MedImmune melanoma Phase I

trametinib Gaithersburg, MD www.medimmune.com
(anti-PD-L1 mAb/murine OX40
agonist/MEK inhibitor)
MGA271 Macrogenics metastatic melanoma (combination therapy) Phase I

(CD276 protein inhibitor) Rockville, MD (see also head/neck, lung) www.macrogenics.com
MORAb-004 Eisai melanoma Phase II

(CD248 antigen inhibitor) Woodcliff Lake, NJ (see also colorectal, sarcoma) www.eisai.com
NY-ESO-1/LAGE-1-specific T-cells Adaptimmune melanoma Phase I/II

Oxon, England (see also myeloma, ovarian, sarcoma) www.adaptimmune.com
onalespib (AT13387) Astex Pharmaceuticals B-raf melanoma Phase II

(Hsp90 inhibitor) Pleasanton, CA (see also lung) www.astx.com
Ontak Eisai metastatic melanoma Phase II

denileukin diftitox Woodcliff Lake, NJ www.eisai.com
Opdivo Bristol-Myers Squibb melanoma (adjuvant), Phase III

hematological, kidney, liver, lung, lymphoma,
Opdivo nivolumab + Bristol-Myers Squibb melanoma (1st-line) Phase III

Yervoy ipilimumab Princeton, NJ (see also kidney, lung, solid tumors) www.bms.com
pasireotide long acting release Novartis Pharmaceuticals merkel cell carcinoma, metastatic melanoma Phase I
(SOM230) East Hanover, NJ (combination therapy) www.novartis.com
(see also prostate, other)
pimasertib EMD Serono melanoma Phase II

(MEK inhibitor) Rockland, MA www.emdserono.com
Skin Cancer
PLX3397 Plexxikon melanoma Phase I

(CSF-1R inhibitor) Berkeley, CA (see also brain, breast, ovarian, other) www.plexxikon.com
Resimmune Angimmune metastatic melanoma Phase I/II

A-dmDT390-bisFv immunotoxin Rockville, MD (see also lymphoma) www.angimmune.com
RG7446 Genentech/Roche metastatic melanoma Phase I

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, breast, kidney, lung, lymphoma) www.roche.com
RTA 408 AbbVie melanoma Phase II

(NF/E2-related factor 2 stimulant) North Chicago, IL www.abbvie.com
Reata Pharmaceuticals www.reatapharma.com
Irving, TX
seviprotimut-L Polynoma metastatic melanoma Phase III

(immunotherapy vaccine) San Diego, CA www.polynoma.com
Orphan Drug
Tafinlar Novartis Pharmaceuticals BRAF V600-positive melanoma (adjuvant) Phase III

dabrafenib East Hanover, NJ (see also colorectal, lung) www.novartis.com
Mekinist
trametinib
combination
talimogene laherparepvec Amgen regionally and distantly metastatic melanoma application submitted
(cancer immunotherapy) Thousand Oaks, CA www.amgen.com
mid- to late-stage metastatic melanoma Phase II

www.amgen.com
TLPLDC Cancer Insight melanoma Phase II

(tumor lysate particle-loaded San Antonio, TX www.cancerinsight.com
dendritic cell vaccine) Elios Therapeutics www.eliostherapeutics.com
Austin, TX
Skin Cancer
TRX518 GITR advanced melanoma Phase I

(GITR receptor antagonist) Cambridge, MA (see also solid tumors) www.gitrrx.com
varlilumab Celldex Therapeutics unresectable stage III or IV melanoma Phase I/II

(CD27 antigen inhibitor) Hampton, NJ (combination therapy) www.celldex.com
(see also hematological, kidney)
veliparib AbbVie melanoma Phase II

(PARP inhibitor) North Chicago, IL (see also brain, breast, colorectal, lung) www.abbvie.com
Yervoy Bristol-Myers Squibb melanoma (adjuvant) Phase III

ipilimumab Princeton, NJ (see also lung) www.bms.com
Orphan Drug
melanoma (adolescent) Phase II

www.bms.com
Zelboraf Genentech/Roche BRAF mutation-positive metastatic Phase III

vemurafenib South San Francisco, CA melanoma (adjuvant) www.roche.com
Daiichi Sankyo (see also colorectal, other)
Parsippany, NJ
BRAF mutation-positive metastatic melanoma Phase I

www.roche.com
Solid Tumors
ABBV-221 AbbVie solid tumors Phase I

(epidermal growth factor modulator) North Chicago, IL www.abbvie.com
ABBV-399 AbbVie solid tumors Phase I

(antibody drug conjugate) North Chicago, IL www.abbvie.com
Solid Tumors
ABT-165 AbbVie solid tumors Phase I

(dual variable immunoglobulin) North Chicago, IL www.abbvie.com
ABT-414 AbbVie squamous cell solid tumors Phase II

(antibody drug conjugate) North Chicago, IL (see also brain) www.abbvie.com

(c-Met inhibitor) North Chicago, IL www.abbvie.com

(PARP inhibitor) North Chicago, IL www.abbvie.com

(epidermal growth factor receptor North Chicago, IL www.abbvie.com
antagonist)
AG-120 Agios Pharmaceuticals solid tumors Phase I

(IDH1 inhibitor) Cambridge, MA (see also brain, leukemia) www.agios.com
Summit, NJ
AG-221 Agios Pharmaceuticals advanced solid tumors Phase I/II

(IDH2 inhibitor) Cambridge, MA (see also leukemia) www.agios.com
Summit, NJ
AG-881 Agios Pharmaceuticals advanced solid tumors Phase I

(pan-IDH inhibitor) Cambridge, MA www.agios.com
Summit, NJ
Solid Tumors
AGS-22ME Agenesys relapsed solid tumors Phase I

(antibody drug conjugate) Santa Monica, CA www.agenesys.com
Seattle Genetics www.seattlegenetics.com
Bothell, WA
ALRN-6924 Aileron Therapeutics advanced solid tumors Phase I/II

(next-generation dual-specific Cambridge, MA www.aileronrx.com
MDM2/MDMX antagonist)
ALT-836 Altor BioScience solid tumors Phase I/II

(recombinant chimeric Miramar, FL www.altorbioscience.com
anti-tissue factor antibody)
altiratinib Deciphera Pharmaceuticals solid tumors Phase I

(MET/TIE2/VEGFR2 kinase Cambridge, MA www.deciphera.com
inhibitor)
AM0010 ARMO BioSciences solid tumors Phase I

(PEGylated recombinant Redwood City, CA www.armobio.com
human IL-10)
AMG 208 Amgen solid tumors Phase I

(c-Met inhibitor) Thousand Oaks, CA www.amgen.com
AMG 211/MEDI-565 Amgen solid tumors Phase I

(anti-CEA BiTE mAb) Thousand Oaks, CA www.amgen.com
MedImmune www.medimmune.com
Gaithersburg, MD

(mAb) Thousand Oaks, CA www.amgen.com

(MDM2 inhibitor) Thousand Oaks, CA (see also leukemia, myeloma, skin) www.amgen.com
Solid Tumors
AMG 780 Amgen advanced solid tumors Phase I

(angiopoietin inhibitor) Thousand Oaks, CA www.amgen.com

(c-fms inhibitor) Thousand Oaks, CA www.amgen.com

(aurora kinase inhibitor) Thousand Oaks, CA (see also hematological) www.amgen.com
anetumab ravtansine Bayer HealthCare Pharmaceuticals solid tumors Phase II

(antibody drug conjugate) Whippany, NJ www.healthcare.bayer.com
anti-LAG3 antibody + Bristol-Myers Squibb solid tumors Phase I

Opdivo nivolumab Princeton, NJ www.bms.com
apatinib mesylate LSK BioPartners Inc. solid tumors Phase I/II

(YN968D1) Salt Lake City, UT www.lskbiopharma.com
Bukwang Pharmaceutical
Seoul, South Korea
APN401 Apeiron Biologics solid tumors Phase I

(siRNA-transfected peripheral blood Vienna, Austria www.apeiron-biologics.com
mononuclear cells)
APS001F Anaeropharma Science solid tumors Phase I

(recombinant anaerobic bacteria) Tokyo, Japan www.anaeropharma.co.jp
APX005M Apexigen solid tumors Phase I

(CD40 antigen inhibitor) San Carlos, CA www.apexigen.com
AR-12 Arno Therapeutics solid tumors Phase I

(PI3K/Akt inhibitor) Flemington, NJ (see also lymphoma) www.arnothera.com
Solid Tumors
AR-42 Arno Therapeutics solid tumors Phase I

(pan-DAC inhibitor) Flemington, NJ (see also hematological) www.arnothera.com
ARQ 087 ArQule metastatic solid tumors Phase I

(FGFR antagonist) Woburn, MA www.arqule.com
ARQ 092 ArQule advanced solid tumors Phase I

(Akt inhibitor) Woburn, MA www.arqule.com
ARQ 761 ArQule advanced solid tumors Phase I

(E2F1 transcription factor Woburn, MA www.arqule.com
stimulant)
ASB183 Novartis Pharmaceuticals solid tumors Phase I

East Hanover, NJ (see also hematological) www.novartis.com
ASP4132 Astellas Pharma US advanced solid tumors Phase I

Northbrook, IL (see also lymphoma) www.astellas.com
AT13148 Astex Pharmaceuticals solid tumors Phase I

(ROCK inhibitor) Pleasanton, CA www.astx.com
ATI-1123 Azaya Therapeutics solid tumors Phase I

(docetaxel liposomal) San Antonio, TX www.azayatherapeutics.com
AV-203 AVEO Oncology advanced solid tumors Phase I completed

(ERBB-3 receptor antagonist) Cambridge, MA www.aveooncology.com
avelumab EMD Serono solid tumors Phase I

(anti-PD-L1 mAb) Rockland, MA (see also lung, skin) www.emdserono.com
New York, NY
Solid Tumors
AZD2014 AstraZeneca solid tumors Phase II

(mTOR serine/threonine Wilmington, DE www.astrazeneca.com
kinase inhibitor)
AZD4547 AstraZeneca solid tumors Phase II

(FGFR tyrosine kinase inhibitor) Wilmington, DE www.astrazeneca.com
AZD5312 AstraZeneca solid tumors Phase I

(androgen receptor inhibitor) Wilmington, DE www.astrazeneca.com
Isis Pharmaceuticals www.isispharm.com
Carlsbad, CA

(ATR serine/threonine Wilmington, DE www.astrazeneca.com
kinase inhibitor)

(PI3K beta inhibitor) Wilmington, DE www.astrazeneca.com

(PI3K alpha inhibitor) Wilmington, DE www.astrazeneca.com
BAY1125976 Bayer HealthCare Pharmaceuticals advanced solid tumors Phase I

(allosteric Akt-1/2 inhibitor) Whippany, NJ www.healthcare.bayer.com

(antibody drug conjugate) Whippany, NJ www.healthcare.bayer.com

(MPS1 inhibitor) Whippany, NJ www.healthcare.bayer.com

(type 2 FGFR antagonist) Whippany, NJ www.healthcare.bayer.com
Solid Tumors

(MPS1 inhibitor) Whippany, NJ www.healthcare.bayer.com
Beigene-283 EMD Serono solid tumors Phase I

(BRAF inhibitor) Rockland, MA www.emdserono.com
Beigene-290 EMD Serono solid tumors Phase I

(PARP inhibitor) Rockland, MA www.emdserono.com
bendamustine ready-to-dilute Eagle Pharmaceuticals solid tumors Phase I

liquid formulation Woodcliff Lake, NJ (see also leukemia, lymphoma) www.eagleus.com
BET inhibitor Bristol-Myers Squibb solid tumors Phase I

BGJ398 Novartis Pharmaceuticals solid tumors Phase II

(FGF-R kinase inhibitor) East Hanover, NJ (see also brain) www.novartis.com
BI 836845 Boehringer Ingelheim Pharmaceuticals solid tumors Phase I

(somatomedin inhibitor) Ridgefield, CT www.boehringer-ingelheim.com

(PTK2 protein inhibitor) Ridgefield, CT www.boehringer-ingelheim.com

Ridgefield, CT www.boehringer-ingelheim.com
BPM31510 Berg Pharma solid tumors Phase I

(ubidecarenone) Framingham, MA www.berghealth.com
briciclib Onconova Therapeutics metastatic solid tumors Phase I

(cyclin D1 modulator) Newtown, PA www.onconova.com
Solid Tumors
brontictuzumab OncoMed Pharmaceuticals solid tumors Phase I

(NOTCH-1 inhibitor) Redwood City, CA (see also hematological) www.oncomed.com
buparlisib (BKM120) Novartis Pharmaceuticals solid tumors Phase I

(PI3K inhibitor) East Hanover, NJ (see also brain, breast) www.novartis.com
BVD-523 BioMed Valley Discoveries advanced solid tumors Phase I/II

(ERK 1/2 kinase inhibitor) Kansas City, MO (see also hematological, leukemia) www.biomed-valley.com
BVD-CNV BioMed Valley Discoveries advanced solid tumors Phase I

(C. novyi-NT) Kansas City, MO www.biomed-valley.com
BYL719 Novartis Pharmaceuticals solid tumors Phase I

(PI3K-alpha inhibitor) East Hanover, NJ www.novartis.com
CB-839 Calithera Biosciences solid tumors Phase I

(glutaminase inhibitor) South San Francisco, CA (see also hematological) www.calithera.com
CBL0102 Cleveland BioLabs advanced solid tumors Phase I

(apoptosis stimulant) Buffalo, NY www.cbiolabs.com
CBL0137 Incuron advanced solid tumors Phase I

(curaxin) Buffalo, NY www.incuron.ru/en
CC-115 Celgene solid tumors Phase I

(dual TORK/DNA PK inhibitor) Summit, NJ www.celgene.com

(dual TORK inhibitor) Summit, NJ www.celgene.com

(anti-CD47 antibody) Summit, NJ www.celgene.com
Solid Tumors

(ERK inhibitor) Summit, NJ www.celgene.com
CEP-37440 Teva Oncology advanced solid tumors Phase I

(dual anaplastic lymphoma Frazer, PA www.tevapharm.com
kinase and PTK2 protein inhibitor)
CGM097 Novartis Pharmaceuticals solid tumors with p53 wild type status Phase I
(p53/MDM2-interaction inhibitor) East Hanover, NJ www.novartis.com
CLR457 Novartis Pharmaceuticals advanced solid tumors Phase I/II

(PI3K inhibitor) East Hanover, NJ www.novartis.com
CMB305 Immune design advanced solid tumors Phase I

(cancer immunotherapy) Seattle, WA www.immunedesign.com
crolibulin Immune Pharmaceuticals solid tumors Phase II

Cambridge, MA www.immunepharmaceuticals.com
CUDC-427 Curis late-stage solid tumors Phase I

(IAP inhibitor) Lexington, MA (see also lymphoma) www.curis.com
CUDC-907 Curis late-stage solid tumors Phase I

(HDAC/PI3K inhibitor) Lexington, MA (see also lymphoma, myeloma) www.curis.com
CX-01 Cantex Pharmaceuticals solid tumors (pediatric) Phase I

(O-desulfated heparin intravenous) Weston, FL (see also leukemia, lung) www.cantex.com
CYT-6091 CytImmune solid tumors Phase I

(nanomedicine) Rockville, MD www.cytimmune.com
Solid Tumors
DCVax-Direct Northwest Biotherapeutics inoperable solid tumors Phase I/II

dendritic cell vaccine Bethesda, MD www.nwbio.com
Debio 1347 Debiopharm late-stage solid tumors Phase I

(FGFR inhibitor) Lausanne, Switzerland www.debiopharm.com
DFP-11207 Delta-Fly Pharma advanced solid tumors Phase I

(thymidylate synthase Tokushima, Japan
expression inhibitor)
DLYE-5953A Genentech/Roche refractory solid tumors Phase I

South San Francisco, CA www.roche.com
DS-3032 Daiichi Sankyo late-stage solid tumors Phase I

(MDM2 inhibitor) Parsippany, NJ (see also lymphoma) www.dsi.com
DS-3078 Daiichi Sankyo solid tumors Phase I

(mTOR inhibitor) Parsippany, NJ (see also lymphoma) www.dsi.com

(ROS1/NTRK inhibitor) Parsippany, NJ www.dsi.com
DS-7423 Daiichi Sankyo solid tumors Phase I

(PI3K/mTOR inhibitor) Parsippany, NJ www.dsi.com

(anti-DR5 antibody) Parsippany, NJ (see also lymphoma) www.dsi.com
duligotuzumab Genentech/Roche solid tumors with mutant KRAS Phase I

(anti-HER3/EGFR DAF mAb) South San Francisco, CA www.roche.com
Solid Tumors
E7046 Eisai solid tumors Phase I

Woodcliff Lake, NJ www.eisai.com
EC1456 Endocyte solid tumors Phase I

(folate tubulysin) West Lafayette, IN www.endocyte.com
entolimod Cleveland BioLabs advanced solid tumors Phase I

(cancer immunotherapy) Buffalo, NY www.cbiolabs.com
EPZ-6438 Epizyme solid tumors Phase I/II

(EZH2 inhibitor) Cambridge, MA (see also lymphoma) www.epizyme.com
GDC-0575 (RG7741) Genentech/Roche solid tumors Phase I

(ChK1 inhibitor) South San Francisco, CA (see also lymphoma) www.roche.com

(IDO inhibitor) South San Francisco, CA www.roche.com

(ERK inhibitor) South San Francisco, CA www.roche.com
gedatolisib Pfizer solid tumors Phase I

(PI3K/mTOR inhibitor) New York, NY www.pfizer.com
GS-5745 Gilead Sciences solid tumors Phase I

(MMP9 mAb inhibitor) Foster City, CA (see also stomach) www.gilead.com
GS-5829 Gilead Sciences solid tumors Phase I

(BET inhibitor) Foster City, CA (see also lymphoma) www.gilead.com
HDM201 Novartis Pharmaceuticals advanced solid tumors Phase I

(tumor suppressor protein East Hanover, NJ (see also hematological, sarcoma) www.novartis.com
p53 modulator)
Solid Tumors
hetIL-15 Admune Therapeutics metastatic solid tumors Phase I

(heterodimeric interleukin-16) Danvers, MA www.admune.com
Bethesda, MD
idasanutlin Genentech/Roche solid tumors Phase I

(MDM2 antagonist) South San Francisco, CA (see also hematological) www.roche.com
IDH305 Novartis Pharmaceuticals advanced solid tumors with IDHR132 Phase I

(IDH inhibitor) East Hanover, NJ mutations www.novartis.com
INCB54828 Incyte solid tumors Phase I

(FGFR inhibitor) Wilmington, DE www.incyte.com
Inlyta Pfizer solid tumors (combination therapy) Phase I

axitinib New York, NY (see also kidney) www.pfizer.com
IT-139 Intezyne solid tumors Phase I

(GRP78 protein inhibitor) Tampa, FL www.intezyne.com
ixazomib Takeda Oncology solid tumors Phase I

(proteasome inhibitor) Cambridge, MA (see also myeloma) www.takedaoncology.com
KBP-5209 Sihuan Pharmaceutical solid tumors Phase I

(pan-HER inhibitor) Beijing, China www.sihuanpharm.com
KiroVAX-002 Kiromic metastatic solid tumors Phase I/II

KiroVAX-003 Kiromic metastatic solid tumors Phase I/II

Solid Tumors
KNK2801/CEP-37250 Kyowa Hakko Kirin Pharma advanced solid tumors Phase I

(anti-tumor specific glycoprotein Princeton, NJ www.kyowa-hakko-kirin.com
humanized antibody) Teva Oncology www.tevapharm.com
Frazer, PA
KTN3379 Kolltan Pharmaceuticals advanced solid tumors Phase I

(ErbB3 kinase inhibitor) New Haven, CT (see also other) www.kolltan.com
LB-100 Lixte Biotechnology solid tumors Phase I

(PP2A inhibitor) East Setauket, NY www.lixte.com
Lenvima Eisai solid tumors (combination therapy) Phase I/II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, lung, skin, other) www.eisai.com
LEQ506 Novartis Pharmaceuticals advanced solid tumors Phase I

(SMO antagonist) East Hanover, NJ www.novartis.com
lirilumab + Opdivo nivolumab Bristol-Myers Squibb solid tumors Phase I

LJM716 Novartis Pharmaceuticals solid tumors Phase I

(ERBB-3 receptor antagonist) East Hanover, NJ www.novartis.com
LOXO-101 Array BioPharma solid tumors Phase I

(PanTrk inhibitor) Boulder, CO www.arraybiopharma.com
Loxo Oncology www.loxooncology.com
Stamford, CT
LY2780301 Eli Lilly solid tumors Phase I

(p70S6/Akt dual inhibitor) Indianapolis, In www.lilly.com
M2698 (MSC 2363318A) EMD Serono solid tumors Phase I

(P70S6K/Akt dual inhibitor) Rockland, MA www.emdserono.com
Solid Tumors
M3814 (MSC 2490484A) EMD Serono solid tumors Phase I

(DNA-PK inhibitor) Rockland, MA www.emdserono.com
M9241 (NHS-IL12) EMD Serono solid tumors Phase I

(cancer immunotherapy) Rockland, MA www.emdserono.com
MEDI0562 MedImmune solid tumors Phase I

(humanized OX40 agonist) Gaithersburg, MD www.medimmune.com

(anti-DLL-4 mAb) Gaithersburg, MD www.medimmune.com

(anti-PD-1 mAb) Gaithersburg, MD www.medimmune.com

(anti-ANG-2 mAb) Gaithersburg, MD www.medimmune.com
MEDI4736 MedImmune solid tumors Phase II

(anti-PD-L1 mAb) Gaithersburg, MD (see also head/neck, lung) www.medimmune.com
solid tumors Phase I

www.medimmune.com
MEDI4736 + MEDI0680 MedImmune solid tumors Phase I

(anti-PD-L1 mAb/anti-PD-1 mAb) Gaithersburg, MD www.medimmune.com
MEDI4736 + MEDI6469 MedImmune solid tumors Phase I

(anti-PD-L1 mAb/murine Gaithersburg, MD www.medimmune.com
OX40 agonist)
Solid Tumors
MEDI4736 + tremelimumab MedImmune solid tumors Phase I

(anti-PD-L1 mAb/anti-CTLA-4 mAb) Gaithersburg, MD www.medimmune.com

(OX40 agonist) Gaithersburg, MD www.medimmune.com

(murine OX40 agonist) Gaithersburg, MD www.medimmune.com
MEDI6469 + rituximab MedImmune solid tumors Phase I

(murine OX40 agonist/anti-CD20 mAb) Gaithersburg, MD www.medimmune.com
MEDI6469 + tremelimumab MedImmune solid tumors Phase I

(murine OX40 agonist/anti-CTLA-4 mAb) Gaithersburg, MD www.medimmune.com
mesothelin antibody drug conjugate Bristol-Myers Squibb solid tumors Phase I

MGCD516 Mirati Therapeutics late-stage solid tumors Phase I

(Trk/RET/DDR kinase inhibitor) San Diego, CA www.mirati.com
MK-2206 Merck solid tumors Phase II

(Akt inhibitor) Kenilworth, NJ www.merck.com
MK-4166 Merck solid tumors Phase I

(TNF-RSF18 protein stimulant) Kenilworth, NJ www.merck.com
MK-8242 Merck solid tumors Phase I completed

(MDM-2 inhibitor) Kenilworth, NJ www.merck.com
Solid Tumors
MM-151 Merrimack Pharmaceuticals refractory advanced solid tumors Phase I

(EGFR antagonist) Cambridge, MA www.merrimackpharma.com
MM-398 Baxalta solid tumors (pediatric) Phase I

(encapsulated irinotecan Cambridge, MA (see also brain, pancreatic) www.baxalta.com
nanotherapeutic)
MNK-010 Mallinckrodt Pharmaceuticals solid tumors Phase I

St. Louis, MO www.mallinckrodt.com
MORAb-066 Eisai solid tumors Phase I

(tissue factor antigen inhibitor) Woodcliff Lake, NJ www.eisai.com
MUC-1 dendritic cancer vaccine MicroVAX solid tumors Phase I

Manassas, VA
MVA-BN Brachyury Bavarian Nordic solid tumors Phase I

(immunotherapy vaccine) Mountain View, CA www.bavarian-nordic.com
Bethesda, MD
NC-4016 NanoCarrier solid tumors Phase I

(DACH platin micelle) Chiba, Japan www.nanocarrier.co.jp
OMP-305B83 OncoMed Pharmaceuticals solid tumors Phase I

(DLL3 protein inhibitor) Redwood City, CA www.oncomed.com
ONC201 Oncoceutics advanced solid tumors Phase I

(TRAIL-inducing compound) Hummelstown, PA www.oncoceutics.com
OPB-111077 Otsuka Pharmaceutical solid tumors Phase I

Rockville, MD www.otsuka.com
Solid Tumors
Opdivo Bristol-Myers Squibb solid tumors (signal detection) Phase I

hematological, kidney, liver, lung, lymphoma,
skin, stomach, other)
Opdivo nivolumab + Bristol-Myers Squibb solid tumors Phase I

Yervoy ipilimumab Princeton, NJ (see also kidney, lung, skin) www.bms.com
oprozomib Onyx Pharmaceuticals advanced solid tumors Phase I

(proteasome inhibitor) South San Francisco, CA (see also hematological, myeloma) www.onyx.com
oratecan Kinex Pharmaceuticals solid tumors Phase I

(oral irinotecan) Buffalo, NY www.kinexpharma.com
oraxol Kinex Pharmaceuticals solid tumors Phase I

(oral paclitaxel) Buffalo, NY www.kinexpharma.com
OTS167 OncoTherapy Science solid tumors Phase I

(MELK protein inhibitor) Kanagawa Prefecture, Japan www.oncotherapy.co.jp
OTX015 Merck solid tumors Phase I

(BET inhibitor) Kenilworth, NJ (see also hematological) ww.merck.com
OVI-117 OncoVista Innovative Therapies solid tumors Phase I/II

(L-nucleoside conjugate) San Antonio, TX www.oncovista.com
p28 peptide CDG Therapeutics solid tumors Phase I completed

Chicago, IL www.cdgti.com
PAC-1 Vanquish Oncology solid tumors Phase I

(procaspase activating compound-1) Champaign, IL (see also hematological) www.vanquishoncology.com
Solid Tumors
paclitaxel liposomal Sun Pharma Advanced Research solid tumors Phase I

Mumbai, India www.sunpharma.in
pbi-shRNA STMN1 LP Gradalis advanced solid tumors Phase I

gene therapy Dallas, TX www.gradalisinc.com
PDR001 Novartis Pharmaceuticals solid tumors Phase I

(PDCD 1 protein inhibitor) East Hanover, NJ www.novartis.com
PEG-BCT-100 Bio-Cancer Treatment International solid tumors Phase I

(recombinant human arginase) Hong Kong www.bio-cancer.org
PF-04518600 Pfizer solid tumors Phase I


(4-1BB [CD-137] protein receptor) New York, NY www.pfizer.com
solid tumors (combination therapy) Phase I

www.pfizer.com


(immunoconjugate) New York, NY www.pfizer.com

PFK-158 Advanced Cancer Therapeutics solid tumors Phase I

(PFKFB3 inhibitor) Louisville, KY www.advancedcancertherapeutics.com
Solid Tumors
PLX8394 Plexxikon BRAF-mutant solid tumors Phase I/II

(BRAF inhibitor) Berkeley, CA www.plexxikon.com
PLX 9486 Plexxikon KIT-mutant solid tumors Phase I

(proto oncogene protein Berkeley, CA (see also stomach) www.plexxikon.com
c-kit inhibitor)
PM060184 PharmaMar solid tumors Phase I

(tubulin polymerisation inhibitor) Madrid, Spain www.pharmamar.com
Poly-ICLC Oncovir advanced accessible solid tumors Phase II

Washington, DC www.oncovir.com
PQR309 PIQUR Therapeutics advanced solid tumors Phase I

(pan-PI3K/mTOR inhibitor) Basel, Switzerland www.piqur.com
PT-112 Phosplatin Therapeutics late-stage solid tumors Phase I

(apoptosis stimulant) New York, NY www.phosplatin.com
PTC596 PTC Therapeutics solid tumors Phase I

(BMI1 protein inhibitor) South Plainfield, NJ www.ptcbio.com
purine nucleoside phosphorylase PNP Therapeutics late-stage solid tumors Phase I

gene therapy Birmingham, AL www.pnptherapeutics.com
QBI-139 Quintessence Biosciences solid tumors Phase I

(RNA inhibitor) Madison, WI www.quintbio.com
rebastinib Deciphera Pharmaceuticals solid tumors Phase I/II

(TRK/BCR-ABL/TIE-2 inhibitor) Cambridge, MA www.deciphera.com
RG6061 Genentech/Roche solid tumors Phase I

(HIF1 alpha inhibitor) South San Francisco, CA www.roche.com
Solid Tumors

(CSF-1R antagonist) South San Francisco, CA www.roche.com

(Raf/MEK dual inhibitor) South San Francisco, CA www.roche.com

(CD3 antigen inhibitor) South San Francisco, CA www.roche.com

(CEA inhibitor) South San Francisco, CA www.roche.com

(antibody drug conjugate) South San Francisco, CA www.roche.com

(CD40 antigen stimulant) South San Francisco, CA www.roche.com

(anti-OX40 mAb) South San Francisco, CA www.roche.com
RX-3117 Rexahn Pharmaceuticals late-stage solid tumors Phase I

(DNA synthesis inhibitor) Rockville, MD www.rexahn.com
RX-5902 Rexahn Pharmaceuticals late-stage solid tumors Phase I

(RNA helicase inhibitor) Rockville, MD www.rexahn.com
RXDX 101 Ignyta advanced solid tumors Phase I/II

(selective tyrosine kinase inhibitor) San Diego, CA www.ignyta.com
RXDX 105 Ignyta advanced solid tumors Phase I

(BRAF kinase inhibitor) San Diego, CA www.ignyta.com
Solid Tumors
sapacitabine/seliciclib Cyclacel Pharmaceuticals solid tumors Phase I

combination Berkeley Heights, N www.cyclacel.com
SAR125844 Sanofi US solid tumors Phase I

c-Met kinase inhibitor) Bridgewater, NJ www.sanofi.com

(PI3K inhibitor) Bridgewater, NJ www.sanofi.com

(antibody drug conjugate) Bridgewater, NJ www.sanofi.com

(maytansin-loaded anti-CA6 mAb) Bridgewater, NJ www.sanofi.com
SEA-CD40 Seattle Genetics relapsed solid tumors Phase I

(CD40 antigen stimulant) Bothell, WA www.seattlegenetics.com
sEphB4-HSA VasGene Therapeutics solid tumors Phase I

(recombinant albumin fusion Los Angeles, CA www.vasgene.com
protein)
Seprehvir Virttu Biologics non-CNS solid tumors Phase I

HSV1716 Glasgow, Scotland (see also brain) www.virttu.com
Nationwide Children's Hospital
Columbus, OH
SF1126 SignalRx Pharmaceuticals solid tumors Phase I completed

(PI3K/mTOR dual inhibitor) San Diego, CA www.signalrx.com
SOR-C13 Soricimed Biopharma cancers that overexpress the TRPV6 Phase I

(TRPV6 protein inhibitor) Sackville, Canada calcium channel www.soricimed.com
Solid Tumors
TAK-117 Takeda Oncology solid tumors Phase I

(PI3K alpha inhibitor) Cambridge, MA www.takedaoncology.com

(UAE inhibitor) Cambridge, MA www.takedaoncology.com

(pan-Raf kinase inhibitor) Cambridge, MA www.takedaoncology.com

(SYK kinase inhibitor) Cambridge, MA (see also hematological) www.takedaoncology.com
TAS-114 Taiho Oncology advanced solid tumors Phase I

(dUTPase/DPD inhibitor) Princeton, NJ www.taihooncology.com
TAS-119 Taiho Oncology advanced solid tumors Phase I

(aurora kinase A inhibitor) Princeton, NJ www.taihooncology.com
TAS-120 Taiho Oncology advanced solid tumors Phase I/II

(FGF/FGFR inhibitor) Princeton, NJ (see also myeloma) www.taihooncology.com
TEN-010 Tensha Therapeutics solid tumors Phase I

(BET inhibitor) Cambridge, MA (see also hematological, leukemia) www.tenshatherapeutics.com
TEW-7197 MedPacto solid tumors Phase I

(TGF-beta type 1 receptor antagonist) Suwan, South Korea www.medpacto.com
thioureidobutyronitrile Cellceutix solid tumors Phase I

(tumor suppressor protein Beverly, MA www.cellceutix.com
p53 stimulant)
Solid Tumors
TRX518 GITR solid tumors Phase I

(GITR receptor antagonist) Cambridge, MA (see also skin) www.gitrrx.com
TVB-2640 3-V Biosciences solid tumors Phase I

(FASN inhibitor) Menlo Park, CA www.3vbio.com
U3-1565 Daiichi Sankyo solid tumors Phase I

(anti-HB=EGF antibody) Parsippany, NJ www.dsi.com
urelumab Bristol-Myers Squibb solid tumors Phase I

Princeton, NJ (see also hematological) www.bms.com
urelumab + Opdivo nivolumab Bristol-Myers Squibb solid tumors Phase I

Princeton, NJ (see also hematological) www.bms.com
VGX 100 Ceres Oncology solid tumors Phase I

(VEGF-C antibody) Victoria, Australia www.ceresoncology.com
VLX600 Vivolux advanced solid tumors Phase I

(UCHL5/USP14 protein inhibitor) Ashburn, VA www.vivolux.com
VS-4718 Verastem late-stage solid tumors Phase I

(FAK inhibitor) Cambridge, MA www.verastem.com
VS-5584 Verastem late-stage solid tumors Phase I

(PI3K/mTOR inhibitor) Cambridge, MA (see also lymphoma) www.verastem.com
VX15 Vaccinex solid tumors Phase I

(CD1000 antigen inhibitor) Rochester, NY www.vaccinex.com
VX-803 Vertex Pharmaceuticals solid tumors Phase I

Boston, MA (see also lymphoma) www.vrtx.com
Solid Tumors
VX-970 Vertex Pharmaceuticals solid tumors Phase I

(ATR protein inhibitor) Boston, MA www.vrtx.com
WT2725 Sunovion Pharmaceuticals solid tumors Phase I

(cancer immunotherapy) Marlborough, MA (see also hematological) www.sunovion.com
Xalkori Pfizer solid tumors Phase I

crizotinib New York, NY www.pfizer.com
Stomach Cancer
ADI-PEG 20 Polaris Pharmaceuticals advanced gastrointestinal malignancies Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, ovarian, pancreatic, skin) www.polarispharma.com
Afinitor Novartis Pharmaceuticals non-functioning gastrointestinal neuroendocrine Phase III

everolimus East Hanover, NJ tumors www.novartis.com
(see also lung)
AMG 337 Amgen gastric/esophageal cancer Phase II

(c-Met inhibitor) Thousand Oaks, CA www.amgen.com
BBI608 Boston Biomedical gastric cancer, gastro-esophageal adenocarcinoma Phase III

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, hematological, liver, www.bostonbiomedical.com
lung, ovarian, pancreatic, skin)
gastrointestinal cancer (combination therapy) Phase I

www.bostonbiomedical.com
crenolanib AROG Pharmaceuticals gastrointestinal stromal tumors (GIST) Phase III

(PDGFR inhibitor) Dallas, TX (see also brain, leukemia, lung) www.arogpharma.com
Stomach Cancer
Cyramza Eli Lilly gastric cancer (1st-line) Phase III

ramucirumab Indianapolis, IN (see also bladder, liver, lung) www.lilly.com
Orphan Drug
docetaxel injection concentrate, Teikoku Pharma USA gastric adenocarcinoma application submitted
non-alcohol formula San Jose, CA (see also breast, head/neck, lung, prostate) www.teikokuusa.com
fosbretabulin OXiGENE gastrointestinal neuroendocrine tumors Phase II

(vascular targeting agent) South San Francisco, CA (see also ovarian) www.oxigene.com
FPA144 Five Prime Therapeutics treatment-resistant gastric cancer Phase I

(FGFR2b antibody) South San Francisco, CA www.fiveprime.com
GS-5745 Gilead Sciences gastric cancer Phase II

(MMP9 mAb inhibitor) Foster City, CA (see also solid tumors) www.gilead.com
Iclusig ARAID Pharmaceuticals GIST Phase II

ponatinib Cambridge, MA (see also leukemia) www.ariad.com
ipatasertib Array BioPharma gastric cancer Phase II

(Akt inhibitor) Boulder, CO (see also breast, prostate) www.roche.com
Genentech/Roche www.arraybiopharma.com
Kadcyla Genentech/Roche HER2-positive gastric cancer (2nd-line) Phase III

ado-trastuzumab emtansine South San Francisco, CA (see also breast, lung) www.roche.com
Keytruda Merck gastric cancer Phase II

pembrolizumab Kenilworth, NJ (see also bladder, breast, head/neck, lung, lymphoma) www.merck.com
Lynparza AstraZeneca gastric cancer (2nd-line) Phase III

olaparib Wilmington, DE (see also breast, ovarian, pancreatic, prostate) www.astrazeneca.com
Stomach Cancer
masitinib AB Science USA late-stage GIST (1st-line) Phase III

Orphan Drug Short Hills, NJ (see also pancreatic) www.ab-science.com
MBP-426 Mebiopharm gastric cancer, gastroesophageal junction carcinoma Phase I/II

(transferrin-conjugated nano-particle Tokyo, Japan www.mebiopharm.com
formulation of oxaliplatin)
Minnelide 001 Minneamrita Therapeutics advanced gastrointestinal cancer Phase I

HSP70 inhibitor Moline, IL
NeuVax Galena Biopharma gastric carcinoma (HER2 IHC 1+/2+ or 3+) Phase I completed
nelipepimut-S Portland, OR (see also breast) www.galenabiopharma.com
Opdivo Bristol-Myers Squibb gastric cancer Phase III

hematological, kidney, liver, lung, lymphoma, skin,
solid tumors, other)
Perjeta Genentech/Roche HER2-positive gastric cancer Phase III

pertuzumab South San Francisco, CA (see also breast) www.roche.com
PLX9486 Plexxikon GIST Phase I

(proto oncogene protein c-kit inhibitor) Berkeley, CA (see also solid tumors) www.plexxikon.com
polyclonal antibody stimulator Cancer Advances gastric cancer Phase III completed
(G17DT) Durham, NC (see also colorectal, pancreatic) www.canceradvancesinc.com
Orphan Drug
pyrotinib Jiangsu Hengrui Medicine HER2-positive gastric cancer Phase I

(tyrosine kinase inhibitor) Jiangsu Province, China (see also breast) www.hrs.com.cn
SM04755 Samumed advanced gastric cancer Phase I

(Wnt inhibitor) San Diego, CA (see also colorectal, liver, pancreatic) www.samumed.com
Stomach Cancer
TAK-264 Takeda Oncology gastric cancer Phase II

(antibody drug conjugate Cambridge, MA (see also pancreatic) www.takedaoncology.com
targeting GCC)
TAS-102 Taiho Oncology advanced gastrointestinal tumors Phase I

(tipiracil/trifluridine) Princeton, NJ (see also colorectal) www.taihooncology.com
telatinib Eddingpharm gastric cancer Phase II completed

(VEGFR inhibitor) Westlake Village, CA www.eddingpharm.com
Orphan Drug
TKM-PLK1 Arbutus Biopharma gastrointestinal neuroendocrine tumors Phase I/II

(PLK1 inhibitor) Burnaby, Canada (see also other) www.arbutusbio.com
Other Cancers
177Lu-DOTATAE Advanced Accelerator Applications somastatin receptor-positive neuroendocrine Phase III

(somastatin receptor antagonist) New York, NY tumors of the small bowel (midgut carcinoid tumors) www.adacap.com
Orphan Drug
212-Pb-TCMC trastuzumab AREVA Med intra-abdominal HER-2 expressing cancers Phase I

Bethesda, MD www.averamed.avera.com
ADXS-HPV Advaxis anal cancer, cervical cancer Phase II

(immunotherapy vaccine) Princeton, NJ (see also head/neck) www.advaxis.com
Orphan Drug
cervical cancer (combination therapy) Phase I/II

www.advaxis.com
AEB071 Novartis Pharmaceuticals metastatic uveal melanoma Phase I/II

(PKC inhibitor) East Hanover, NJ (combination therapy) www.novartis.com
(see also lymphoma)
Other Cancers
ATR-101 Atterocor adrenocortical carcinoma Phase I

(ACAT1 inhibitor) Ann Arbor, MI www.atterocor.com
Orphan Drug
Avastin Genentech/Roche high-risk carcinoid tumors Phase III

bevacizumab South San Francisco, CA (see also brain, breast, lung, ovarian) www.roche.com
Azedra Progenics Pharmaceuticals neuroblastoma (pediatric), neuroendocrine Phase II

iobenguane I-131 Tarrytown, NY tumors (pediatric), pheochromocytoma (Fast Track) www.progenics.com
Orphan Drug
BAY1143572 Bayer HealthCare Pharmaceuticals advanced cancer Phase I

Whippany, NJ (see also leukemia) www.healthcare.bayer.com
BEL-0222 Belrose Pharma pediatric neuroblastoma Phase I/II

(angiogenesis inhibitor) Princeton, NJ (see also breast) www.belrosepharma.com
Orphan Drug
CC-486 Celgene advanced nasopharyngeal carcinoma Phase II

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, leukemia, www.celgene.com
lung, lymphoma)
CPI-613 Cornerstone Pharmaceuticals advanced malignancies Phase I/II

(KGDH/PHD complex inhibitor) Cranbury, NJ (see also pancreatic) www.cornerstonepharma.com
CPP-1X Cancer Prevention Pharmaceuticals neuroblastoma Phase II

(eflornithine) Tucson, AZ (see also colorectal) www.canprevent.com
CPP-1X/sulindac Cancer Prevention Pharmaceuticals colorectal cancer (risk reduction) Phase III
(eflornithine/sulindac) Tucson, AZ (see also other) www.canprevent.com
Other Cancers
cridanimod Kevelt endometrial cancer Phase II

(progesterone receptor modulator) Tallinn, Estonia www.kevelt.ee.en
Pharmsynthez www.pharmsynthez.com
St. Petersburg, Russia
DKN-01 HealthCare Pharmaceuticals esophageal cancer Phase I

(DKK1 protein inhibitor) Cambridge, MA (see also lung, myeloma) www.healthcarepharmaceuticals.com
emibetuzumab Eli Lilly advanced cancers Phase I/II

(c-Met antibody) Indianapolis, IN (see also lung) www.lilly.com
epacadostat Incyte fallopian tube cancer, peritoneal cancer Phase II

(IDO1 inhibitor) Wilmington, DE (see also lung, ovarian, skin) www.incyte.com
fenretinide lipid matrix BioMolecular Products recurrent/resistant neuroblastoma Phase I

Newburyport, MA www.biomolecularproducts.com
The EVAN Foundation
Germantown, MD
Texas Tech University
Lubbock, TX
GALE-301 Galena Biopharma endometrial cancer Phase II

(folate binding protein Portland, OR (see also ovarian) www.galenabiopharma.com
immunotherapy)
GI-6207 GlobeImmune medullary thyroid cancer Phase II

(T-cell stimulator) Louisville, CO www.globeimmune.com
GI-6301 GlobeImmune chordoma Phase II

(brachyury peptide vaccine) Louisville, CO www.globeimmune.com
advanced cancers Phase I

www.globeimmune.com
Other Cancers
GL-ONC1 Genelux peritoneal carcinomatosis Phase I/II

(oncolytic virus immunomodulator) San Diego, CA (see also head/neck, lung) www.genelux.com
HPV-16 E6 TCR Kite Pharma HPV-associated cancers (vaginal, cervical, anal, Phase I/II
(T-cell receptor antigen antagonist) Santa Monica, CA penile, or oropharyngeal cancers) www.kitepharma.com
Bethesda, MD
IMMU-132 Immunomedics advanced epithelial cancer Phase I/II

(sacituzumab govitecan) Morris Plains, NJ (see also breast) www.immunomedics.com
INO-3106 Inovio Pharmaceuticals HPV-6-associated aerodigestive cancers Phase I/II

(cancer immunotherapy) Plymouth Meeting, PA www.inovio.com
INO-3112 Inovio Pharmaceuticals cervical cancer caused by HPV types 16 and 18 Phase I/II
(cancer immunotherapy) Plymouth Meeting, PA www.inovio.com
JCAR023 Juno Therapeutics neuroblastoma (pediatric) Phase I

KTN3379 Kolltan Pharmaceuticals BRAF mutant, radioiodine-refractory thyroid cancer Phase I

(ErbB3 kinase inhibitor) New Haven, CT (see also solid tumors) www.kolltan.com
Lenvima Eisai endometrial cancer Phase II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, lung, skin, solid tumors) www.eisai.com
LY2940680 Eli Lilly advanced cancer Phase II

(hedgehog/SMO inhibitor) Indianapolis, IN www.lilly.com
milciclib Nerviano Medical Sciences malignant thymoma Phase II

(CDK inhibitor) Nerviano, Italy www.nervianoms.com
Other Cancers
mirvetuximab soravtansine ImmunoGen FOLR1-overexpressing endometrial cancer Phase I

(folate receptor 1 inhibitor) Waltham, MA (see also ovarian) www.immunogen.com
neuroblastoma vaccine MabVax Therapeutics neuroblastoma Phase I

Orphan Drug San Diego, CA www.mabvax.com
Nexavar Bayer HealthCare Pharmaceuticals differentiated thyroid cancer Phase III

sorafenib Whippany, NJ (see also kidney) www.healthcare.bayer.com
Opdivo Bristol-Myers Squibb esophageal cancer Phase II

hematological, kidney, liver, lung, lymphoma, skin,
solid tumors, stomach)
pediatric cancer Phase I

www.bms.com
pasireotide long acting release Novartis Pharmaceuticals neuroendocrine tumors, pituitary cancer Phase II
(SOM230) East Hanover, NJ (see also prostate, skin) www.novartis.com
PDS0101 PDS Biotechnology cervical cancer prevention (HPV-16) Phase I

(cancer immunotherapy) North Brunswick, NJ www.pdsbiotech.com
PLX3397 Plexxikon tenosynovial giant cell tumor Phase III

(CSF-1R inhibitor) Berkeley, CA (see also brain, breast, ovarian, skin) www.plexxikon.com
Orphan Drug
PU-H71 Samus Therapeutics advanced malignancies Phase I

(HSP90 heat-shock protein inhibitor) New York, NY
Memorial Sloan-Kettering Cancer Center
New York, NY
Other Cancers
refametinib Bayer HealthCare Pharmaceuticals advanced or metastatic cancer Phase II

(MEK inhibitor) Whippany, NJ www.healthcare.bayer.com
Reolysin Oncolytics Biotech fallopian tube cancer, peritoneal cancer Phase II

Orphan Drug myeloma, ovarian, pancreatic)
RRx-001 EpicentRx neuroendocrine tumors Phase II

(free radical stimulant) Mountain View, CA (see also colorectal, liver, lung, lymphoma) www.radiorx.com
rucaparib Clovis Oncology fallopian tube cancer, peritoneal cancer Phase III
(PARP inhibitor) Boulder, CO (see also breast, ovarian, pancreatic) www.clovisoncology.com
SC-002 Stemcentrx neuroendocrine tumors Phase I

(immunoconjugate) South San Francisco, CA (see also lung) www.stemcentrx.com
selinexor (oral) Karyopharm Therapeutics gynecologic malignancies Phase II

leukemia, lymphoma, myeloma, prostate, sarcoma)
selumetinib AstraZeneca differentiated thyroid cancer, Phase III

(MEK inhibitor) Wilmington, DE uveal melanoma www.astrazeneca.com
Orphan Drug
TAK-228 Takeda Oncology endometrial cancer Phase II

(mTORC1/2 inhibitor) Cambridge, MA (see also breast, kidney) www.takedaoncology.com
telotristat etiprate Lexicon Pharmaceuticals malignant carcinoid syndrome (Fast Track) Phase III
(TPH1 inhibitor) The Woodlands, TX www.lexicon-genetics.com
Orphan Drug
Other Cancers
TKM-PLK1 Arbutus Biopharma adrenocortical carcinoma Phase I

(PLK1 inhibitor) Burnaby, Canada (see other stomach) www.arbutusbio.com
TRC105 TRACON Pharmaceuticals choriocarcinoma Phase II

lung, sarcoma)
Triapine Nanotherapeutics non-localized cervical cancer Phase II

ribonuclease inhibitor Alachua, FL www.nanotherapeutics.com
Bethesda, MD
Unituxin United Therapeutics neuroblastoma (adults up to age 30 years) Phase III

dinutuximab Silver Spring, MD www.unither.com
Orphan Drug
VB-111 VBL Therapeutics thyroid cancer Phase II

(targeted anti-angiogenic agent) Tel Aviv, Israel (see also brain, ovarian) www.vblrx.com
WNT974 Novartis Pharmaceuticals malignancies dependent on Wnt ligands Phase I

(WNT signaling pathway inhibitor) East Hanover, NJ www.novartis.com
Zelboraf Genentech/Roche BRAF mutation-positive papillary thyroid cancer Phase II

vemurafenib South San Francisco, CA (see also colorectal, skin) www.roche.com
Daiichi Sankyo
Parsippany, NJ
zoptarelin doxorubicin Aeterna Zentaris endometrial cancer (2nd-line) Phase III

(type II DNA topoisomerase Quebec, Canada (see also prostate) www.aezsinc.com
inhibitor)
Unspecified
ABBV-075 AbbVie Phase I

(bromodomain inhibitor) North Chicago, IL www.abbvie.com
AGS67E Agensys Phase I

Astellas Pharma www.astellas.com
Tokyo, Japan
BAY1082439 Bayer HealthCare Pharmaceuticals Phase I

(allosteric Akt 1/2 inhibitor) Whippany, NJ www.healthcare.bayer.com

(Pan-FGFR inhibitor) Whippany, NJ www.healthcare.bayer.com

(FGFR2 antibody drug conjugate) Whippany, NJ www.healthcare.bayer.com

(PSMA BiTE antibody) Whippany, NJ www.healthcare.bayer.com
CHML Glory Pharmaceuticals in clinical trials

(cytotropic heterogeneous molecular lipids) Vienna, VA www.anticancerdrug.com
CSF-1R mAb Eli Lilly Phase I

(LY3022855) Indianapolis, IN www.lilly.com
fenretinide intravenous CerRx Phase I

Lubbock, TX www.cerrx.com
G1T28 G1 Therapeutics Phase I

(CDK 4/6 inhibitor) Research Triangle Park, NC www.g1therapeutics.com
Unspecified
HBI-8000 Huya Bioscience Phase I

(HDAC inhibitor) San Diego, CA www.huyabio.com
IGF-methotrexate conjugate IGF Oncology Phase I

Birchwood, MN www.igfoncology.com
IP-112 InnoPharma application submitted

Piscataway, NJ www.innopharmainc.com
LY2874455 Eli Lilly Phase II

(FGF receptor inhibitor) Indianapolis, IN www.lilly.com
LY3009120 Eli Lilly Phase I

(Pan-Raf inhibitor) Indianapolis, IN www.lilly.com

(NOTCH inhibitor) Indianapolis, IN www.lilly.com

(MET/EGFR bispecific antibody) Indianapolis, IN www.lilly.com
merestinib Eli Lilly Phase II

(c-Met inhibitor) Indianapolis, IN www.lilly.com
notch inhibitor Bristol-Myers Squibb Phase I

OMN54 Omnitura Therapeutics Phase I

(signal transduction pathway Redwood Shores, CA www.omnitura.com
inhibitor)
Unspecified
OPB-51602 Otsuka Pharmaceutical Phase I

(molecular targeting drug) Rockville, MD www.otsuka.com
REGN1400 Regeneron Pharmaceuticals Phase I

(ERBB-3 receptor modulator) Tarrytown, NY www.regeneron.com
REGN2810 Regeneron Pharmaceuticals Phase I

(PD-1 protein inhibitor) Tarrytown, NY www.regeneron.com
SNX-5422 Esanex Phase I

(Hsp90 inhibitor) Indianapolis, In
TRF-DOX Faulk Pharmaceuticals Phase I completed

(doxorubicin transferrin conjugate) Raleigh, NC www.faulkpharma.com
Panther Biotechnology www.pantherbiotechnology.com
Chicago, IL
VEGFR-3 mAb Eli Lilly Phase I

Indianapolis, IN www.lilly.com
VOLT03 Levolta Pharmaceuticals Phase I

(thromboxane synthase inhibitor) Bethlehem, PA www.levoltapharma.com
Definitions
Application SubmittedAn application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA).
Fast TrackUpon request by a sponsor, the FDA can grant this designation to facilitate the development and expedite the review of a drug or biologic to treat a serious condition and fill an
unmet medical need. When considering a biopharmaceutical companys request for Fast Track designation for an investigational drug or biologic, the FDA evaluates whether it will affect
factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one, and whether a condition
can be adequately addressed by available therapy. With Fast Track designation, early and frequent communication between the FDA and the biopharmaceutical company is encouraged
throughout the entire drug development and review process to help to quickly resolve and questions or issues that arise, potentially leading to an earlier approval and access by patients.
Orphan DesignationUpon request by a sponsor, the FDA can grant special status (orphan status) to a drug or biologic to treat a rare disease or disease or condition. In order to
receive an orphan designation, a qualifying drug or biologic must be intended for the treatment, diagnosis, or prevention of a rare disease or condition that affects fewer than 200,000
people in the United States, or that affects more than 200,000 persons but is not expected to recover the costs of its development and marketing.
Phase IResearchers test the investigational drug or biologic in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and
tolerability profile, determine a safe dosage range, and identify potential side effects.
Phase IIThe investigational drug or biologic is given to volunteer patients, usually between 100 and 500, to determine whether it is effective, identify an optimal dose, and to further
evaluate its short-term safety.
Phase IIIThe investigational drug or biologic is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients ( but sometimes many more),
to generate statistically significant evidence to confirm its safety and effectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world.
The content of this report has been obtained through public, government and industry sources, and the Adis R&D Insight database based on the latest information. Report current as of
August 21, 2015. The medicines in this listing include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting
trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. The information may not be comprehensive. For more specific information about a
particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA's website at www.phrma.org.

2015 Cancer Drug List PDF

Hochgeladen von

Dokumentinformationen

Originaltitel

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

2015 Cancer Drug List PDF

Hochgeladen von

Copyright:

Verfügbare Formate

2015 Medicines in Development for Cancer

ABI-009 AADi non-muscle invasive bladder cancer Phase I/II

ACP-196 Acerta Pharma platinum-refractory bladder cancer Phase II

ALT-801 Altor BioScience advanced bladder cancer, Phase II

ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase I/II

apatorsen OncoGenex Pharmaceuticals metastatic bladder cancer Phase II

apaziquone Spectrum Pharmaceuticals non-muscle invasive bladder cancer Phase III

ASG-15ME Agensys relapsed bladder cancer Phase I

B-701 BioClin Therapeutics metastatic bladder cancer (2nd-line) Phase II

BC-819 BioCancell Therapeutics bladder cancer (2nd-line) Phase II

CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II/III

CV-301 Bavarian Nordic bladder cancer Phase II

Cyramza Eli Lilly urothelial cancer Phase III

bladder cancer (2nd-line) Phase II

DN24-02 Dendreon HER2-positive urothelial cancer Phase II

Halaven Eisai bladder cancer Phase I/II

instiladrin FKD Therapies superficial bladder cancer Phase II

JNJ-42756493 Janssen Research & Development urothelial cancer Phase II

MCNA Telesta Therapeutics refractory non-muscle invasive application submitted

Keytruda Merck bladder cancer Phase III

mocetinostat Mirati Therapeutics bladder cancer Phase II

Opdivo Bristol-Myers Squibb bladder cancer (2nd-line) Phase II

RG7446 Genentech/Roche bladder cancer (2nd-line) (Breakthrough Therapy) Phase III

bladder cancer (1st-line) Phase II

TMX-101 Telormedix bladder cancer Phase II

vesigenurtucel-L Heat Biologics bladder cancer Phase II

2B3-101 BBB Therapeutics brain metastases in advanced solid tumors, Phase II

ABT-414 AbbVie glioblastoma Phase I/II

ADU-623 Aduro Biotech glioblastoma Phase I

AG-120 Agios Pharmaceuticals glioma Phase I

aglatimagene besadenovec Advantagene glioma Phase II

glioma (pediatric) Phase I/II

aldoxorubicin CytRx glioblastoma Phase II

AMG 595 Amgen anaplastic astrocytoma, recurrent glioblastoma Phase I

Avastin Genentech/Roche glioblastoma (1st-line) Phase III

BGJ398 Novartis Pharmaceuticals recurrent glioblastoma Phase II

buparlisib (BKM120) Novartis Pharmaceuticals glioblastoma Phase I/II

CC-122 Celgene glioblastoma Phase I

Cometriq Exelixis astrocytoma, glioblastoma Phase II completed

Cotara Peregrine Pharmaceuticals recurrent glioblastoma (Fast Track) Phase II completed

crenolanib AROG Pharmaceuticals glioma (pediatric) Phase II

CTO Tactical Therapeutics glioma (combination therapy) Phase I/II

DCVax-L Northwest Biotherapeutics glioblastoma Phase III

DM-CHOC-PEN Dekk-Tec brain tumors Phase II

DNX-2401 DNAtrix glioblastoma (Fast Track) Phase I

ERC1671 Epitopoietic Research grade IV glioblastoma Phase II

ETS2101 e-Therapeutics glioma Phase I

evofosfamide (TH-302) Threshold Pharmaceuticals high grade glioma Phase I/II

galunisertib Eli Lilly glioblastoma Phase II

glioma Phase I/II

Gilotrif Boehringer Ingelheim Pharmaceuticals recurrent glioma Phase II

heat shock protein vaccine Agenus recurrent or newly-diagnosed glioblastoma Phase II

ICT-107 ImmunoCellular Therapeutics newly-diagnosed glioblastoma Phase II

ICT-121 ImmunoCellular Therapeutics recurrent glioblastoma Phase I

indoximod NewLink Genetics primary malignant brain tumors Phase I/II

INXN-2001 ZIOPHARM Oncology anaplastic oligo astrocytoma, glioblastoma Phase I/II

Jevtana Sanofi US malignant central nervous system tumors Phase I/II

KX02 Kinex Pharmaceuticals glioma Phase I

MM-398 Baxalta glioma Phase I

macitentan Actelion Pharmaceuticals glioblastoma Phase I

marizomib Triphase Accelerator glioblastoma Phase I

mibefradil Cavion high-grade glioma Phase I

mipsagargin GenSpera glioblastoma Phase II